Carrel name: keyword-ibd-cord Creating study carrel named keyword-ibd-cord Initializing database parallel: Warning: Only enough available processes to run 44 jobs in parallel. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf parallel: Warning: or /proc/sys/kernel/pid_max may help. parallel: Warning: No more processes: Decreasing number of running jobs to 43. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf may help. parallel: Warning: No more processes: Decreasing number of running jobs to 42. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf may help. parallel: Warning: No more processes: Decreasing number of running jobs to 41. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf may help. file: cache/cord-013370-gktnz644.json key: cord-013370-gktnz644 authors: Abreu, Maria T; Peyrin-Biroulet, Laurent title: Providing Guidance During a Global Viral Pandemic for the Care of Patients With Inflammatory Bowel Disease date: 2020-10-21 journal: J Crohns Colitis DOI: 10.1093/ecco-jcc/jjaa116 sha: doc_id: 13370 cord_uid: gktnz644 file: cache/cord-017342-qsfykh1k.json key: cord-017342-qsfykh1k authors: Nedelsky, Natalia B.; Kuballa, Petric; Castoreno, Adam B.; Xavier, Ramnik J. title: Inflammatory Bowel Disease at the Intersection of Autophagy and Immunity: Insights from Human Genetics date: 2013-06-21 journal: Molecular Genetics of Inflammatory Bowel Disease DOI: 10.1007/978-1-4614-8256-7_12 sha: doc_id: 17342 cord_uid: qsfykh1k file: cache/cord-256143-9u5a0jqz.json key: cord-256143-9u5a0jqz authors: Grassia, Roberto; Soro, Sara; Conti, Clara Benedetta title: Inflammatory Bowel Diseases and Biological Treatment in SARS-CoV-2 Era. Why Not? date: 2020-05-09 journal: Inflamm Bowel Dis DOI: 10.1093/ibd/izaa110 sha: doc_id: 256143 cord_uid: 9u5a0jqz file: cache/cord-259585-mjtxiu0t.json key: cord-259585-mjtxiu0t authors: Occhipinti, Vincenzo; Pastorelli, Luca title: Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a “Red Zone” Area in Northern Italy date: 2020-04-21 journal: Inflamm Bowel Dis DOI: 10.1093/ibd/izaa084 sha: doc_id: 259585 cord_uid: mjtxiu0t file: cache/cord-026792-jsqa4pmu.json key: cord-026792-jsqa4pmu authors: Samanta, Jayanta; Dhar, Jahnvi; Khaliq, Abdul; Kochhar, Rakesh title: 2019 Novel Coronavirus Infection: Gastrointestinal Manifestations date: 2020-05-16 journal: nan DOI: 10.1055/s-0040-1712077 sha: doc_id: 26792 cord_uid: jsqa4pmu file: cache/cord-258066-ncuegrq7.json key: cord-258066-ncuegrq7 authors: nan title: Inflammatory Bowel Disease date: 2013-12-31 journal: Clinical Veterinary Advisor DOI: 10.1016/b978-1-4160-3969-3.00215-8 sha: doc_id: 258066 cord_uid: ncuegrq7 file: cache/cord-267260-8l831mre.json key: cord-267260-8l831mre authors: Brenner, Erica J.; Ungaro, Ryan C.; Gearry, Richard B.; Kaplan, Gilaad G.; Kissous-Hunt, Michele; Lewis, James D.; Ng, Siew C.; Rahier, Jean-Francois; Reinisch, Walter; Ruemmele, Frank M.; Steinwurz, Flavio; Underwood, Fox E.; Zhang, Xian; Colombel, Jean-Frederic; Kappelman, Michael D. title: Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry date: 2020-05-18 journal: Gastroenterology DOI: 10.1053/j.gastro.2020.05.032 sha: doc_id: 267260 cord_uid: 8l831mre file: cache/cord-027386-23exaaik.json key: cord-027386-23exaaik authors: Rao, Vishwas; Maulik, Romit; Constantinescu, Emil; Anitescu, Mihai title: A Machine-Learning-Based Importance Sampling Method to Compute Rare Event Probabilities date: 2020-05-25 journal: Computational Science - ICCS 2020 DOI: 10.1007/978-3-030-50433-5_14 sha: doc_id: 27386 cord_uid: 23exaaik file: cache/cord-026025-xqj877en.json key: cord-026025-xqj877en authors: PETRAS, ROBERT E.; FRANKEL, WENDY L. title: Large Intestine (Colon) date: 2009-10-30 journal: Modern Surgical Pathology DOI: 10.1016/b978-1-4160-3966-2.00023-0 sha: doc_id: 26025 cord_uid: xqj877en file: cache/cord-253001-xmcwuuk4.json key: cord-253001-xmcwuuk4 authors: Papa, Alfredo; Gasbarrini, Antonio; Tursi, Antonio title: Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease date: 2020-08-19 journal: Am J Gastroenterol DOI: 10.14309/ajg.0000000000000830 sha: doc_id: 253001 cord_uid: xmcwuuk4 file: cache/cord-031937-qhlatg84.json key: cord-031937-qhlatg84 authors: Verma, Anukriti; Sharda, Shivani; Rathi, Bhawna; Somvanshi, Pallavi; Pandey, Bimlesh Dhar title: Elucidating potential molecular signatures through host-microbe interactions for reactive arthritis and inflammatory bowel disease using combinatorial approach date: 2020-09-15 journal: Sci Rep DOI: 10.1038/s41598-020-71674-8 sha: doc_id: 31937 cord_uid: qhlatg84 file: cache/cord-014516-r59usk02.json key: cord-014516-r59usk02 authors: nan title: Research Communications of the 24th ECVIM‐CA Congress date: 2015-01-10 journal: J Vet Intern Med DOI: 10.1111/jvim.12491 sha: doc_id: 14516 cord_uid: r59usk02 file: cache/cord-276267-77903fld.json key: cord-276267-77903fld authors: Al‐Ani, Aysha H.; Prentice, Ralley E.; Rentsch, Clarissa A.; Johnson, Doug; Ardalan, Zaid; Heerasing, Neel; Garg, Mayur; Campbell, Sian; Sasadeusz, Joe; Macrae, Finlay A.; Ng, Siew C.; Rubin, David T.; Christensen, Britt title: Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient date: 2020-05-26 journal: Aliment Pharmacol Ther DOI: 10.1111/apt.15779 sha: doc_id: 276267 cord_uid: 77903fld file: cache/cord-281275-i9920nvm.json key: cord-281275-i9920nvm authors: Schlabitz, Franziska; Teich, Niels; Michl, Patrick; Walldorf, Jens title: Inflammatory Bowel Disease and COVID-19—“Preventive” Sick Certificates as a Frequent Coping Strategy in the Face of the Pandemic date: 2020-06-12 journal: Inflamm Bowel Dis DOI: 10.1093/ibd/izaa155 sha: doc_id: 281275 cord_uid: i9920nvm file: cache/cord-285820-g8b7u3yf.json key: cord-285820-g8b7u3yf authors: Taxonera, Carlos; Alba, Cristina; Olivares, David; Martin, María; Ventero, Alejandro; Cañas, Mercedes title: Innovation in IBD Care During the COVID-19 Pandemic: Results of a Cross-Sectional Survey on Patient-Reported Experience Measures date: 2020-08-19 journal: Inflamm Bowel Dis DOI: 10.1093/ibd/izaa223 sha: doc_id: 285820 cord_uid: g8b7u3yf file: cache/cord-266392-bayabroa.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-266392-bayabroa authors: Brenner, Erica J.; Pigneur, Bénédicte; Focht, Gili; Zhang, Xian; Ungaro, Ryan C.; Colombel, Jean-Frederic; Turner, Dan; Kappelman, Michael D.; Ruemmele, Frank M. title: BENIGN EVOLUTION OF SARS-CoV2 INFECTIONS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM TWO INTERNATIONAL DATABASES date: 2020-10-12 journal: Clin Gastroenterol Hepatol DOI: 10.1016/j.cgh.2020.10.010 sha: doc_id: 266392 cord_uid: bayabroa parallel: Warning: No more processes: Decreasing number of running jobs to 40. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf may help. file: cache/cord-287885-1jwwmoys.json key: cord-287885-1jwwmoys authors: D'Amico, Ferdinando; Rahier, Jean-François; Leone, Salvo; Peyrin-Biroulet, Laurent; Danese, Silvio title: Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey date: 2020-05-13 journal: Lancet Gastroenterol Hepatol DOI: 10.1016/s2468-1253(20)30151-5 sha: doc_id: 287885 cord_uid: 1jwwmoys file: cache/cord-263419-qeo6qn0d.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: Resource temporarily unavailable key: cord-263419-qeo6qn0d authors: Fiorino, Gionata; Peyrin-Biroulet, Laurent; Danese, Silvio title: Protecting patients with IBD during the COVID-19 pandemic date: 2020-05-20 journal: Lancet Gastroenterol Hepatol DOI: 10.1016/s2468-1253(20)30152-7 sha: doc_id: 263419 cord_uid: qeo6qn0d file: cache/cord-261029-befymalm.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-261029-befymalm authors: Sultan, Keith; Mone, Anjali; Durbin, Laura; Khuwaja, Samreen; Swaminath, Arun title: Review of inflammatory bowel disease and COVID-19 date: 2020-10-07 journal: World J Gastroenterol DOI: 10.3748/wjg.v26.i37.5534 sha: doc_id: 261029 cord_uid: befymalm file: cache/cord-283279-1qcdnd1y.json key: cord-283279-1qcdnd1y authors: Barberio, Brigida; Zingone, Fabiana; Bertani, Lorenzo; Savarino, Edoardo title: The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients During COVID-19 Pandemic: Is It Really a Problem? date: 2020-07-17 journal: Gastroenterology DOI: 10.1053/j.gastro.2020.07.017 sha: doc_id: 283279 cord_uid: 1qcdnd1y file: cache/cord-022555-a7ie82fs.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-022555-a7ie82fs authors: nan title: Digestive System, Liver, and Abdominal Cavity date: 2011-12-05 journal: The Cat DOI: 10.1016/b978-1-4377-0660-4.00023-5 sha: doc_id: 22555 cord_uid: a7ie82fs file: cache/cord-275447-nx45kwn6.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-275447-nx45kwn6 authors: Ehrenpreis, Eli D.; Kruchko, David H. title: Rapid Review: Nonsteroidal Anti-inflammatory Agents and Aminosalicylates in COVID-19 Infections date: 2020-06-10 journal: J Clin Gastroenterol DOI: 10.1097/mcg.0000000000001371 sha: doc_id: 275447 cord_uid: nx45kwn6 file: cache/cord-288014-rrr4x755.json key: cord-288014-rrr4x755 authors: Wang, Hong-Gang; Xie, Rui; Ma, Tian-Heng; Yang, Xiao-Zhong title: Excessive anxiety in IBD patients is unnecessary for COVID-19 date: 2020-05-12 journal: Clin Res Hepatol Gastroenterol DOI: 10.1016/j.clinre.2020.03.001 sha: doc_id: 288014 cord_uid: rrr4x755 file: cache/cord-300963-1n1f8mf2.json key: cord-300963-1n1f8mf2 authors: Gajendran, Mahesh; Perisetti, Abhilash; Aziz, Muhammad; Raghavapuram, Saikiran; Bansal, Pardeep; Tharian, Benjamin; Goyal, Hemant title: Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned date: 2020-10-12 journal: Ann Gastroenterol DOI: 10.20524/aog.2020.0547 sha: doc_id: 300963 cord_uid: 1n1f8mf2 file: cache/cord-284234-9cd2v6bt.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-284234-9cd2v6bt authors: Sebastian, S; Gonzalez, H A; Peyrin-Biroulet, L title: Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD date: 2020-06-10 journal: J Crohns Colitis DOI: 10.1093/ecco-jcc/jjaa120 sha: doc_id: 284234 cord_uid: 9cd2v6bt file: cache/cord-275199-y7b12vml.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-275199-y7b12vml authors: Suárez-Fariñas, Mayte; Tokuyama, Minami; Wei, Gabrielle; Huang, Ruiqi; Livanos, Alexandra; Jha, Divya; Levescot, Anais; Irizar, Haritz; Kosoy, Roman; Cording, Sascha; Wang, Wenhui; Losic, Bojan; Ungaro, Ryan; Di’Narzo, Antonio; Martinez-Delgado, Gustavo; Suprun, Maria; Corley, Michael J.; Stojmirovic, Aleksandar; Houten, Sander M.; Peters, Lauren; Curran, Mark; Brodmerkel, Carrie; Perrigoue, Jacqueline; Friedman, Joshua R.; Hao, Ke; Schadt, Eric E.; Zhu, Jun; Ko, Huaibin M.; Cho, Judy; Dubinsky, Marla C.; Sands, Bruce E.; Ndhlovu, Lishomwa; Cerf-Bensusan, Nadine; Kasarskis, Andrew; Colombel, Jean Frederic; Harpaz, Noam; Argmann, Carmen; Mehandru, Saurabh title: Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease date: 2020-09-25 journal: Gastroenterology DOI: 10.1053/j.gastro.2020.09.029 sha: doc_id: 275199 cord_uid: y7b12vml file: cache/cord-290750-85731og8.json key: cord-290750-85731og8 authors: Danese, Silvio; Cecconi, Maurizio; Spinelli, Antonino title: Management of IBD during the COVID-19 outbreak: resetting clinical priorities date: 2020-03-25 journal: Nat Rev Gastroenterol Hepatol DOI: 10.1038/s41575-020-0294-8 sha: doc_id: 290750 cord_uid: 85731og8 file: cache/cord-288439-srzysoqy.json key: cord-288439-srzysoqy authors: Segal, Jonathan P.; Mullish, Benjamin H.; Quraishi, Mohammed N.; Iqbal, Tariq; Marchesi, Julian R.; Sokol, Harry title: Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease date: 2020-09-03 journal: Therap Adv Gastroenterol DOI: 10.1177/1756284820946904 sha: doc_id: 288439 cord_uid: srzysoqy file: cache/cord-302717-hn3airxq.json key: cord-302717-hn3airxq authors: Bayoumy, Ahmed B.; van Liere, Elsa L. S. A.; Simsek, Melek; Warner, Ben; Loganayagam, Aathavan; Sanderson, Jeremy D.; Anderson, Simon; Nolan, Jonathan; de Boer, Nanne K.; Mulder, Chris J. J.; Ansari, Azhar title: Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom date: 2020-09-11 journal: BMC Gastroenterol DOI: 10.1186/s12876-020-01441-6 sha: doc_id: 302717 cord_uid: hn3airxq file: cache/cord-295066-76se8mxq.json key: cord-295066-76se8mxq authors: Botti, Fiorenzo; Mazza, Stefano; Costa, Stefano; Farina, Elisa; Baldari, Ludovica; Prati, Matteo title: URGENT SURGERY FOR INFLAMMATORY BOWEL DISEASES DURING THE COVID-19 OUTBREAK IN A HIGH INCIDENCE AREA - EXPERIENCE FROM A HIGH-VOLUME CENTRE date: 2020-08-31 journal: Dig Liver Dis DOI: 10.1016/j.dld.2020.08.039 sha: doc_id: 295066 cord_uid: 76se8mxq file: cache/cord-032753-icteg34y.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-032753-icteg34y authors: Namai, Fu; Shigemori, Suguru; Ogita, Tasuku; Sato, Takashi; Shimosato, Takeshi title: Microbial therapeutics for acute colitis based on genetically modified Lactococcus lactis hypersecreting IL-1Ra in mice date: 2020-09-28 journal: Exp Mol Med DOI: 10.1038/s12276-020-00507-5 sha: doc_id: 32753 cord_uid: icteg34y file: cache/cord-255930-2bobmkvu.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: Resource temporarily unavailable /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-255930-2bobmkvu authors: Kaplan, Gilaad G.; Windsor, Joseph W. title: The four epidemiological stages in the global evolution of inflammatory bowel disease date: 2020-10-08 journal: Nat Rev Gastroenterol Hepatol DOI: 10.1038/s41575-020-00360-x sha: doc_id: 255930 cord_uid: 2bobmkvu file: cache/cord-306760-05my504t.json key: cord-306760-05my504t authors: Turner, Dan; Huang, Ying; Martín-de-Carpi, Javier; Aloi, Marina; Focht, Gili; Kang, Ben; Zhou, Ying; Sanchez, Cesar; Kappelman, Michael D.; Uhlig, Holm H.; Pujol-Muncunill, Gemma; Ledder, Oren; Lionetti, Paolo; Dias, Jorge Amil; Ruemmele, Frank M.; Russell, Richard K. title: Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition date: 2020-03-31 journal: J Pediatr Gastroenterol Nutr DOI: 10.1097/mpg.0000000000002729 sha: doc_id: 306760 cord_uid: 05my504t file: cache/cord-269390-4yn8c34i.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-269390-4yn8c34i authors: Rimondi, Alessandro; Tontini, Gian Eugenio; Mazza, Stefano; Caprioli, Flavio; Sangiovanni, Angelo; Lampertico, Pietro; Vecchi, Maurizio title: Fogging IBD Management: An Unusual Case of IBD Flare-up During the COVID-19 Outbreak date: 2020-07-28 journal: Inflamm Bowel Dis DOI: 10.1093/ibd/izaa184 sha: doc_id: 269390 cord_uid: 4yn8c34i file: cache/cord-285238-bpk3xl8x.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-285238-bpk3xl8x authors: Dong, Xiuli; Ye, Xiaohua; Chen, Xiangrong; Chen, Tanzhou; Xie, Saili; Li, Qinfan; Lin, Xiaoxiao; Huang, Zhiming title: Intestinal and Peripheral Fibrinogen-Like Protein 2 Expression in Inflammatory Bowel Disease date: 2013-11-28 journal: Dig Dis Sci DOI: 10.1007/s10620-013-2962-9 sha: doc_id: 285238 cord_uid: bpk3xl8x file: cache/cord-285426-iyl12ber.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: Resource temporarily unavailable key: cord-285426-iyl12ber authors: Ghavami, Shaghayegh Baradaran; Shahrokh, Shabnam; Hossein-Khannazer, Nikoo; Shpichka, Anastasia; Asadzadeh Aghdaei, Hamid; Timashev, Peter; Vosough, Massoud title: IBD Patients Could Be Silent Carriers for Novel Coronavirus and Less Prone to its Severe Adverse Events: True or False? date: 2020-09-08 journal: Cell J DOI: 10.22074/cellj.2020.7603 sha: doc_id: 285426 cord_uid: iyl12ber file: cache/cord-280023-r3qgdgeu.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: Resource temporarily unavailable key: cord-280023-r3qgdgeu authors: Dipasquale, Valeria; Cucchiara, Salvatore; Martinelli, Massimo; Miele, Erasmo; Aloi, Marina; Romano, Claudio title: Challenges in paediatric inflammatory bowel diseases in the COVID-19 time date: 2020-04-08 journal: Dig Liver Dis DOI: 10.1016/j.dld.2020.03.015 sha: doc_id: 280023 cord_uid: r3qgdgeu file: cache/cord-266648-962r0vm8.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: Resource temporarily unavailable key: cord-266648-962r0vm8 authors: Grossberg, Laurie B; Pellish, Randall S; Cheifetz, Adam S; Feuerstein, Joseph D title: Review of Societal Recommendations Regarding Management of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic date: 2020-07-03 journal: Inflamm Bowel Dis DOI: 10.1093/ibd/izaa174 sha: doc_id: 266648 cord_uid: 962r0vm8 file: cache/cord-258930-60yn4hg7.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: Resource temporarily unavailable /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-258930-60yn4hg7 authors: D’Amico, Ferdinando; Peyrin-Biroulet, Laurent; Danese, Silvio title: Inflammatory bowel diseases and COVID-19: the invisible enemy date: 2020-04-16 journal: Gastroenterology DOI: 10.1053/j.gastro.2020.04.032 sha: doc_id: 258930 cord_uid: 60yn4hg7 file: cache/cord-306325-9alfvda1.json key: cord-306325-9alfvda1 authors: Galmozzi, E.; Lampertico, P. title: Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks? date: 2014-02-04 journal: Aliment Pharmacol Ther DOI: 10.1111/apt.12615 sha: doc_id: 306325 cord_uid: 9alfvda1 file: cache/cord-286912-cww4ha3j.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: Resource temporarily unavailable key: cord-286912-cww4ha3j authors: Manolakis, Anastassios C; Christodoulidis, Gregory; Kapsoritakis, Andreas N; Georgoulias, Panagiotis; Tiaka, Elisavet K; Oikonomou, Kostas; Valotassiou, Varvara J; Potamianos, Spyros P title: α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease date: 2017-01-21 journal: World J Gastroenterol DOI: 10.3748/wjg.v23.i3.437 sha: doc_id: 286912 cord_uid: cww4ha3j file: cache/cord-307769-rjseio5s.json key: cord-307769-rjseio5s authors: Sim, Winnie H; Wagner, Josef; Cameron, Donald J; Catto‐Smith, Anthony G; Bishop, Ruth F; Kirkwood, Carl D title: Expression profile of genes involved in pathogenesis of pediatric Crohn's disease date: 2012-05-24 journal: J Gastroenterol Hepatol DOI: 10.1111/j.1440-1746.2011.06973.x sha: doc_id: 307769 cord_uid: rjseio5s file: cache/cord-310042-9z8rkzq8.json key: cord-310042-9z8rkzq8 authors: Aysha, Al‐Ani; Rentsch, Clarissa; Prentice, Ralley; Johnson, Doug; Bryant, Robert V.; Ward, Mark G.; Costello, Samuel P.; Lewindon, Peter; Ghaly, Simon; Connor, Susan J.; Begun, Jakob; Christensen, Britt title: Practical management of inflammatory bowel disease patients during the COVID‐19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty date: 2020-07-12 journal: Intern Med J DOI: 10.1111/imj.14889 sha: doc_id: 310042 cord_uid: 9z8rkzq8 file: cache/cord-023134-y665agnh.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: Resource temporarily unavailable key: cord-023134-y665agnh authors: nan title: Oral Research Communications of the 22(nd) ECVIM‐CA Congress date: 2012-11-20 journal: J Vet Intern Med DOI: 10.1111/jvim.12000 sha: doc_id: 23134 cord_uid: y665agnh file: cache/cord-311162-kbqh7beq.json key: cord-311162-kbqh7beq authors: Behzad, Catherine; Taheri, Hassan; Kashifard, Mehrdad title: Establishing Safe Out-of-Hospital Infusion Centers May Improve the Quality of Care in Patients With IBD During the COVID-19 Pandemic date: 2020-09-09 journal: Inflamm Bowel Dis DOI: 10.1093/ibd/izaa246 sha: doc_id: 311162 cord_uid: kbqh7beq file: cache/cord-269835-mz7i66qp.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-269835-mz7i66qp authors: Furfaro, Federica; Vuitton, Lucine; Fiorino, Gionata; Koch, Stephane; Allocca, Mariangela; Gilardi, Daniela; Zilli, Alessandra; D’Amico, Ferdinando; Radice, Simona; Chevaux, Jean-Baptiste; Schaefer, Marion; Chaussade, Stanislas; Danese, Silvio; Peyrin-Biroulet, Laurent title: SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience date: 2020-06-11 journal: Nat Rev Gastroenterol Hepatol DOI: 10.1038/s41575-020-0319-3 sha: doc_id: 269835 cord_uid: mz7i66qp file: cache/cord-021852-o0k2r0yo.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-021852-o0k2r0yo authors: Simpson, Kenneth W. title: The Role of the Microbiota in Feline Inflammatory Bowel Disease date: 2015-12-04 journal: August's Consultations in Feline Internal Medicine, Volume 7 DOI: 10.1016/b978-0-323-22652-3.00010-4 sha: doc_id: 21852 cord_uid: o0k2r0yo file: cache/cord-311804-39mu0tdr.json key: cord-311804-39mu0tdr authors: Zingone, Fabiana; Buda, Andrea; Savarino, Edoardo Vincenzo title: Screening for Active COVID-19 Infection and Immunization Status Prior to Biologic Therapy in IBD Patients at the Time of the Pandemic Outbreak date: 2020-04-10 journal: Dig Liver Dis DOI: 10.1016/j.dld.2020.04.004 sha: doc_id: 311804 cord_uid: 39mu0tdr file: cache/cord-312663-hhd5f823.json key: cord-312663-hhd5f823 authors: Fiorino, Gionata; Allocca, Mariangela; Furfaro, Federica; Gilardi, Daniela; Zilli, Alessandra; Radice, Simona; Spinelli, Antonino; Danese, Silvio title: Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience date: 2020-03-24 journal: J Crohns Colitis DOI: 10.1093/ecco-jcc/jjaa058 sha: doc_id: 312663 cord_uid: hhd5f823 file: cache/cord-312374-gu9tq48n.json key: cord-312374-gu9tq48n authors: Martin Arranz, Eduardo; Suarez Ferrer, Cristina; García Ramírez, Laura; Rueda García, Jose Luis; Sánchez-Azofra, María; Poza Cordón, Joaquín; Noci, Jesus; Zabana, Yamile; Barreiro-de Acosta, Manuel; Martín-Arranz, María Dolores title: Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey date: 2020-06-04 journal: Inflamm Bowel Dis DOI: 10.1093/ibd/izaa142 sha: doc_id: 312374 cord_uid: gu9tq48n file: cache/cord-297768-tjqpiyp1.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: Resource temporarily unavailable key: cord-297768-tjqpiyp1 authors: Day, Alice S.; Wood, Jessica A.; Halmos, Emma P.; Bryant, Robert V. title: Practical guidance for dietary management of patients with inflammatory bowel disease during the SARS-CoV2 pandemic date: 2020-07-20 journal: J Acad Nutr Diet DOI: 10.1016/j.jand.2020.07.019 sha: doc_id: 297768 cord_uid: tjqpiyp1 file: cache/cord-306859-aqfgl9cm.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-306859-aqfgl9cm authors: Clough, Jennie N; Hill, Katie L; Duff, Alexa; Sharma, Esha; Ray, Shuvra; Mawdsley, Joel E; Anderson, Simon; Irving, Peter M; Samaan, Mark A title: Managing an IBD Infusion Unit During the COVID-19 Pandemic: Service Modifications and the Patient Perspective date: 2020-06-27 journal: Inflamm Bowel Dis DOI: 10.1093/ibd/izaa171 sha: doc_id: 306859 cord_uid: aqfgl9cm file: cache/cord-337204-14gxpeaf.json key: cord-337204-14gxpeaf authors: Piciucchi, Matteo; Sbrozzi-Vanni, Andrea; Rossi, Alice; Satriano, Alissa; Dell’Amico, Iginio; Francesco, Vincenzo De; Zullo, Angelo; Manta, Raffaele title: Preliminary considerations regarding the risk of COVID-19 and disease severity in chronic gastrointestinal conditions date: 2020-05-25 journal: Ann Gastroenterol DOI: 10.20524/aog.2020.0498 sha: doc_id: 337204 cord_uid: 14gxpeaf file: cache/cord-323553-bukm9m9q.json key: cord-323553-bukm9m9q authors: Song, Woo-Jin; Li, Qiang; Ryu, Min-Ok; Nam, Aryung; An, Ju-Hyun; Jung, Yun Chan; Ahn, Jin-Ok; Youn, Hwa-Young title: Canine adipose tissue-derived mesenchymal stem cells pre-treated with TNF-alpha enhance immunomodulatory effects in inflammatory bowel disease in mice date: 2019-08-31 journal: Research in Veterinary Science DOI: 10.1016/j.rvsc.2019.06.012 sha: doc_id: 323553 cord_uid: bukm9m9q file: cache/cord-317151-cxx5pcln.json key: cord-317151-cxx5pcln authors: Papa, Alfredo; Papa, Valerio; Lopetuso, Loris Riccardo; Gasbarrini, Antonio; Tursi, Antonio title: Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase date: 2020-10-24 journal: Therap Adv Gastroenterol DOI: 10.1177/1756284820968747 sha: doc_id: 317151 cord_uid: cxx5pcln file: cache/cord-307201-keec6fzo.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-307201-keec6fzo authors: Barberio, Brigida; Buda, Andrea; Savarino, Edoardo Vincenzo title: Should IBD Patients Be Tested for Active COVID-19 Prior Starting a Biological Treatment? date: 2020-08-30 journal: Gastroenterology DOI: 10.1053/j.gastro.2020.08.049 sha: doc_id: 307201 cord_uid: keec6fzo file: cache/cord-316354-pix0hmpj.json key: cord-316354-pix0hmpj authors: Kennedy, Nicholas A; Hansen, Richard; Younge, Lisa; Mawdsley, Joel; Beattie, R Mark; Din, Shahida; Lamb, Christopher A; Smith, Philip J; Selinger, Christian; Limdi, Jimmy; Iqbal, Tariq H; Lobo, Alan; Cooney, Rachel; Brain, Oliver; Gaya, Daniel R; Murray, Charles; Pollok, Richard; Kent, Alexandra; Raine, Tim; Bhala, Neeraj; Lindsay, James O; Irving, Peter M; Lees, Charlie W; Sebastian, Shaji title: Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic date: 2020-06-15 journal: Frontline Gastroenterol DOI: 10.1136/flgastro-2020-101520 sha: doc_id: 316354 cord_uid: pix0hmpj file: cache/cord-322957-clf8f90t.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: Resource temporarily unavailable key: cord-322957-clf8f90t authors: Crespo, Javier; Andrade, Raúl; Parras, Fernando Alberca de las; Balaguer, Francesc; Acosta, Manuel Barreiro-de; Bujanda, Luís; Gutiérrez, Ana; Jorquera, Francisco; Iglesias-García, Julio; Sánchez-Yagüe, Andrés; Calleja, José Luis title: Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG date: 2020-04-28 journal: nan DOI: 10.1016/j.gastre.2020.04.001 sha: doc_id: 322957 cord_uid: clf8f90t file: cache/cord-331703-4hwmajt3.json key: cord-331703-4hwmajt3 authors: Occhipinti, Vincenzo; Saibeni, Simone; Sampietro, Gianluca M.; Pastorelli, Luca title: Impact of COVID-19 outbreak on the management of patients with severe IBD: a domino effect date: 2020-05-12 journal: Gastroenterology DOI: 10.1053/j.gastro.2020.05.027 sha: doc_id: 331703 cord_uid: 4hwmajt3 file: cache/cord-343832-xg3swuzs.json key: cord-343832-xg3swuzs authors: Pugliese, Daniela; Papi, Claudio; Privitera, Giuseppe; Aratari, Annalisa; Festa, Stefano; Armuzzi, Alessandro title: The management of Inflammatory Bowel Diseases in the era of COVID-19 pandemic: when “non-urgent” does not mean “deferrable” date: 2020-06-18 journal: Dig Liver Dis DOI: 10.1016/j.dld.2020.05.053 sha: doc_id: 343832 cord_uid: xg3swuzs file: cache/cord-337896-mct29erg.json key: cord-337896-mct29erg authors: Kornbluth, Asher; Kissous-Hunt, Michele; George, James; Legnani, Peter title: Management of Inflammatory Bowel Disease and COVID-19 in New York City 2020: The Epicenter of IBD in the First Epicenter of the Global Pandemic date: 2020-09-03 journal: Inflamm Bowel Dis DOI: 10.1093/ibd/izaa212 sha: doc_id: 337896 cord_uid: mct29erg file: cache/cord-351566-z6onmkrn.json key: cord-351566-z6onmkrn authors: Bezzio, Cristina; Saibeni, Simone title: SEVERE IBD FLARES AND COVID-19: EXPAND THE GASTROENTEROLOGY-SURGERY TEAM TO INCLUDE AN INFECTIOUS DISEASE SPECIALIST date: 2020-06-16 journal: Gastroenterology DOI: 10.1053/j.gastro.2020.05.082 sha: doc_id: 351566 cord_uid: z6onmkrn file: cache/cord-349500-603v8lfb.json key: cord-349500-603v8lfb authors: Neurath, Markus F title: Covid-19 and immunomodulation in IBD date: 2020-04-16 journal: Gut DOI: 10.1136/gutjnl-2020-321269 sha: doc_id: 349500 cord_uid: 603v8lfb file: cache/cord-303942-77nbi3ws.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: Resource temporarily unavailable /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-303942-77nbi3ws authors: Segal, Jonathan P; Quraishi, Mohammed Nabil; Bhala, Neeraj; Brookes, Matthew James title: Prevention of COVID-19 in patients with IBD date: 2020-05-20 journal: Lancet Gastroenterol Hepatol DOI: 10.1016/s2468-1253(20)30153-9 sha: doc_id: 303942 cord_uid: 77nbi3ws file: cache/cord-347607-ydbyonbg.json key: cord-347607-ydbyonbg authors: Spagnuolo, Rocco; Larussa, Tiziana; Iannelli, Chiara; Cosco, Cristina; Nisticò, Eleonora; Manduci, Elena; Bruno, Amalia; Boccuto, Luigi; Abenavoli, Ludovico; Luzza, Francesco; Doldo, Patrizia title: COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey date: 2020-08-13 journal: Medicina (Kaunas) DOI: 10.3390/medicina56080407 sha: doc_id: 347607 cord_uid: ydbyonbg file: cache/cord-345786-1o9nx7z9.json key: cord-345786-1o9nx7z9 authors: Bernstein, Charles N; Ng, Siew C; Banerjee, Rupa; Steinwurz, Flavio; Shen, Bo; Carbonnel, Franck; Hamid, Saeed; Sood, Ajit; Yamamoto-Furusho, Jesus K; Griffiths, Anne; Benchimol, Eric I; Travis, Simon; Lopes, Susana; Rubin, David T; Kaplan, Gilaad G; Armstrong, David; Gearry, Richard title: Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey date: 2020-08-14 journal: Inflamm Bowel Dis DOI: 10.1093/ibd/izaa202 sha: doc_id: 345786 cord_uid: 1o9nx7z9 file: cache/cord-022888-dnsdg04n.json key: cord-022888-dnsdg04n authors: nan title: Poster Sessions date: 2009-08-19 journal: Eur J Immunol DOI: 10.1002/eji.200990224 sha: doc_id: 22888 cord_uid: dnsdg04n file: cache/cord-023095-4dannjjm.json key: cord-023095-4dannjjm authors: nan title: Research Abstract Program of the 2011 ACVIM Forum Denver, Colorado, June 15–18, 2011 date: 2011-05-03 journal: J Vet Intern Med DOI: 10.1111/j.1939-1676.2011.0726.x sha: doc_id: 23095 cord_uid: 4dannjjm file: cache/cord-014527-nvzfpntu.json /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes /data-disk/reader-compute/reader-cord/bin/json2txt-carrel.sh: fork: retry: No child processes key: cord-014527-nvzfpntu authors: nan title: Research Communications of the 25th ECVIM‐CA Congress date: 2015-11-09 journal: J Vet Intern Med DOI: 10.1111/jvim.13647 sha: doc_id: 14527 cord_uid: nvzfpntu Reading metadata file and updating bibliogrpahics === updating bibliographic database Building study carrel named keyword-ibd-cord parallel: Warning: Only enough available processes to run 15 jobs in parallel. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf parallel: Warning: or /proc/sys/kernel/pid_max may help. parallel: Warning: Only enough available processes to run 12 jobs in parallel. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf parallel: Warning: or /proc/sys/kernel/pid_max may help. parallel: Warning: Only enough available processes to run 13 jobs in parallel. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf parallel: Warning: or /proc/sys/kernel/pid_max may help. parallel: Warning: Only enough available processes to run 17 jobs in parallel. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf parallel: Warning: or /proc/sys/kernel/pid_max may help. parallel: Warning: Only enough available processes to run 30 jobs in parallel. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf parallel: Warning: or /proc/sys/kernel/pid_max may help. parallel: Warning: No more processes: Decreasing number of running jobs to 11. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf may help. parallel: Warning: No more processes: Decreasing number of running jobs to 16. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf may help. parallel: Warning: No more processes: Decreasing number of running jobs to 14. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf may help. parallel: Warning: No more processes: Decreasing number of running jobs to 29. parallel: Warning: Raising ulimit -u or /etc/security/limits.conf may help. /data-disk/reader-compute/reader-cord/bin/txt2urls.sh: fork: retry: No child processes /data-disk/reader-compute/reader-cord/bin/cordpos2carrel.sh: fork: retry: No child processes /data-disk/reader-compute/reader-cord/bin/txt2urls.sh: fork: retry: Resource temporarily unavailable /data-disk/reader-compute/reader-cord/bin/cordent2carrel.sh: fork: retry: No child processes /data-disk/reader-compute/reader-cord/bin/txt2urls.sh: fork: retry: Resource temporarily unavailable === file2bib.sh === id: cord-258066-ncuegrq7 author: nan title: Inflammatory Bowel Disease date: 2013-12-31 pages: extension: .txt txt: ./txt/cord-258066-ncuegrq7.txt cache: ./cache/cord-258066-ncuegrq7.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 1 resourceName b'cord-258066-ncuegrq7.txt' === file2bib.sh === id: cord-256143-9u5a0jqz author: Grassia, Roberto title: Inflammatory Bowel Diseases and Biological Treatment in SARS-CoV-2 Era. Why Not? date: 2020-05-09 pages: extension: .txt txt: ./txt/cord-256143-9u5a0jqz.txt cache: ./cache/cord-256143-9u5a0jqz.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-256143-9u5a0jqz.txt' === file2bib.sh === id: cord-253001-xmcwuuk4 author: Papa, Alfredo title: Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease date: 2020-08-19 pages: extension: .txt txt: ./txt/cord-253001-xmcwuuk4.txt cache: ./cache/cord-253001-xmcwuuk4.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-253001-xmcwuuk4.txt' === file2bib.sh === id: cord-013370-gktnz644 author: Abreu, Maria T title: Providing Guidance During a Global Viral Pandemic for the Care of Patients With Inflammatory Bowel Disease date: 2020-10-21 pages: extension: .txt txt: ./txt/cord-013370-gktnz644.txt cache: ./cache/cord-013370-gktnz644.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-013370-gktnz644.txt' === file2bib.sh === id: cord-259585-mjtxiu0t author: Occhipinti, Vincenzo title: Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a “Red Zone” Area in Northern Italy date: 2020-04-21 pages: extension: .txt txt: ./txt/cord-259585-mjtxiu0t.txt cache: ./cache/cord-259585-mjtxiu0t.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-259585-mjtxiu0t.txt' === file2bib.sh === id: cord-026792-jsqa4pmu author: Samanta, Jayanta title: 2019 Novel Coronavirus Infection: Gastrointestinal Manifestations date: 2020-05-16 pages: extension: .txt txt: ./txt/cord-026792-jsqa4pmu.txt cache: ./cache/cord-026792-jsqa4pmu.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-026792-jsqa4pmu.txt' === file2bib.sh === id: cord-267260-8l831mre author: Brenner, Erica J. title: Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry date: 2020-05-18 pages: extension: .txt txt: ./txt/cord-267260-8l831mre.txt cache: ./cache/cord-267260-8l831mre.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-267260-8l831mre.txt' === file2bib.sh === id: cord-027386-23exaaik author: Rao, Vishwas title: A Machine-Learning-Based Importance Sampling Method to Compute Rare Event Probabilities date: 2020-05-25 pages: extension: .txt txt: ./txt/cord-027386-23exaaik.txt cache: ./cache/cord-027386-23exaaik.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-027386-23exaaik.txt' === file2bib.sh === id: cord-276267-77903fld author: Al‐Ani, Aysha H. title: Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient date: 2020-05-26 pages: extension: .txt txt: ./txt/cord-276267-77903fld.txt cache: ./cache/cord-276267-77903fld.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-276267-77903fld.txt' === file2bib.sh === id: cord-281275-i9920nvm author: Schlabitz, Franziska title: Inflammatory Bowel Disease and COVID-19—“Preventive” Sick Certificates as a Frequent Coping Strategy in the Face of the Pandemic date: 2020-06-12 pages: extension: .txt txt: ./txt/cord-281275-i9920nvm.txt cache: ./cache/cord-281275-i9920nvm.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-281275-i9920nvm.txt' === file2bib.sh === id: cord-031937-qhlatg84 author: Verma, Anukriti title: Elucidating potential molecular signatures through host-microbe interactions for reactive arthritis and inflammatory bowel disease using combinatorial approach date: 2020-09-15 pages: extension: .txt txt: ./txt/cord-031937-qhlatg84.txt cache: ./cache/cord-031937-qhlatg84.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-031937-qhlatg84.txt' === file2bib.sh === id: cord-266392-bayabroa author: Brenner, Erica J. title: BENIGN EVOLUTION OF SARS-CoV2 INFECTIONS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM TWO INTERNATIONAL DATABASES date: 2020-10-12 pages: extension: .txt txt: ./txt/cord-266392-bayabroa.txt cache: ./cache/cord-266392-bayabroa.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-266392-bayabroa.txt' === file2bib.sh === id: cord-287885-1jwwmoys author: D'Amico, Ferdinando title: Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey date: 2020-05-13 pages: extension: .txt txt: ./txt/cord-287885-1jwwmoys.txt cache: ./cache/cord-287885-1jwwmoys.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-287885-1jwwmoys.txt' === file2bib.sh === id: cord-263419-qeo6qn0d author: Fiorino, Gionata title: Protecting patients with IBD during the COVID-19 pandemic date: 2020-05-20 pages: extension: .txt txt: ./txt/cord-263419-qeo6qn0d.txt cache: ./cache/cord-263419-qeo6qn0d.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-263419-qeo6qn0d.txt' === file2bib.sh === id: cord-017342-qsfykh1k author: Nedelsky, Natalia B. title: Inflammatory Bowel Disease at the Intersection of Autophagy and Immunity: Insights from Human Genetics date: 2013-06-21 pages: extension: .txt txt: ./txt/cord-017342-qsfykh1k.txt cache: ./cache/cord-017342-qsfykh1k.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-017342-qsfykh1k.txt' === file2bib.sh === id: cord-285820-g8b7u3yf author: Taxonera, Carlos title: Innovation in IBD Care During the COVID-19 Pandemic: Results of a Cross-Sectional Survey on Patient-Reported Experience Measures date: 2020-08-19 pages: extension: .txt txt: ./txt/cord-285820-g8b7u3yf.txt cache: ./cache/cord-285820-g8b7u3yf.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-285820-g8b7u3yf.txt' === file2bib.sh === id: cord-283279-1qcdnd1y author: Barberio, Brigida title: The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients During COVID-19 Pandemic: Is It Really a Problem? date: 2020-07-17 pages: extension: .txt txt: ./txt/cord-283279-1qcdnd1y.txt cache: ./cache/cord-283279-1qcdnd1y.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 1 resourceName b'cord-283279-1qcdnd1y.txt' === file2bib.sh === id: cord-261029-befymalm author: Sultan, Keith title: Review of inflammatory bowel disease and COVID-19 date: 2020-10-07 pages: extension: .txt txt: ./txt/cord-261029-befymalm.txt cache: ./cache/cord-261029-befymalm.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-261029-befymalm.txt' === file2bib.sh === id: cord-275447-nx45kwn6 author: Ehrenpreis, Eli D. title: Rapid Review: Nonsteroidal Anti-inflammatory Agents and Aminosalicylates in COVID-19 Infections date: 2020-06-10 pages: extension: .txt txt: ./txt/cord-275447-nx45kwn6.txt cache: ./cache/cord-275447-nx45kwn6.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-275447-nx45kwn6.txt' === file2bib.sh === id: cord-288014-rrr4x755 author: Wang, Hong-Gang title: Excessive anxiety in IBD patients is unnecessary for COVID-19 date: 2020-05-12 pages: extension: .txt txt: ./txt/cord-288014-rrr4x755.txt cache: ./cache/cord-288014-rrr4x755.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-288014-rrr4x755.txt' === file2bib.sh === id: cord-290750-85731og8 author: Danese, Silvio title: Management of IBD during the COVID-19 outbreak: resetting clinical priorities date: 2020-03-25 pages: extension: .txt txt: ./txt/cord-290750-85731og8.txt cache: ./cache/cord-290750-85731og8.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-290750-85731og8.txt' === file2bib.sh === id: cord-295066-76se8mxq author: Botti, Fiorenzo title: URGENT SURGERY FOR INFLAMMATORY BOWEL DISEASES DURING THE COVID-19 OUTBREAK IN A HIGH INCIDENCE AREA - EXPERIENCE FROM A HIGH-VOLUME CENTRE date: 2020-08-31 pages: extension: .txt txt: ./txt/cord-295066-76se8mxq.txt cache: ./cache/cord-295066-76se8mxq.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 1 resourceName b'cord-295066-76se8mxq.txt' === file2bib.sh === id: cord-284234-9cd2v6bt author: Sebastian, S title: Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD date: 2020-06-10 pages: extension: .txt txt: ./txt/cord-284234-9cd2v6bt.txt cache: ./cache/cord-284234-9cd2v6bt.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-284234-9cd2v6bt.txt' === file2bib.sh === id: cord-300963-1n1f8mf2 author: Gajendran, Mahesh title: Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned date: 2020-10-12 pages: extension: .txt txt: ./txt/cord-300963-1n1f8mf2.txt cache: ./cache/cord-300963-1n1f8mf2.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-300963-1n1f8mf2.txt' === file2bib.sh === id: cord-275199-y7b12vml author: Suárez-Fariñas, Mayte title: Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease date: 2020-09-25 pages: extension: .txt txt: ./txt/cord-275199-y7b12vml.txt cache: ./cache/cord-275199-y7b12vml.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-275199-y7b12vml.txt' === file2bib.sh === id: cord-032753-icteg34y author: Namai, Fu title: Microbial therapeutics for acute colitis based on genetically modified Lactococcus lactis hypersecreting IL-1Ra in mice date: 2020-09-28 pages: extension: .txt txt: ./txt/cord-032753-icteg34y.txt cache: ./cache/cord-032753-icteg34y.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-032753-icteg34y.txt' === file2bib.sh === id: cord-302717-hn3airxq author: Bayoumy, Ahmed B. title: Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom date: 2020-09-11 pages: extension: .txt txt: ./txt/cord-302717-hn3airxq.txt cache: ./cache/cord-302717-hn3airxq.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-302717-hn3airxq.txt' === file2bib.sh === id: cord-288439-srzysoqy author: Segal, Jonathan P. title: Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease date: 2020-09-03 pages: extension: .txt txt: ./txt/cord-288439-srzysoqy.txt cache: ./cache/cord-288439-srzysoqy.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-288439-srzysoqy.txt' === file2bib.sh === id: cord-306760-05my504t author: Turner, Dan title: Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition date: 2020-03-31 pages: extension: .txt txt: ./txt/cord-306760-05my504t.txt cache: ./cache/cord-306760-05my504t.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-306760-05my504t.txt' === file2bib.sh === id: cord-269390-4yn8c34i author: Rimondi, Alessandro title: Fogging IBD Management: An Unusual Case of IBD Flare-up During the COVID-19 Outbreak date: 2020-07-28 pages: extension: .txt txt: ./txt/cord-269390-4yn8c34i.txt cache: ./cache/cord-269390-4yn8c34i.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 1 resourceName b'cord-269390-4yn8c34i.txt' === file2bib.sh === id: cord-285426-iyl12ber author: Ghavami, Shaghayegh Baradaran title: IBD Patients Could Be Silent Carriers for Novel Coronavirus and Less Prone to its Severe Adverse Events: True or False? date: 2020-09-08 pages: extension: .txt txt: ./txt/cord-285426-iyl12ber.txt cache: ./cache/cord-285426-iyl12ber.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-285426-iyl12ber.txt' === file2bib.sh === id: cord-280023-r3qgdgeu author: Dipasquale, Valeria title: Challenges in paediatric inflammatory bowel diseases in the COVID-19 time date: 2020-04-08 pages: extension: .txt txt: ./txt/cord-280023-r3qgdgeu.txt cache: ./cache/cord-280023-r3qgdgeu.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-280023-r3qgdgeu.txt' === file2bib.sh === id: cord-285238-bpk3xl8x author: Dong, Xiuli title: Intestinal and Peripheral Fibrinogen-Like Protein 2 Expression in Inflammatory Bowel Disease date: 2013-11-28 pages: extension: .txt txt: ./txt/cord-285238-bpk3xl8x.txt cache: ./cache/cord-285238-bpk3xl8x.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-285238-bpk3xl8x.txt' === file2bib.sh === id: cord-258930-60yn4hg7 author: D’Amico, Ferdinando title: Inflammatory bowel diseases and COVID-19: the invisible enemy date: 2020-04-16 pages: extension: .txt txt: ./txt/cord-258930-60yn4hg7.txt cache: ./cache/cord-258930-60yn4hg7.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-258930-60yn4hg7.txt' === file2bib.sh === id: cord-266648-962r0vm8 author: Grossberg, Laurie B title: Review of Societal Recommendations Regarding Management of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic date: 2020-07-03 pages: extension: .txt txt: ./txt/cord-266648-962r0vm8.txt cache: ./cache/cord-266648-962r0vm8.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-266648-962r0vm8.txt' === file2bib.sh === id: cord-255930-2bobmkvu author: Kaplan, Gilaad G. title: The four epidemiological stages in the global evolution of inflammatory bowel disease date: 2020-10-08 pages: extension: .txt txt: ./txt/cord-255930-2bobmkvu.txt cache: ./cache/cord-255930-2bobmkvu.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-255930-2bobmkvu.txt' === file2bib.sh === id: cord-306325-9alfvda1 author: Galmozzi, E. title: Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks? date: 2014-02-04 pages: extension: .txt txt: ./txt/cord-306325-9alfvda1.txt cache: ./cache/cord-306325-9alfvda1.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 1 resourceName b'cord-306325-9alfvda1.txt' === file2bib.sh === id: cord-310042-9z8rkzq8 author: Aysha, Al‐Ani title: Practical management of inflammatory bowel disease patients during the COVID‐19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty date: 2020-07-12 pages: extension: .txt txt: ./txt/cord-310042-9z8rkzq8.txt cache: ./cache/cord-310042-9z8rkzq8.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-310042-9z8rkzq8.txt' === file2bib.sh === id: cord-311162-kbqh7beq author: Behzad, Catherine title: Establishing Safe Out-of-Hospital Infusion Centers May Improve the Quality of Care in Patients With IBD During the COVID-19 Pandemic date: 2020-09-09 pages: extension: .txt txt: ./txt/cord-311162-kbqh7beq.txt cache: ./cache/cord-311162-kbqh7beq.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 1 resourceName b'cord-311162-kbqh7beq.txt' === file2bib.sh === id: cord-307769-rjseio5s author: Sim, Winnie H title: Expression profile of genes involved in pathogenesis of pediatric Crohn's disease date: 2012-05-24 pages: extension: .txt txt: ./txt/cord-307769-rjseio5s.txt cache: ./cache/cord-307769-rjseio5s.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-307769-rjseio5s.txt' === file2bib.sh === id: cord-286912-cww4ha3j author: Manolakis, Anastassios C title: α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease date: 2017-01-21 pages: extension: .txt txt: ./txt/cord-286912-cww4ha3j.txt cache: ./cache/cord-286912-cww4ha3j.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-286912-cww4ha3j.txt' === file2bib.sh === id: cord-311804-39mu0tdr author: Zingone, Fabiana title: Screening for Active COVID-19 Infection and Immunization Status Prior to Biologic Therapy in IBD Patients at the Time of the Pandemic Outbreak date: 2020-04-10 pages: extension: .txt txt: ./txt/cord-311804-39mu0tdr.txt cache: ./cache/cord-311804-39mu0tdr.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-311804-39mu0tdr.txt' === file2bib.sh === id: cord-312663-hhd5f823 author: Fiorino, Gionata title: Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience date: 2020-03-24 pages: extension: .txt txt: ./txt/cord-312663-hhd5f823.txt cache: ./cache/cord-312663-hhd5f823.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-312663-hhd5f823.txt' === file2bib.sh === id: cord-312374-gu9tq48n author: Martin Arranz, Eduardo title: Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey date: 2020-06-04 pages: extension: .txt txt: ./txt/cord-312374-gu9tq48n.txt cache: ./cache/cord-312374-gu9tq48n.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-312374-gu9tq48n.txt' === file2bib.sh === id: cord-021852-o0k2r0yo author: Simpson, Kenneth W. title: The Role of the Microbiota in Feline Inflammatory Bowel Disease date: 2015-12-04 pages: extension: .txt txt: ./txt/cord-021852-o0k2r0yo.txt cache: ./cache/cord-021852-o0k2r0yo.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-021852-o0k2r0yo.txt' === file2bib.sh === id: cord-297768-tjqpiyp1 author: Day, Alice S. title: Practical guidance for dietary management of patients with inflammatory bowel disease during the SARS-CoV2 pandemic date: 2020-07-20 pages: extension: .txt txt: ./txt/cord-297768-tjqpiyp1.txt cache: ./cache/cord-297768-tjqpiyp1.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-297768-tjqpiyp1.txt' === file2bib.sh === id: cord-306859-aqfgl9cm author: Clough, Jennie N title: Managing an IBD Infusion Unit During the COVID-19 Pandemic: Service Modifications and the Patient Perspective date: 2020-06-27 pages: extension: .txt txt: ./txt/cord-306859-aqfgl9cm.txt cache: ./cache/cord-306859-aqfgl9cm.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 10 resourceName b'cord-306859-aqfgl9cm.txt' === file2bib.sh === id: cord-269835-mz7i66qp author: Furfaro, Federica title: SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience date: 2020-06-11 pages: extension: .txt txt: ./txt/cord-269835-mz7i66qp.txt cache: ./cache/cord-269835-mz7i66qp.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-269835-mz7i66qp.txt' === file2bib.sh === id: cord-337204-14gxpeaf author: Piciucchi, Matteo title: Preliminary considerations regarding the risk of COVID-19 and disease severity in chronic gastrointestinal conditions date: 2020-05-25 pages: extension: .txt txt: ./txt/cord-337204-14gxpeaf.txt cache: ./cache/cord-337204-14gxpeaf.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-337204-14gxpeaf.txt' === file2bib.sh === id: cord-323553-bukm9m9q author: Song, Woo-Jin title: Canine adipose tissue-derived mesenchymal stem cells pre-treated with TNF-alpha enhance immunomodulatory effects in inflammatory bowel disease in mice date: 2019-08-31 pages: extension: .txt txt: ./txt/cord-323553-bukm9m9q.txt cache: ./cache/cord-323553-bukm9m9q.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-323553-bukm9m9q.txt' === file2bib.sh === id: cord-307201-keec6fzo author: Barberio, Brigida title: Should IBD Patients Be Tested for Active COVID-19 Prior Starting a Biological Treatment? date: 2020-08-30 pages: extension: .txt txt: ./txt/cord-307201-keec6fzo.txt cache: ./cache/cord-307201-keec6fzo.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-307201-keec6fzo.txt' === file2bib.sh === id: cord-331703-4hwmajt3 author: Occhipinti, Vincenzo title: Impact of COVID-19 outbreak on the management of patients with severe IBD: a domino effect date: 2020-05-12 pages: extension: .txt txt: ./txt/cord-331703-4hwmajt3.txt cache: ./cache/cord-331703-4hwmajt3.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-331703-4hwmajt3.txt' === file2bib.sh === id: cord-317151-cxx5pcln author: Papa, Alfredo title: Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase date: 2020-10-24 pages: extension: .txt txt: ./txt/cord-317151-cxx5pcln.txt cache: ./cache/cord-317151-cxx5pcln.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-317151-cxx5pcln.txt' === file2bib.sh === id: cord-351566-z6onmkrn author: Bezzio, Cristina title: SEVERE IBD FLARES AND COVID-19: EXPAND THE GASTROENTEROLOGY-SURGERY TEAM TO INCLUDE AN INFECTIOUS DISEASE SPECIALIST date: 2020-06-16 pages: extension: .txt txt: ./txt/cord-351566-z6onmkrn.txt cache: ./cache/cord-351566-z6onmkrn.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 1 resourceName b'cord-351566-z6onmkrn.txt' === file2bib.sh === id: cord-343832-xg3swuzs author: Pugliese, Daniela title: The management of Inflammatory Bowel Diseases in the era of COVID-19 pandemic: when “non-urgent” does not mean “deferrable” date: 2020-06-18 pages: extension: .txt txt: ./txt/cord-343832-xg3swuzs.txt cache: ./cache/cord-343832-xg3swuzs.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 1 resourceName b'cord-343832-xg3swuzs.txt' === file2bib.sh === id: cord-316354-pix0hmpj author: Kennedy, Nicholas A title: Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic date: 2020-06-15 pages: extension: .txt txt: ./txt/cord-316354-pix0hmpj.txt cache: ./cache/cord-316354-pix0hmpj.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-316354-pix0hmpj.txt' === file2bib.sh === id: cord-322957-clf8f90t author: Crespo, Javier title: Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG date: 2020-04-28 pages: extension: .txt txt: ./txt/cord-322957-clf8f90t.txt cache: ./cache/cord-322957-clf8f90t.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-322957-clf8f90t.txt' === file2bib.sh === id: cord-337896-mct29erg author: Kornbluth, Asher title: Management of Inflammatory Bowel Disease and COVID-19 in New York City 2020: The Epicenter of IBD in the First Epicenter of the Global Pandemic date: 2020-09-03 pages: extension: .txt txt: ./txt/cord-337896-mct29erg.txt cache: ./cache/cord-337896-mct29erg.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-337896-mct29erg.txt' === file2bib.sh === id: cord-303942-77nbi3ws author: Segal, Jonathan P title: Prevention of COVID-19 in patients with IBD date: 2020-05-20 pages: extension: .txt txt: ./txt/cord-303942-77nbi3ws.txt cache: ./cache/cord-303942-77nbi3ws.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 1 resourceName b'cord-303942-77nbi3ws.txt' === file2bib.sh === id: cord-349500-603v8lfb author: Neurath, Markus F title: Covid-19 and immunomodulation in IBD date: 2020-04-16 pages: extension: .txt txt: ./txt/cord-349500-603v8lfb.txt cache: ./cache/cord-349500-603v8lfb.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-349500-603v8lfb.txt' === file2bib.sh === id: cord-347607-ydbyonbg author: Spagnuolo, Rocco title: COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey date: 2020-08-13 pages: extension: .txt txt: ./txt/cord-347607-ydbyonbg.txt cache: ./cache/cord-347607-ydbyonbg.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-347607-ydbyonbg.txt' === file2bib.sh === id: cord-345786-1o9nx7z9 author: Bernstein, Charles N title: Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey date: 2020-08-14 pages: extension: .txt txt: ./txt/cord-345786-1o9nx7z9.txt cache: ./cache/cord-345786-1o9nx7z9.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-345786-1o9nx7z9.txt' === file2bib.sh === id: cord-023134-y665agnh author: nan title: Oral Research Communications of the 22(nd) ECVIM‐CA Congress date: 2012-11-20 pages: extension: .txt txt: ./txt/cord-023134-y665agnh.txt cache: ./cache/cord-023134-y665agnh.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 5 resourceName b'cord-023134-y665agnh.txt' === file2bib.sh === id: cord-026025-xqj877en author: PETRAS, ROBERT E. title: Large Intestine (Colon) date: 2009-10-30 pages: extension: .txt txt: ./txt/cord-026025-xqj877en.txt cache: ./cache/cord-026025-xqj877en.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 6 resourceName b'cord-026025-xqj877en.txt' === file2bib.sh === id: cord-014516-r59usk02 author: nan title: Research Communications of the 24th ECVIM‐CA Congress date: 2015-01-10 pages: extension: .txt txt: ./txt/cord-014516-r59usk02.txt cache: ./cache/cord-014516-r59usk02.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 6 resourceName b'cord-014516-r59usk02.txt' === file2bib.sh === id: cord-022555-a7ie82fs author: nan title: Digestive System, Liver, and Abdominal Cavity date: 2011-12-05 pages: extension: .txt txt: ./txt/cord-022555-a7ie82fs.txt cache: ./cache/cord-022555-a7ie82fs.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 6 resourceName b'cord-022555-a7ie82fs.txt' === file2bib.sh === id: cord-014527-nvzfpntu author: nan title: Research Communications of the 25th ECVIM‐CA Congress date: 2015-11-09 pages: extension: .txt txt: ./txt/cord-014527-nvzfpntu.txt cache: ./cache/cord-014527-nvzfpntu.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 6 resourceName b'cord-014527-nvzfpntu.txt' === file2bib.sh === id: cord-023095-4dannjjm author: nan title: Research Abstract Program of the 2011 ACVIM Forum Denver, Colorado, June 15–18, 2011 date: 2011-05-03 pages: extension: .txt txt: ./txt/cord-023095-4dannjjm.txt cache: ./cache/cord-023095-4dannjjm.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 6 resourceName b'cord-023095-4dannjjm.txt' === file2bib.sh === id: cord-022888-dnsdg04n author: nan title: Poster Sessions date: 2009-08-19 pages: extension: .txt txt: ./txt/cord-022888-dnsdg04n.txt cache: ./cache/cord-022888-dnsdg04n.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 9 resourceName b'cord-022888-dnsdg04n.txt' Que is empty; done keyword-ibd-cord === reduce.pl bib === id = cord-017342-qsfykh1k author = Nedelsky, Natalia B. title = Inflammatory Bowel Disease at the Intersection of Autophagy and Immunity: Insights from Human Genetics date = 2013-06-21 pages = extension = .txt mime = text/plain words = 8796 sentences = 424 flesch = 36 summary = Although historically considered to be a relatively nonselective process of degradation of cytosolic contents, autophagy has recently been revealed to have several selective and immune-specific functions that are relevant to the maintenance of intestinal homeostasis, including xenophagy, mitophagy, antigen presentation, secretion, and inflammasome regulation. We summarize the basic molecular events underlying general and selective autophagy and present evidence suggesting possible pathogenic mechanisms revealed by studies of IBD-associated risk alleles of ATG16L1 and IRGM. As mentioned above, autophagy has been implicated in several immune-related processes that infl uence IBD pathogenesis, including xenophagy, mitophagy, antigen presentation, secretion and vesicular traffi cking, and cytokine-based regulation of infl ammasome activity. In epithelial cells, bacteria become ubiquitinated and targeted for autophagic degradation in a process that requires the CD-associated genes ATG16L1 and IRGM appears to have different effects on these functions depending on the cell type examined [ 42 , 67 ] . cache = ./cache/cord-017342-qsfykh1k.txt txt = ./txt/cord-017342-qsfykh1k.txt === reduce.pl bib === id = cord-013370-gktnz644 author = Abreu, Maria T title = Providing Guidance During a Global Viral Pandemic for the Care of Patients With Inflammatory Bowel Disease date = 2020-10-21 pages = extension = .txt mime = text/plain words = 1840 sentences = 83 flesch = 56 summary = We have partnered closely with the European Crohn's and Colitis Organisation because of our shared desire to provide the best guidance to patients with inflammatory bowel disease at a global level, as well as to the physicians that are caring for these patients. The process is called a RAND panel wherein the members of IOIBD, as well as other very knowledgeable practitioners of IBD, voted on a series of statements largely having to do with the risk of infection with the SARS-CoV-2 virus and the development of COVID-19 in patients who have IBD. We urge you to continue to check the IOIBD or the ECCO websites for the most up-to-date information, and we hope to keep updating the guidance in all of the various dimensions of IBD care. cache = ./cache/cord-013370-gktnz644.txt txt = ./txt/cord-013370-gktnz644.txt === reduce.pl bib === id = cord-256143-9u5a0jqz author = Grassia, Roberto title = Inflammatory Bowel Diseases and Biological Treatment in SARS-CoV-2 Era. Why Not? date = 2020-05-09 pages = extension = .txt mime = text/plain words = 535 sentences = 45 flesch = 56 summary = title: Inflammatory Bowel Diseases and Biological Treatment in SARS-CoV-2 Era. Why Not? 1 In this setting, the initial indication from the inflammatory bowel disease (IBD) center in Wuhan was to discontinue all biological and immunosuppressive treatments. 3 In an Italian observational study, among 522 IBD patients (89% adults), 16% under biological therapy, none was hospitalized for COVID-19. Further studies are needed to investigate if IBD patients under biological treatment could be protected against the COVID-19 pneumonia, whereas those under immunosuppressive therapy (ie, thiopurines) could remain at higher risk of developing the disease due to the different mechanism of action. Protection of 318 Inflammatory Bowel Disease Patients from the Outbreak and Rapid Spread of COVID-19 Infection in Wuhan Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? cache = ./cache/cord-256143-9u5a0jqz.txt txt = ./txt/cord-256143-9u5a0jqz.txt === reduce.pl bib === id = cord-259585-mjtxiu0t author = Occhipinti, Vincenzo title = Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a “Red Zone” Area in Northern Italy date = 2020-04-21 pages = extension = .txt mime = text/plain words = 2803 sentences = 122 flesch = 46 summary = Every possible effort was made to quickly increase the capacity of intensive care units (ICUs) to accommodate the alarming numbers of very sick CoViD-19 patients, including constructing new units in unused areas of the hospital or converting surgical rooms into ICUs. These drastic measures were implemented in a very short period of time, and although necessary to counteract the devastation brought about by the outbreak, they also posed tremendous challenges to the care of patients with GI conditions, including those with inflammatory bowel diseases (IBD). However, for patients on biologic therapies, we have implemented a mandatory phone call-in the day before any planned hospital visit to screen for possible CoViD-19 symptoms or contact with infected individuals and to reassure patients that all possible precautions are being taken by the IBD center to reduce the risk of infection. cache = ./cache/cord-259585-mjtxiu0t.txt txt = ./txt/cord-259585-mjtxiu0t.txt === reduce.pl bib === id = cord-026792-jsqa4pmu author = Samanta, Jayanta title = 2019 Novel Coronavirus Infection: Gastrointestinal Manifestations date = 2020-05-16 pages = extension = .txt mime = text/plain words = 3792 sentences = 218 flesch = 51 summary = The modern world is facing a major public health crisis due to novel corona virus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) which has caused a pandemic involving at least 210 countries. The extrapulmonary effects and modes of transmission gained attention when the first confirmed case of SARS-CoV-2 reported from the United States had gastrointestinal (GI) complaints of nausea and vomiting followed later by diarrhea and patient's fecal specimen tested positive on day 7 of illness. This review aims to comprehensively outline the GI manifestations of this virus, its potential to spread via the feco-oral route and its implications and an overview of management strategies for other GI diseases, such as inflammatory bowel disease (IBD) coexisting with coronavirus-19 disease (COVID-19) infection. cache = ./cache/cord-026792-jsqa4pmu.txt txt = ./txt/cord-026792-jsqa4pmu.txt === reduce.pl bib === id = cord-267260-8l831mre author = Brenner, Erica J. title = Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry date = 2020-05-18 pages = extension = .txt mime = text/plain words = 3136 sentences = 170 flesch = 43 summary = Risk factors for severe COVID-19 among IBD patients included increasing age (adjusted odds ratio [aOR] 1.04, 95% CI 1.01-1.02), ≥2 comorbidities (aOR 2.9, 95% CI 1.1-7.8), systemic corticosteroids (aOR 6.9, 95% CI 2.3-20.5), and sulfasalazine or 5-aminosalicylate use (aOR 3.1, 95% CI 1.3-7.7). To understand the impact of IBD on case fatality, we computed expected and observed deaths and age-standardized mortality ratios (SMR) utilizing published agestratified COVID-19 case fatality rates from China and Italy 2, 23 and publically available data from the U.S. 24, 25 Multivariable logistic regression estimated the independent effects of age, sex, disease (CD vs UC/IBD-U), disease activity, smoking, BMI ≥30, and number of comorbidities (0, 1, ≥2) on the primary outcome of severe COVID-19, defined as a composite of ICU admission, ventilator use, and/or death, consistent with existing COVID-19 literature. In our exploratory analyses, we found that TNF antagonist combination therapy, compared to monotherapy, was positively associated with the outcome of hospitalization or death (aOR 5.0, 95% CI 2.0-12.3), after adjusting for clinical and demographic variables and use of systemic corticosteroids and 5-ASA/sulfasalazine. cache = ./cache/cord-267260-8l831mre.txt txt = ./txt/cord-267260-8l831mre.txt === reduce.pl bib === id = cord-258066-ncuegrq7 author = nan title = Inflammatory Bowel Disease date = 2013-12-31 pages = extension = .txt mime = text/plain words = 621 sentences = 55 flesch = 46 summary = Inflammatory bowel disease (IBD) is a poorly defined and often incorrectly used term in ferrets and other small animals for a systemic inflammatory disease primarily involving the gastrointestinal tract. The umbrella term IBD used in ferrets and other small animals for a variety of gastrointestinal diseases is not the same disease that is seen in humans. • Ferrets are susceptible to several gastrointestinal inflammatory conditions that have erroneously been placed under the umbrella term of IBD. Endoscopic biopsies are often done early, after symptomatic medical therapy (see Acute General Treatment) has failed to control clinical signs. • It is not appropriate for a pathologist to issue a diagnosis of "inflammatory bowel disease." It is more appropriate to list the histologic findings, and to indicate that the changes could be "compatible with" a clinical diagnosis of that syndrome. • Chronic gastrointestinal inflammatory disease in ferrets is not always cured. Treatment of inflammatory bowel disease (IBD) in dogs and cats cache = ./cache/cord-258066-ncuegrq7.txt txt = ./txt/cord-258066-ncuegrq7.txt === reduce.pl bib === id = cord-027386-23exaaik author = Rao, Vishwas title = A Machine-Learning-Based Importance Sampling Method to Compute Rare Event Probabilities date = 2020-05-25 pages = extension = .txt mime = text/plain words = 4292 sentences = 303 flesch = 57 summary = title: A Machine-Learning-Based Importance Sampling Method to Compute Rare Event Probabilities We develop a novel computational method for evaluating the extreme excursion probabilities arising from random initialization of nonlinear dynamical systems. The method uses excursion probability theory to formulate a sequence of Bayesian inverse problems that, when solved, yields the biasing distribution. To alleviate the computational cost, we build machine-learning-based surrogates to solve the Bayesian inverse problems that give rise to the biasing distribution. The most commonly used method to determine the probability of rare and extreme events is Monte Carlo simulation (MCS). In this paper, we build on our recent algorithm [25] , which we used to construct an importance biasing distribution (IBD) to accelerate the computation of extreme event probabilities. IS, instead, uses problem-specific information to construct an IBD; computing the rare event probability using the IBD requires fewer samples. cache = ./cache/cord-027386-23exaaik.txt txt = ./txt/cord-027386-23exaaik.txt === reduce.pl bib === id = cord-026025-xqj877en author = PETRAS, ROBERT E. title = Large Intestine (Colon) date = 2009-10-30 pages = extension = .txt mime = text/plain words = 48309 sentences = 3034 flesch = 42 summary = 27, 28 These guidelines consider colonoscopic polypectomy definitive treatment for a patient with a malignant polyp if the following criteria are fulfilled: (1) the polyp is considered completely excised at endoscopy, (2) the specimen is properly processed by the pathology laboratory, (3) the cancer is not poorly differentiated, (4) no histologic evidence of vascular or lymphatic involvement exists, and (5) the resection margin is not involved by carcinoma. Pathologic features of colorectal cancer that suggest MSI/Lynch's syndrome include right-sided location, synchronous or metachronous large bowel cancers, large and bulky polypoid tumors with circumscribed pushing margins, tumors showing prominent lymphoid infiltrate, and cancers of poor differentiation (medullary or undifferentiated carcinoma) or mucinous and signet ring cell histologic pattern (Figs. [352] [353] [354] [355] The trauma-type histologic features can be seen in the solitary rectal ulcer syndrome, localized colitis cystica profunda, inflammatory cloacogenic polyp, the mucosa adjacent to orifices of colonic diverticula, 356 and inflammatory cap polyposis 357 and are frequent findings adjacent to neoplasia and in the vicinity of the ileocecal valve. cache = ./cache/cord-026025-xqj877en.txt txt = ./txt/cord-026025-xqj877en.txt === reduce.pl bib === id = cord-014516-r59usk02 author = nan title = Research Communications of the 24th ECVIM‐CA Congress date = 2015-01-10 pages = extension = .txt mime = text/plain words = 55041 sentences = 2919 flesch = 51 summary = Serum prolactin concentration measured in 22/23 dogs at time zero, 6 weeks and 6 months was 3.35 ng/ml (range, 1.4-6.36), 3.57 ng/ml (range, 1.87-7.39) and 3.92 ng/ml (range, 2.01-12.92) and did not differ significantly in either time period when compared with time zero (P = 0.99 and P = 0.52).Altogether, results of this study failed to demonstrate a significant role of thyroid supplementation on the majority of evaluated behavioural symptoms as well as neurohormonal status of hypothyroid dogs during 6 months of therapy. The aims of the present study were (1) to describe a clinical series of recent autochtonous cases and (2) to retrospectively assess Angiostrongylus vasorum qPCR in bronchoalveolar lavage fluid (BALF) samples, collected over the last 7 years from a larger series of dogs, healthy or with other respiratory conditions, in order to investigate the past prevalence of the disease in Belgium. cache = ./cache/cord-014516-r59usk02.txt txt = ./txt/cord-014516-r59usk02.txt === reduce.pl bib === id = cord-253001-xmcwuuk4 author = Papa, Alfredo title = Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease date = 2020-08-19 pages = extension = .txt mime = text/plain words = 1451 sentences = 79 flesch = 49 summary = A retrospective study from the United States including a large cohort of patients with IBD reported that the use of antitumor necrosis factor (TNF)-a agents or thiopurines was not associated with an increased risk of developing COVID-19 (9) . In the Surveillance Epidemiology of Coronavirus Under Research Exclusion-IBD database, we found evidence of greater prevalence of milder COVID-19 cases in patients treated with anti-TNF-a than that in patients undergoing steroid treatments (3) . Further support to this theory comes from the results of the Italian Group for the Study of Inflammatory Bowel Disease study, which reported a 60% reduction in mortality among patients receiving anti-TNF-a antibodies (although not statistically significant); however, corticosteroid use was associated, with a trend toward statistical significance, with COVID-19-related pneumonia (P 5 0.05) and death (P 5 0.064) (4). Furthermore, anti-TNF-a agents could achieve effective control of inflammatory mediators, which makeup the "cytokine storm" that occurs in severe COVID-19-related pneumonia, thereby mitigating the course of the disease. cache = ./cache/cord-253001-xmcwuuk4.txt txt = ./txt/cord-253001-xmcwuuk4.txt === reduce.pl bib === id = cord-031937-qhlatg84 author = Verma, Anukriti title = Elucidating potential molecular signatures through host-microbe interactions for reactive arthritis and inflammatory bowel disease using combinatorial approach date = 2020-09-15 pages = extension = .txt mime = text/plain words = 6760 sentences = 326 flesch = 31 summary = In-silico analysis involving text mining, metabolic network reconstruction, simulation, filtering, host-microbe interaction, docking and molecular mimicry studies results in robust drug target/s and biomarker/s for co-evolved IBD and ReA. The contributions of the microorganisms in the co-evolved IBD and ReA as part of the disease network was created through the interactive maps of the essential host interaction proteins (verified using literature survey) and the information processed through gene expression data analysis 64 . The pathways of the above host interacting proteins were found out using KEGG database that provides ontologies for proteins related to biological processes 67 www.nature.com/scientificreports/ Subsequently, the role of drugs or inhibitors used to suppress the effect of IBD and ReA such as indomethacin, prednisone, ciprofloxacin, sulfasalazine, azathioprine, methotrexate and hydroxychloroquine was scored in the disease network through their docking studies against the potential targets (both host as well microbial targets) as per published methodologies 68, 69 . cache = ./cache/cord-031937-qhlatg84.txt txt = ./txt/cord-031937-qhlatg84.txt === reduce.pl bib === id = cord-276267-77903fld author = Al‐Ani, Aysha H. title = Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient date = 2020-05-26 pages = extension = .txt mime = text/plain words = 5481 sentences = 355 flesch = 42 summary = 6 Consequently, there is a concern that IBD patients are at greater risk of developing COVID-19 and at increased risk of progressing to a more severe clinical course or even death compared to the general population. 18 Furthermore, there is a recent case report of a possible SARS-CoV-2 gastrointestinal infection causing acute haemorrhagic colitis and signalling COVID-19 disease. Clinical assessment of risk factors for infection in inflammatory bowel disease patients Protection of 318 inflammatory bowel disease patients from the outbreak and rapid spread of COVID-19 infection in Wuhan Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials cache = ./cache/cord-276267-77903fld.txt txt = ./txt/cord-276267-77903fld.txt === reduce.pl bib === id = cord-281275-i9920nvm author = Schlabitz, Franziska title = Inflammatory Bowel Disease and COVID-19—“Preventive” Sick Certificates as a Frequent Coping Strategy in the Face of the Pandemic date = 2020-06-12 pages = extension = .txt mime = text/plain words = 629 sentences = 40 flesch = 52 summary = title: Inflammatory Bowel Disease and COVID-19—"Preventive" Sick Certificates as a Frequent Coping Strategy in the Face of the Pandemic 1 The authors report their experiences and challenges in managing patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic. We complement this important information by presenting a survey conducted among German patients with IBD regarding their personal evaluation of their work-related risk of contracting SARS-CoV-2. However, during the COVID-19 pandemic, the survey participants have used this coping strategy frequently. Clearly, the ability to work is very important to most patients with IBD. Therefore, straightforward recommendations stating clearly who is at risk and who should avoid which type of work are very important for managing the daily life of our patients. Niels Teich: acquisition of data, analysis, critical revision of the manuscript for important intellectual content. Challenges in the care of IBD patients during the CoViD-19 pandemic: report from a "Red Zone" area in Northern Italy cache = ./cache/cord-281275-i9920nvm.txt txt = ./txt/cord-281275-i9920nvm.txt === reduce.pl bib === id = cord-285820-g8b7u3yf author = Taxonera, Carlos title = Innovation in IBD Care During the COVID-19 Pandemic: Results of a Cross-Sectional Survey on Patient-Reported Experience Measures date = 2020-08-19 pages = extension = .txt mime = text/plain words = 2788 sentences = 143 flesch = 45 summary = We evaluated the feasibility of a strategy based on the conversion of face-to-face visits to telephone consultations to manage IBD outpatients during the COVID-19 pandemic. 8, 9 The aim of this study was to assess the feasibility of a strategy based on the conversion of face-to-face visits to remote telephone consultations to improve care of patients with IBD during the COVID-19 pandemic, and to evaluate satisfaction of patients with telephone consultations. 10 Here, we report the outcomes and patient perception of a strategy based on the conversion of face-to-face visits to remote telephone consultations to improve care of outpatients with IBD during the COVID-19 pandemic. Results of a global telemedicine survey among gastroenterologists by the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) demonstrated the shift from face-to face clinics to remote telemedicine during COVID-19, with telephone consultations increasing the most, currently accounting for over half of all IBD visits. cache = ./cache/cord-285820-g8b7u3yf.txt txt = ./txt/cord-285820-g8b7u3yf.txt === reduce.pl bib === id = cord-266392-bayabroa author = Brenner, Erica J. title = BENIGN EVOLUTION OF SARS-CoV2 INFECTIONS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM TWO INTERNATIONAL DATABASES date = 2020-10-12 pages = extension = .txt mime = text/plain words = 1244 sentences = 82 flesch = 46 summary = 2 Since highest ACE2 expression is in the terminal ileum and colon, further upregulated during inflammation, and many COVID-19 patients experience gastrointestinal symptoms, longitudinal data are necessary determine whether inflammatory bowel diseases (IBD) patients are at risk for severe or complicated COVID-19. A recent analysis in IBD patients from the SECURE-IBD registry revealed older age, steroid medication and comorbidities as risk factors for severe evolution, while the same study showed that the 29 IBD patients less 20 years had only mild disease courses. Factors associated with hospitalization included comorbid conditions other than IBD (50% hospitalized vs 12% not; p value <0.01), moderate/severe IBD disease activity (64% vs 15%; p value <0.01 overall), gastrointestinal symptoms (71% vs 19%, p value <0.01), sulfasalazine/mesalamine use (57% vs 21%; p value 0.01), and steroid use (29% vs 8%, p value 0.03). The six-year-old colitis patient requiring ICU care in this series is in line with the recent reports of multi-systemic inflammatory (Kawasaki-like) syndrome temporarily related to SARS-CoV-2 infection in children. cache = ./cache/cord-266392-bayabroa.txt txt = ./txt/cord-266392-bayabroa.txt === reduce.pl bib === id = cord-287885-1jwwmoys author = D'Amico, Ferdinando title = Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey date = 2020-05-13 pages = extension = .txt mime = text/plain words = 599 sentences = 38 flesch = 49 summary = title: Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey Therefore, we did an anonymous web survey with the support of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) between March 30 and April 16, 2020, to investigate the concerns, fears, and behaviours of patients with IBD during the early phase of the COVID-19 pandemic. The European Crohn's and Colitis Organisation, the British Society of Gastroenterology, and the International Organization for the Study of Inflammatory Bowel Diseases have responded to this request, providing practical guidelines for the management of patients with IBD during the pandemic, focusing not only on drug treatment but also on advice for daily life (eg, social distancing, use of masks, and travel avoidance). Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic cache = ./cache/cord-287885-1jwwmoys.txt txt = ./txt/cord-287885-1jwwmoys.txt === reduce.pl bib === id = cord-263419-qeo6qn0d author = Fiorino, Gionata title = Protecting patients with IBD during the COVID-19 pandemic date = 2020-05-20 pages = extension = .txt mime = text/plain words = 417 sentences = 31 flesch = 44 summary = An and colleagues stopped biologics (infliximab infusions) and immunosuppressive treatments for all patients with IBD. Indeed, a systematic review 4 showed that the risk of hospital admission (odds ratio 0·48, 95% CI 0·29-0·80) and surgery (0·67, 0·46-0·97) is significantly reduced by use of biologics for patients with IBD. The probability of relapse after stopping effective immunomodulators or biological therapy is about 50% and is associated with an increased need for steroids, and risk of hospital admission and surgery. Thus, the risk and benefits of continuing or stopping biologics should be carefully balanced and should not be assumed to be a general rule for all patients with IBD, especially given the length of time the pandemic is likely to last. Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease cache = ./cache/cord-263419-qeo6qn0d.txt txt = ./txt/cord-263419-qeo6qn0d.txt === reduce.pl bib === id = cord-261029-befymalm author = Sultan, Keith title = Review of inflammatory bowel disease and COVID-19 date = 2020-10-07 pages = extension = .txt mime = text/plain words = 3257 sentences = 153 flesch = 48 summary = Early reports of the virus, now known as severe acute respiratory syndrome coronavirus 2, and its clinical disease coronavirus disease 2019 (COVID-19), has shown higher rates of morbidity and mortality in the elderly and those with pre-existing medical conditions. The authors also reported that there had been no cases of IBD/SARS-CoV-2 infected patients in the three largest tertiary IBD centers in Wuhan (Tongji Hospital, Union Hospital, and Zhongnan Hospital) at the time their manuscript was prepared, March 8, 2020. Rodriguez-Lago et al [29] reported on 40 cases of IBD (21 hospitalized) with confirmed positive tests for SARS-CoV-2 from 5 sites in the Basque Country (Spain), median age 59 years, 60% male, 32% Crohn's disease (CD), with 28% on immune therapy, 18% biologic, and 10% systemic corticosteroids. To date, the largest national case reporting has come from a combined 24 IBD referral centers in Italy, affiliated with the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) [32] . cache = ./cache/cord-261029-befymalm.txt txt = ./txt/cord-261029-befymalm.txt === reduce.pl bib === id = cord-283279-1qcdnd1y author = Barberio, Brigida title = The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients During COVID-19 Pandemic: Is It Really a Problem? date = 2020-07-17 pages = extension = .txt mime = text/plain words = 662 sentences = 42 flesch = 51 summary = title: The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients During COVID-19 Pandemic: Is It Really a Problem? 1 a evaluating the adherence to infusible biologic therapies, defined as receiving an infusion within ten weeks of the prior infusion, in patients with Inflammatory Bowel Disease (IBD) during the current Coronavirus disease 2019 (COVID-19) pandemic. 4, 5 For instance, at our Center, one week before the infusion, patients were contacted by email to reassure about the lack of risk in moving to the Hospital and the benefit of continuing medical therapy. We should explain to our patients with chronic diseases why it is important that they adhere to therapies which are relative safe and manageable despite the COVID-19 pandemic. Adherence of infusible biologics during the time of COVID-19 among patients with Inflammatory Bowel Disease: A nationwide VA cohort study cache = ./cache/cord-283279-1qcdnd1y.txt txt = ./txt/cord-283279-1qcdnd1y.txt === reduce.pl bib === id = cord-022555-a7ie82fs author = nan title = Digestive System, Liver, and Abdominal Cavity date = 2011-12-05 pages = extension = .txt mime = text/plain words = 66452 sentences = 3846 flesch = 48 summary = One study found that, of cats investigated for gastrointestinal disease, 9 of 33 cats (27%) had no pathology recognized proximal to the jejunum (i.e., the effective length of diagnostic endoscopes would have precluded diagnosis), and other organs were affected in 9 of 10 cats with inflammatory bowel diseases and 7 of 8 cats with intestinal small cell lymphoma. 60, 64 Quantification of serum cobalamin levels is recommended in cats with clinical signs of small bowel diarrhea, ones suspected to have an infiltrative disease of the small intestine (inflammatory bowel disease or gastrointestinal lymphoma), or ones with pancreatic dysfunction. Survey radiographs may be normal in cats with esophagitis and strictures, but are useful to rule out other causes for the clinical signs, such as a foreign body, or to detect related problems, such as aspiration pneumonia. 8, 29 Other non-neoplastic causes reported for gastric or gastroduodenal ulceration in cats include parasites (e.g., Ollulanus tricuspis, Toxocara cati, Aonchotheca putorii, Gnathostoma spp.), bacterial infections, toxins, inflammatory bowel disease, and foreign bodies. cache = ./cache/cord-022555-a7ie82fs.txt txt = ./txt/cord-022555-a7ie82fs.txt === reduce.pl bib === id = cord-275447-nx45kwn6 author = Ehrenpreis, Eli D. title = Rapid Review: Nonsteroidal Anti-inflammatory Agents and Aminosalicylates in COVID-19 Infections date = 2020-06-10 pages = extension = .txt mime = text/plain words = 2326 sentences = 130 flesch = 45 summary = Since 5-ASAs are a mainstay treatment for inflammatory bowel disease, the authors review the pharmacology of both classes of drugs and discuss the potential relevance of 5-ASAs in the ongoing discussion of medication use in patients infected with COVID-19. T here has been recent controversy regarding the risk that ibuprofen (and possibly other nonsteroidal antiinflammatory drugs, NSAIDs) may worsen the clinical course of patients that are infected with COVID-19. It is therefore the purpose of this brief review to inform practitioners treating patients with 5-ASAs about the potential relationships between 5-ASAs and NSAIDs. At the time of this writing, both the World Health Organization (WHO) and the Food and Drug Administration (FDA) have not recommended the avoidance of ibuprofen in patients with known or suspected COVID-19 infections. cache = ./cache/cord-275447-nx45kwn6.txt txt = ./txt/cord-275447-nx45kwn6.txt === reduce.pl bib === id = cord-288014-rrr4x755 author = Wang, Hong-Gang title = Excessive anxiety in IBD patients is unnecessary for COVID-19 date = 2020-05-12 pages = extension = .txt mime = text/plain words = 648 sentences = 47 flesch = 62 summary = To the editor, Currently, 2019 novel coronavirus (SARS-CoV-2) infection disease (COVID-19) broke out in Wuhan, China and spread worldwide [1, 2] . Inflammatory bowel disease (IBD) is a chronic non-specific intestinal disease, including ulcerative colitis (UC) and Crohn's disease (CD), and many of these patients have anxiety [3] . Analysis of the transcriptome data of these samples, we found that the expression of ACE2 in the terminal ileum was significantly higher than that in the rectal colon, with a fold change of 9.8 times (P < 0.001). The expression of ACE2 in the UC rectum was not significantly higher than that in non-IBD. In the terminal ileum of CD, ACE2 expression was also not higher than that of non-IBD. These results indicate that the expression of ACE2 does not show a significant difference between IBD and non-IBD patients. Compared with non-IBD, there was no significant difference in TMPRSS2 expression in the rectum and terminal ileum of patients with IBD. cache = ./cache/cord-288014-rrr4x755.txt txt = ./txt/cord-288014-rrr4x755.txt === reduce.pl bib === id = cord-300963-1n1f8mf2 author = Gajendran, Mahesh title = Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned date = 2020-10-12 pages = extension = .txt mime = text/plain words = 6681 sentences = 350 flesch = 46 summary = Previous studies based on SARS-CoV-1 showed that the "cytokine storm" was strongly associated with viral sepsis, inflammation-induced lung injury, and acute respiratory distress syndrome (ARDS) [32, 34] . With regard to IBD-specific risk factors, it is speculated that patients on immunosuppressive agents, those with active IBD symptoms, malnutrition, and frequent visits to clinics or hospitals are at greater risk of acquiring SARS-CoV-2 infection [50] . The International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) maintains a registry for reporting COVID-19 in IBD patients called SECURE-IBD registry. Hence, all the societies have recommended that patients continue their IBD medications to sustain remission, because the risk of disease flare-up outweighs the chance of contracting SARS-CoV-2 infection. The management strategy will depend on multiple factors, such as the patient's age, the severity of the COVID-19 infection, the clinical status of the IBD, and the presence of other comorbid conditions. cache = ./cache/cord-300963-1n1f8mf2.txt txt = ./txt/cord-300963-1n1f8mf2.txt === reduce.pl bib === id = cord-284234-9cd2v6bt author = Sebastian, S title = Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD date = 2020-06-10 pages = extension = .txt mime = text/plain words = 4483 sentences = 256 flesch = 44 summary = Understandable concerns have been raised on the safety of steroids, immunosuppressive drugs, and biologics used in patients for a variety of indications including immune mediated inflammatory disease such as inflammatory bowel diseases (IBD), which do increase the risk of opportunistic bacterial, viral and fungal infections (5) . Therefore, continuing concerns remain both from IBD patients and the A c c e p t e d M a n u s c r i p t clinicians managing them, regarding the potential of IBD related drugs causing more frequent infections by SARS-CoV2, and increased risk of severe complications from COVID-19 (13) . Corticosteroids are thought to have a divergent effect on viral infections including SARS COV viruses; on one hand they inhibit host immune response acting on migration and chemokines production leading to impaired viral clearance and the resultant prolonged Moreover, a prospective, randomized double-blinded, placebo-controlled trial compared early hydrocortisone treatment (before day seven of the illness) with a placebo and found that early hydrocortisone therapy was associated with a higher subsequent plasma viral load (61) . cache = ./cache/cord-284234-9cd2v6bt.txt txt = ./txt/cord-284234-9cd2v6bt.txt === reduce.pl bib === id = cord-290750-85731og8 author = Danese, Silvio title = Management of IBD during the COVID-19 outbreak: resetting clinical priorities date = 2020-03-25 pages = extension = .txt mime = text/plain words = 1798 sentences = 86 flesch = 49 summary = Because of the very high transmission capacity, the WHO declared the outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 infection a public health emergency of international concern. Additional recommendations for patients with IBD from the IOIBD: • Medicines such as mesalamine are safe • If possible, withdraw from steroid use • Biologic agents used to treat IBD (e.g. anti-TNF agents, ustekinumab and vedolizumab) are generally safe; there are no recommendations to stop taking these medications and the effects of these drugs are present for many months • Thiopurines and tofacitinib tend to inhibit the immune response to viral infections, but stopping these agents in the short-term will not help • Get the influenza vaccination • Stay at home and minimize social contact c | Strategies to enable maintenance of our biologic agent clinic during the COVID-19 outbreak in Italy include checkpoints at hospital entrances for symptom screening and use of surgical masks for clinical staff and patients. cache = ./cache/cord-290750-85731og8.txt txt = ./txt/cord-290750-85731og8.txt === reduce.pl bib === id = cord-275199-y7b12vml author = Suárez-Fariñas, Mayte title = Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease date = 2020-09-25 pages = extension = .txt mime = text/plain words = 5683 sentences = 331 flesch = 47 summary = The RISK cohort 18 : ACE2 and TMPRSS2 in treatment-free pediatric CD (<17 years of age) patients was studied using RNA-seq expression profiles from GSE57945, which includes ileal biopsies from endoscopically defined inflamed samples (n=160), non-inflamed (n=53) and non-IBD controls (n=42). Genes differentially expressed in blood 22 , lung NHBE/A549 23 or human small intestinal organoids 24 (hSIO) following SARS-CoV-2 infection; IBD inflammation; or response to medications were separately projected onto various BGRNs allowing for 1 or 2 nearest neighbors depending on the signature sizes. The expression of ACE2 and TMPRSS2 was similar when comparing active smokers to non-smokers, either between healthy controls or IBD patients (data not shown) and no significant interactions with inflammation status, region or other covariates were found. We observed that genes: up-regulated with inflammation, or positively associated with macroscopic or microscopic measures of disease, or associated with the risk of IBD, were significantly enriched with genes up-regulated by SARS-CoV2 infection of lung epithelial cells ( Figure S10e ). cache = ./cache/cord-275199-y7b12vml.txt txt = ./txt/cord-275199-y7b12vml.txt === reduce.pl bib === id = cord-288439-srzysoqy author = Segal, Jonathan P. title = Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease date = 2020-09-03 pages = extension = .txt mime = text/plain words = 6842 sentences = 359 flesch = 38 summary = Faecal microbiota transplantation (FMT) is currently a recommended therapy for recurrent/ refractory Clostridioides difficile infection (CDI). Faecal microbiota transplantation (FMT) is currently a recommended therapy for recurrent/ refractory Clostridioides difficile infection (CDI). Rodent studies supported the concept that restoration of bacterial bile-metabolising capacity to the gut microbiota was protective against CDI, 39 prompting interest into whether this could also be a mechanism of efficacy of FMT. difficile; administration of an FXR agonist in a mouse model of colitis resulted in significantly reduced colonic inflammation and a more intact intestinal barrier, 44 while microbially mediated production of particular secondary bile acids exhibit anti-inflammatory effects on intestinal epithelial cells 45 and have been recently recognised as promoting generation of peripheral regulatory T cells. Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection cache = ./cache/cord-288439-srzysoqy.txt txt = ./txt/cord-288439-srzysoqy.txt === reduce.pl bib === id = cord-302717-hn3airxq author = Bayoumy, Ahmed B. title = Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom date = 2020-09-11 pages = extension = .txt mime = text/plain words = 6481 sentences = 347 flesch = 54 summary = title: Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom BACKGROUND: Thioguanine (TG) is a thiopurine which has been used for patients with inflammatory bowel disease (IBD), who have failed azathioprine (AZA) or mercaptopurine (MP) due to adverse events or suboptimal response. The aim of this study was to investigate the long-term efficacy and safety of low-dose TG therapy in IBD patients failing AZA and MP. METHODS: A retrospective multicentre study was performed in IBD patients who failed prior treatment with conventional thiopurines with or without following immunomodulation (thiopurine-allopurinol, biologicals, methotrexate, tacrolimus) and were subsequently treated with TG as rescue monotherapy between 2003 and 2019 at three hospitals in the United Kingdom. They reported results of 11 studies, comprising of 353 patients who were treated with a median TG starting dose of 20 mg/day after failing prior conventional thiopurine therapy. cache = ./cache/cord-302717-hn3airxq.txt txt = ./txt/cord-302717-hn3airxq.txt === reduce.pl bib === id = cord-295066-76se8mxq author = Botti, Fiorenzo title = URGENT SURGERY FOR INFLAMMATORY BOWEL DISEASES DURING THE COVID-19 OUTBREAK IN A HIGH INCIDENCE AREA - EXPERIENCE FROM A HIGH-VOLUME CENTRE date = 2020-08-31 pages = extension = .txt mime = text/plain words = 1720 sentences = 80 flesch = 47 summary = [4] As a tertiary referral centre for the surgical management of IBD patients, it was important to clearly define which complicated IBD cases were to be operated, by taking into account several variables including disease severity and quality of life, presence of comorbidities, feasibility of an alternative procedure. According to the British Society of Gastroenterology (BSG) guidelines on the IBD management during the COVID-19 pandemic, [5] routine elective operations should be deferred, while emergency procedures (e.g. colectomy in acute severe ulcerative colitis [UC] or intestinal resection in septic complications of penetrating Crohn's disease [CD]) should continue. Complex surgical IBD cases should also be deferred when possible and its timing must be regularly reviewed at multidisciplinary meetings, trying to optimize medical treatment (e.g. using partial or exclusive enteral nutrition regimens or draining abscesses in combination with antibiotic therapy) and to avoid surgery or change the timing from emergency to urgent or semi-urgent. cache = ./cache/cord-295066-76se8mxq.txt txt = ./txt/cord-295066-76se8mxq.txt === reduce.pl bib === id = cord-032753-icteg34y author = Namai, Fu title = Microbial therapeutics for acute colitis based on genetically modified Lactococcus lactis hypersecreting IL-1Ra in mice date = 2020-09-28 pages = extension = .txt mime = text/plain words = 5311 sentences = 313 flesch = 51 summary = Oral administration of these gmLAB suppressed body weight reduction and exacerbation of the disease activity index score in mice with acute colitis and decreased the number of CD4(+) IL-17A(+) cells in the mesenteric lymph nodes. HE staining of colon sections removed on the last day revealed a decrease in immune cell infiltration in the NZ-IL1Ra administration group and a significant decrease in the total mucosal tissue area (Fig. 5e-g) . Production of IL-2 by EL4.NOB-1 cells stimulated with IL-1β was suppressed by increasing the concentration of rmIL-1Ra purified from NZ-IL1Ra supernatant, commercially available mIL-1Ra, or hIL-1Ra. These results indicate that rmIL-1Ra produced by gmLAB can play an effective role as an endogenous antagonist of IL-1. In conclusion, we successfully constructed gmLAB that hypersecrete bioactive mIL-1Ra. Oral administration of NZ-IL1Ra to acute colitis mice alleviated colitis symptoms and suppressed excessive immune reactions in the intestinal tract and MLNs. These results suggest that rmIL-1Ra reaches the colon via NZ-IL1Ra and inhibits IL-1 signaling. cache = ./cache/cord-032753-icteg34y.txt txt = ./txt/cord-032753-icteg34y.txt === reduce.pl bib === id = cord-255930-2bobmkvu author = Kaplan, Gilaad G. title = The four epidemiological stages in the global evolution of inflammatory bowel disease date = 2020-10-08 pages = extension = .txt mime = text/plain words = 9023 sentences = 417 flesch = 44 summary = Inflammatory bowel disease (IBD) is a global disease; its evolution can be stratified into four epidemiological stages: Emergence, Acceleration in Incidence, Compounding Prevalence and Prevalence Equilibrium. Western regions will eventually transition to the Prevalence Equilibrium stage, in which the accelerating prevalence levels off as the IBD population ages and possibly as a result of an unexpected rise in mortality during the COVID-19 pandemic. The evolution of IBD occurs within Omran's Degenerative and Human-Influenced Diseases age and has occurred across three distinct epidemiological stages ( Fig. 1) : Emergence, Acceleration in Incidence and Compounding Prevalence. In the meantime, developing, newly industrialized regions and countries of the Western world all need to innovate their current health-care delivery to address the evolving demographics of their IBD populations as they transition across epidemiological stages. cache = ./cache/cord-255930-2bobmkvu.txt txt = ./txt/cord-255930-2bobmkvu.txt === reduce.pl bib === id = cord-306760-05my504t author = Turner, Dan title = Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition date = 2020-03-31 pages = extension = .txt mime = text/plain words = 3832 sentences = 209 flesch = 46 summary = METHODS: An electronic reporting system of children with IBD infected with SARS-CoV-2 has been circulated among 102 PIBD centres affiliated with the Porto and Interest-group of ESPGHAN. Standard IBD treatments including biologics should continue at present through the pandemic, especially in children who generally have more severe IBD course on one hand, and milder SARS-CoV-2 infection on the other. In light of the hyperinflammatory immune response seen in patients with COVID-19 it is highly relevant that blockade of IL-6R with tocilizumab resulted in clinical improvement associated with normalisation of fever, lymphocyte counts, and CRP in a retrospective group of 21 adults with severe SARS-CoV-2 infection (20) . Therefore, uninfected children should generally continue their medical treatment, including immunomodulators and biologic therapies, as the risk of a disease flare outweighs any estimated risk of SARS-CoV2 infection. cache = ./cache/cord-306760-05my504t.txt txt = ./txt/cord-306760-05my504t.txt === reduce.pl bib === id = cord-269390-4yn8c34i author = Rimondi, Alessandro title = Fogging IBD Management: An Unusual Case of IBD Flare-up During the COVID-19 Outbreak date = 2020-07-28 pages = extension = .txt mime = text/plain words = 605 sentences = 44 flesch = 51 summary = We have read with interest the article by Occhipinti and Pastorelli, with particular reference to the management of inflammatory bowel diseases (IBD) relapse during the COVID-19 outbreak. 1 Diagnostic challenges may arise in the presence of symptoms that overlap between active IBD and COVID-19, and concerns about the use of immunosuppressive drugs, mainly corticosteroids, which potentially lead to an increased risk for infections. We hereby report on a representative case of how COVID-19 has redefined priorities and changed our clinical approach to active IBD patients. 3 Therefore, the differential diagnosis between IBD relapse and SARS-CoV-2 infection has possibly proved challenging at the peak of the COVID-19 outbreak. Ageusia, as reported by our patient, contributed to increase the suspicion of SARS-CoV-2 infection and made the differential diagnosis trickier. Challenges in the care of IBD patients during the CoViD-19 pandemic: report from a "Red Zone" area in Northern Italy cache = ./cache/cord-269390-4yn8c34i.txt txt = ./txt/cord-269390-4yn8c34i.txt === reduce.pl bib === id = cord-285426-iyl12ber author = Ghavami, Shaghayegh Baradaran title = IBD Patients Could Be Silent Carriers for Novel Coronavirus and Less Prone to its Severe Adverse Events: True or False? date = 2020-09-08 pages = extension = .txt mime = text/plain words = 1967 sentences = 111 flesch = 47 summary = Interestingly, in the recent pandemic of coronavirus disease (COVID19) , and the SARS-CoV epidemic in 2003, while the fecal samples of these patients were positive for the virus, they did not present any severe respiratory distress syndrome (4). Remarkably, the angiotensin-converting enzyme-2 (ACE2) is the receptor for SARS-CoV-2 and it is expressed in different organs including the lungs, testis and ileum. showed that when rheumatoid arthritis patients were treated with anti-TNF-α biologicals (infliximab, adalimumab, and certolizumab pegol), the expression of IFN-α-regulated genes was increased in the peripheral blood mononuclear cell (PBMC) compared to the control group. Besides, in IBD patients, particularly those who are under anti-TNF-α treatment, the host innate immune system interferes more efficiently with viral replication cycle and the clinical presentations are more moderate (9, 12) . Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? cache = ./cache/cord-285426-iyl12ber.txt txt = ./txt/cord-285426-iyl12ber.txt === reduce.pl bib === id = cord-285238-bpk3xl8x author = Dong, Xiuli title = Intestinal and Peripheral Fibrinogen-Like Protein 2 Expression in Inflammatory Bowel Disease date = 2013-11-28 pages = extension = .txt mime = text/plain words = 3457 sentences = 196 flesch = 47 summary = AIM: The purpose of this work was to investigate intestinal and peripheral expression of FGL2 in patients with inflammatory bowel disease (IBD), mainly ulcerative colitis (UC) and Crohn's disease (CD). Correlations of FGL2 expression with disease type, activity, and location, and with measured laboratory data, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), were examined. However, our study demonstrated that intestinal and peripheral expression of FGL2 was significantly higher in UC and CD patients with active disease, and decreased in inactive disease. Reduced FGL2 expression in patients with inactive disease may be because successful treatment, including immune modifiers, anti-TNF-a therapy, and other anti-inflammatory treatment, made up for the deficiency of Treg cells, or reversed the deficiency to exert sufficient suppression against other subsets of T lymphocytes through multiple other suppression molecules. cache = ./cache/cord-285238-bpk3xl8x.txt txt = ./txt/cord-285238-bpk3xl8x.txt === reduce.pl bib === id = cord-280023-r3qgdgeu author = Dipasquale, Valeria title = Challenges in paediatric inflammatory bowel diseases in the COVID-19 time date = 2020-04-08 pages = extension = .txt mime = text/plain words = 1064 sentences = 56 flesch = 42 summary = The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in China in December 2019, now involves the whole world [1 , 2] . Currently no cases of IBD patients infected by SARS-CoV-2 have been reported. As the risk of infections is generally higher in case of combination therapy (biologics plus immunomodulators) in adult and paediatric patients with IBD [6 , 7] , caution should be used with this therapeutic strategy during the COVID-19 epidemic. In conclusion, while waiting for more specific data concerning the risk of COVID-19 in children with IBD and, more generally, in paediatric patients on immunosuppressive therapy, it seems reasonable to carefully weigh the risks/benefits ratio of treatment with immunomodulators and biologics, especially in areas of high infection rate or outbreaks. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China cache = ./cache/cord-280023-r3qgdgeu.txt txt = ./txt/cord-280023-r3qgdgeu.txt === reduce.pl bib === id = cord-266648-962r0vm8 author = Grossberg, Laurie B title = Review of Societal Recommendations Regarding Management of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic date = 2020-07-03 pages = extension = .txt mime = text/plain words = 3613 sentences = 234 flesch = 50 summary = title: Review of Societal Recommendations Regarding Management of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic Although data in patients with IBD contracting COVID-19 are still limited, both providers and patients have particular concerns regarding the risk of infection with SARS-CoV-2 and how to manage their medications during the COVID-19 pandemic. Information regarding risk factors, prevention, routine care (including office visits, testing, endoscopy, and surgery), and medication management of patients with IBD in the setting of COVID-19 was collected from each reference and is summarized in the Results. 10, 11 Other organizations, including the American Gastroenterological Association doi: 10.1093/ibd/izaa174 Published online 3 July 2020 (AGA), the Gastroenterological Society of Australia, and the European Crohn's and Colitis Organisation (ECCO), agree that there are no data to support an increased risk of infection among patients with IBD. cache = ./cache/cord-266648-962r0vm8.txt txt = ./txt/cord-266648-962r0vm8.txt === reduce.pl bib === id = cord-258930-60yn4hg7 author = D’Amico, Ferdinando title = Inflammatory bowel diseases and COVID-19: the invisible enemy date = 2020-04-16 pages = extension = .txt mime = text/plain words = 1027 sentences = 65 flesch = 47 summary = All biological and immunosuppressive treatments were discontinued, visits in person were replaced by online consultations, and 318 patients were daily recommended to wash their hands frequently, to reduce the time spent outside the home and to use masks outside the home 7 . It is important to underline that a relevant percentage of evaluated patients had risk factors of infection: chronic diseases (15.4%), immunosuppressive agent therapy (11.0%), elderly (10.4%), high-risk professional categories (7.5%), and biological therapy (6.3%) 7 . Telemedicine has also been associated with a reduction in gastroenterological consultations and hospitalizations and could be a valid alternative to improve the quality of IBD patient care during the COVID-19 outbreak 23 . Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis Protection of 318 inflammatory bowel disease patients from the outbreak and rapid spread of COVID-19 infection in Wuhan cache = ./cache/cord-258930-60yn4hg7.txt txt = ./txt/cord-258930-60yn4hg7.txt === reduce.pl bib === id = cord-306325-9alfvda1 author = Galmozzi, E. title = Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks? date = 2014-02-04 pages = extension = .txt mime = text/plain words = 1009 sentences = 59 flesch = 47 summary = 1 The authors have evaluated and discussed current evidence regarding the roles of vitamin D deficiency in the pathogenesis and progression of inflammatory bowel disease (IBD). [4] [5] [6] It is therefore interesting that vitamin D deficiency has been shown to play a role in both psychological 7 and sleep disorders 8 in non-IBD populations, although the underlying mechanisms are still unknown. There is no study till now evaluating the effects of vitamin D deficiency on psychological health or sleep quality in IBD patients. Although several factors can affect psycho-logical health and sleep quality in IBD patients including demographic-and disease-related factors, 2, 4 a role for vitamin D deficiency is also plausible. 1, 2 We agree that our study does not provide insights on the causal relationship between IFNL4 and treatment response in patients with chronic hepatitis C virus (HCV) infection. cache = ./cache/cord-306325-9alfvda1.txt txt = ./txt/cord-306325-9alfvda1.txt === reduce.pl bib === id = cord-286912-cww4ha3j author = Manolakis, Anastassios C title = α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease date = 2017-01-21 pages = extension = .txt mime = text/plain words = 5348 sentences = 272 flesch = 48 summary = METHODS: AHSG serum levels were determined in treatment-naïve newly-diagnosed patients, 96 with ulcerative colitis (UC), 84 with Crohn's disease (CD), 62 with diarrhea-predominant or mixed irritable bowel syndrome (IBS, Dand Mtypes) and 180 healthy controls (HC), by an enzyme linked immunosorbent assay (ELISA). Low levels of AHSG have been recorded in patients on hemodialysis, those with cirrhosis, hepatoma or rheumatoid arthritis (RA), an entity sharing common inflammatory pathways with IBD, and have been linked to vascular -excessive valvular and coronary artery calcification, ischemic events-and skeletal disorders -osteopenia [14, 17, 18] . In order to perform additional testing of the link between lower AHSG levels and complicated disease behavior, logistic regression was applied, while considering penetrating or stricturing CD, as dependent, and AHSG concentrations, in quartiles -lowest, low, high, highest -as independent variables. After multivariate analysis -also considering age, sex, activity, duration, smoking status-the inverse association between AHSG and need for anti-TNFα therapy or surgery remained statistically significant (partial correlation coefficients: -0.33 and -0.41, respectively -P < 0.05, in both cases). cache = ./cache/cord-286912-cww4ha3j.txt txt = ./txt/cord-286912-cww4ha3j.txt === reduce.pl bib === id = cord-307769-rjseio5s author = Sim, Winnie H title = Expression profile of genes involved in pathogenesis of pediatric Crohn's disease date = 2012-05-24 pages = extension = .txt mime = text/plain words = 4673 sentences = 270 flesch = 41 summary = Methods: We used suppressive subtractive hybridization (SSH) and differential screening analysis to profile the mRNA expression patterns of children with CD and age‐ and sex‐matched controls without inflammatory bowel disease (IBD). The real-time RT-PCR results validated that genes represented by > 10 clones enriched by subtractive hybridization were expressed in higher abundance in CD as compared with non-IBD ileal biopsies. To contextualize our SSH findings, we compared our results with the data tables from seven microarray studies published previously, that had reported differential expression of genes between inflamed biopsies of CD and non-inflamed biopsies of non-IBD controls. The antigen presentation, inflammatory response and cancer gene network (Network 1) comprise one-third Figure 1 The relative expression levels of REG1A, MMP2 and ANPEP in ileal biopsies from 13 Crohn's disease (CD) and nine non-inflammatory bowel disease (IBD) patients. Primers used for real-time reverse transcription polymerase chain reaction quantification of ANPEP, REG1A, MMP2 and RPL32 Table S2 Differentially expressed genes specific to Crohn's Disease (CD) ileum. cache = ./cache/cord-307769-rjseio5s.txt txt = ./txt/cord-307769-rjseio5s.txt === reduce.pl bib === id = cord-310042-9z8rkzq8 author = Aysha, Al‐Ani title = Practical management of inflammatory bowel disease patients during the COVID‐19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty date = 2020-07-12 pages = extension = .txt mime = text/plain words = 3471 sentences = 214 flesch = 43 summary = This review aims to summarise the current literature and provide guidance on the management of inflammatory bowel disease (IBD) patients in the context of the COVID‐19 pandemic in the Australasian setting. A significant proportion of IBD patients are treated with long-term immunomodulator/immunosuppressive therapy which potentially places them at increased risk of infections and associated complications. Practitioners and patients alike are therefore concerned about the risk and implications of COVID-19 infection in the IBD patient, despite a paucity of evidence supporting an altered predisposition to disease or more severe disease course. Despite concerns regarding immunosuppression and consequent predisposition to infection, there is no evidence to suggest increased infection rates of COVID-19 in IBD patients to date. 8, 9 Hence, expert consensus currently is that patients with IBD do not appear to be at increased risk of SARS-CoV-2 infection compared with the general population. 2 • Reducing disease activitythere is evidence that moderate to severe disease activity increases the risk of infection in IBD patients. cache = ./cache/cord-310042-9z8rkzq8.txt txt = ./txt/cord-310042-9z8rkzq8.txt === reduce.pl bib === id = cord-023134-y665agnh author = nan title = Oral Research Communications of the 22(nd) ECVIM‐CA Congress date = 2012-11-20 pages = extension = .txt mime = text/plain words = 29595 sentences = 1548 flesch = 50 summary = Doppler echocardiographic indices of diastolic function of the right ventricle are good prognostic markers during left ventricular (LV) failure secondary to ischemic and dilated cardiomyopathy.The aims of the present study were: to assess LV and RV diastolic function by conventional Doppler and pulsed-wave tissue Doppler imaging (PW-TDI) in dogs with mitral valve disease (MVD), with or without pulmonary hypertension (PH); to test if echocardiographic parameters of LV and RV diastolic dysfunction correlate to the Doppler-estimated pulmonary artery systolic pressure (PASP).114 dogs were prospectively evaluated, including 86 dogs with MVD. The aims of the present study were to assess whether diabetic cats have pathological evidence of islet inflammation or pancreatitis and to define islet lesions in comparison to a well-matched control population.Formalin-fixed, paraffin-embedded pancreatic samples were collected from post-mortem examination performed on diabetic and control cats died due to any disease at the Clinic for Small Animal Internal Medicine, University of Zurich (Switzerland) between 1997 and 2009. cache = ./cache/cord-023134-y665agnh.txt txt = ./txt/cord-023134-y665agnh.txt === reduce.pl bib === id = cord-311162-kbqh7beq author = Behzad, Catherine title = Establishing Safe Out-of-Hospital Infusion Centers May Improve the Quality of Care in Patients With IBD During the COVID-19 Pandemic date = 2020-09-09 pages = extension = .txt mime = text/plain words = 491 sentences = 33 flesch = 55 summary = title: Establishing Safe Out-of-Hospital Infusion Centers May Improve the Quality of Care in Patients With IBD During the COVID-19 Pandemic We read with great interest the article by Occhipinti and Pastorelli 1 about the challenges in the care of patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic. However, 2 medical wards were maintained COVID-19-free to provide care for patients with urgent situations and essential services. In addition, we gave special consideration to patients with IBD who were on immunosuppressive therapy and decided to continue biologic infusions in the hospital's COVID-19-free wards. In our experience, 92% of the patients whose scheduled biologic infusion dates were during the peak of the outbreak in early February through March refused to come to the hospital to receive their infusions. Challenges in the care of IBD patients during the CoViD-19 pandemic: report from a "Red Zone" area in Northern Italy cache = ./cache/cord-311162-kbqh7beq.txt txt = ./txt/cord-311162-kbqh7beq.txt === reduce.pl bib === id = cord-269835-mz7i66qp author = Furfaro, Federica title = SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience date = 2020-06-11 pages = extension = .txt mime = text/plain words = 7275 sentences = 295 flesch = 38 summary = The current coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has required a complete change in the management of patients with inflammatory bowel disease (IBD) who need to undergo endoscopic procedures. In particular, recommendations regarding the use of personal protective equipment to prevent COVID-19 transmission, both for patients and health-care professionals, are proposed and different scenarios in endoscopic IBD management are evaluated to suggest when endoscopy could be rescheduled and replaced by alternative biomarkers. The panel of experts con sidered possible aerosolization during colonoscopy, in particular during the insertion and removal of instruments through the biopsy channel and the presence of the virus in the stool and advised on the use of N95 masks for lower gastrointestinal procedures as a precautionary measure to protect the endoscopist from the risk of possible COVID-19 transmission from the patient if infected by SARS-CoV-2 (ref. cache = ./cache/cord-269835-mz7i66qp.txt txt = ./txt/cord-269835-mz7i66qp.txt === reduce.pl bib === id = cord-021852-o0k2r0yo author = Simpson, Kenneth W. title = The Role of the Microbiota in Feline Inflammatory Bowel Disease date = 2015-12-04 pages = extension = .txt mime = text/plain words = 3665 sentences = 189 flesch = 33 summary = The only culture-independent study of the duodenal mucosal bacteria in cats to date employed FISH analysis to evaluate the numbers and types of bacteria associated with the duodenal mucosa and their relationship to clinical signs, histopathology, and mucosal cytokines. This study shows that changes in the number and type of mucosa-associated bacteria are related to the presence and severity of IBD in cats and raises the possibility that abnormal mucosal flora are involved in the etiopathogenesis of feline IBD. 13 For example, FISH analysis enabled the identification of invasive spiral bacteria in the ileum, colon, and regional lymph nodes of a cat with pyogranulomatous ileocolitis associated with recurrent episodes of fever and leukocytosis whose inflammatory process was considered sterile on the basis of histopathology (see Figure 10 -4C). cache = ./cache/cord-021852-o0k2r0yo.txt txt = ./txt/cord-021852-o0k2r0yo.txt === reduce.pl bib === id = cord-311804-39mu0tdr author = Zingone, Fabiana title = Screening for Active COVID-19 Infection and Immunization Status Prior to Biologic Therapy in IBD Patients at the Time of the Pandemic Outbreak date = 2020-04-10 pages = extension = .txt mime = text/plain words = 866 sentences = 60 flesch = 39 summary = title: Screening for Active COVID-19 Infection and Immunization Status Prior to Biologic Therapy in IBD Patients at the Time of the Pandemic Outbreak When clinical conditions and the disease activity do not allow a treatment delay, before starting a biological therapy, screening of IBD patients for COVID-19 active infection by RT-PCR should be advisable, even in absence of clinical suspicion. When clinical conditions and the disease activity do not allow a treatment delay, before starting a biological therapy, screening of IBD patients for COVID-19 active infection by RT-PCR should be advisable, even in absence of clinical suspicion. Accumulating evidence shows that patients with COVID-19 infection may also experience gastrointestinal symptoms, including diarrhea, nausea, vomiting and abdominal discomfort prior to the common respiratory symptoms Current recommendation suggests postponing the start of treatment with immunosuppressive drugs and biologics, whenever possible, based on an individual risk assessment during the COVID19 pandemic (5-7). cache = ./cache/cord-311804-39mu0tdr.txt txt = ./txt/cord-311804-39mu0tdr.txt === reduce.pl bib === id = cord-312663-hhd5f823 author = Fiorino, Gionata title = Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience date = 2020-03-24 pages = extension = .txt mime = text/plain words = 2199 sentences = 109 flesch = 52 summary = The outbreak of the COVID-19 caused by coronavirus SARS-CoV2, is rapidly spreading worldwide. IBD patients are severely worried about the impact of their disease and medications on the risk and the prognosis of COVID-19, and many of them are forced to come to hospital because of active disease, complications and drug administration. Patients scheduled for a follow-up visit are required to stay at home and to complete a questionnaire about IBD symptoms and quality of life, together with their routine laboratory tests, to the nurse and the dedicated doctor, who give recommendations and information about therapy and follow-up procedures. Based on the assumption that the risk of coronavirus infection is not different between the general population and IBD patients, but that IBD flares are difficult to manage in this situation, we advise all patients to continue their therapies, especially if in remission. cache = ./cache/cord-312663-hhd5f823.txt txt = ./txt/cord-312663-hhd5f823.txt === reduce.pl bib === id = cord-312374-gu9tq48n author = Martin Arranz, Eduardo title = Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey date = 2020-06-04 pages = extension = .txt mime = text/plain words = 2486 sentences = 131 flesch = 48 summary = The survey included items in 5 sections asking about the structure of IBD units, structural changes adopted because of the current pandemic, recommendations regarding immunosuppressive and biologic treatments during the SARS-CoV-2 pandemic, adopted measures regarding suspected COVID-19 in patients with IBD, and management of patients with IBD with confirmed COVID-19. During the COVID-19 crisis, 100% of hospitals surveyed have cancelled elective onsite consultation and changed to phone assistance, 40% have also attended patients via e-mail, and 13% have used social media to inform patients about the latest updates regarding IBD and SARS-CoV-2. The COVID-19 pandemic has severely affected Spain, with 205,905 cases confirmed by polymerase chain reaction and 22,902 deaths registered up to April 24, 2020, and has forced all hospitals to change their clinical practice, suspending all ambulatory procedures to minimize the risk of infection and relocating doctors and nurses to attend COVID-19 patients. cache = ./cache/cord-312374-gu9tq48n.txt txt = ./txt/cord-312374-gu9tq48n.txt === reduce.pl bib === id = cord-297768-tjqpiyp1 author = Day, Alice S. title = Practical guidance for dietary management of patients with inflammatory bowel disease during the SARS-CoV2 pandemic date = 2020-07-20 pages = extension = .txt mime = text/plain words = 1180 sentences = 56 flesch = 44 summary = Coronavirus disease (COVID-19) has resulted in considerable morbidity and mortality along with major disruption to global financial markets and social function with mandated social isolation precautions in many countries. 6, 7 It must 55 be acknowledged that it is unlikely any high quality evidence will allow timely production of 56 guidelines specific for IBD patients during the COVID-19 pandemic, so observational data 57 and anecdotal lessons learned from the first countries affected by the novel coronavirus are 58 providing direction for the rest of the world. 2 59 60 Despite reassuring registry data and published guidelines, many patients with IBD and their 61 treating clinicians alike may be reticent to persist with immunosuppressive therapy in the 62 setting of the COVID-19 pandemic. 8 Moreover, EEN has been shown to delay or avoid IBD surgery, 70 which is critical at a time when hospitalization increases risk of COVID-19 exposure as well 71 as in the setting of stretched health care resources. cache = ./cache/cord-297768-tjqpiyp1.txt txt = ./txt/cord-297768-tjqpiyp1.txt === reduce.pl bib === id = cord-306859-aqfgl9cm author = Clough, Jennie N title = Managing an IBD Infusion Unit During the COVID-19 Pandemic: Service Modifications and the Patient Perspective date = 2020-06-27 pages = extension = .txt mime = text/plain words = 518 sentences = 36 flesch = 58 summary = title: Managing an IBD Infusion Unit During the COVID-19 Pandemic: Service Modifications and the Patient Perspective The COVID-19 pandemic has posed significant challenges to the provision of inflammatory bowel disease (IBD) unit infusion services in terms of the redeployment of specialist staff and reduced capacity because of social distancing. Given the recommendation for patients to remain on their usual biologic medication wherever possible, 1 we modified our service to ensure that our patients were adequately protected on the unit and surveyed attenders regarding their views and concerns. Patients were telephoned 24 hours before their infusion to screen for COVID-19 symptoms and were advised to attend the unit unaccompanied. In addition, 25.2% of patients felt "very" or "somewhat uncomfortable" at the prospect of attending hospital for their usual infusion, but 80.2% felt on attending that the measures taken to reduce the risk of contact with COVID-19 were "completely adequate." cache = ./cache/cord-306859-aqfgl9cm.txt txt = ./txt/cord-306859-aqfgl9cm.txt === reduce.pl bib === id = cord-337204-14gxpeaf author = Piciucchi, Matteo title = Preliminary considerations regarding the risk of COVID-19 and disease severity in chronic gastrointestinal conditions date = 2020-05-25 pages = extension = .txt mime = text/plain words = 1637 sentences = 90 flesch = 43 summary = Since the discovery of SARS-CoV-2 at the end of 2019, several studies of the epidemiology, risk factors, clinical findings, therapy and virological features of this infection have become available and are totally free to clinicians via a PubMed search [1, 2] . In particular, several risk factors that are involved in acquiring the infection and that affect the clinical course and severity of COVID-19related diseases have been identified (Figure 1 ), but conclusive data are still lacking [2, 4] . As far as inflammatory bowel disease (IBD) is concerned, there are no data to suggest a higher risk of SARS-CoV-2 infection or a higher severity of related diseases in these patients, compared to the general population. More specifically, prospective studies to analyze the risk of the infection and its possible course in patients with IBD, pancreatitis and liver diseases are needed in order to improve care for these patients. cache = ./cache/cord-337204-14gxpeaf.txt txt = ./txt/cord-337204-14gxpeaf.txt === reduce.pl bib === id = cord-323553-bukm9m9q author = Song, Woo-Jin title = Canine adipose tissue-derived mesenchymal stem cells pre-treated with TNF-alpha enhance immunomodulatory effects in inflammatory bowel disease in mice date = 2019-08-31 pages = extension = .txt mime = text/plain words = 4238 sentences = 256 flesch = 52 summary = title: Canine adipose tissue-derived mesenchymal stem cells pre-treated with TNF-alpha enhance immunomodulatory effects in inflammatory bowel disease in mice Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF-α)-induced gene/protein 6 (TSG-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for IBD treatment in veterinary medicine. (C) Canine adipose tissue-derived mesenchymal stem cells (cAT-MSCs) stimulated with TNF-α released higher concentrations of immunomodulatory factors such as TSG-6 and PGE2 compared to levels released by naive cAT-MSCs. Results are shown as the mean ± standard deviation of three independent experiments. Canine adipose tissue-derived mesenchymal stem cells (cAT-MSCs) stimulated with TNF-α showed enhanced therapeutic effects on mice with dextran sodium sulfate (DSS)-induced colitis. Canine adipose tissue-derived mesenchymal stem cells (cAT-MSCs) stimulated with TNF-α showed enhanced therapeutic effects on mice with dinitrobenzene sulfonic acid (DNBS)-induced colitis. cache = ./cache/cord-323553-bukm9m9q.txt txt = ./txt/cord-323553-bukm9m9q.txt === reduce.pl bib === id = cord-317151-cxx5pcln author = Papa, Alfredo title = Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase date = 2020-10-24 pages = extension = .txt mime = text/plain words = 5030 sentences = 254 flesch = 44 summary = 14 Since the beginning of the pandemic, the World Health Organization has provided general recommendations for the prevention of They include: to wash hands frequently and properly with soap or alcohol-based sanitizer, to maintain social distancing (at least 1 m of distance), to avoid touching eyes, nose and mouth, to cover mouth and nose when coughing or sneezing, to seek medical care early when fever, cough or difficulty in breathing are recorded, to wear personal protective equipment (PPE), in particular the facial mask when social distancing is not possible to maintain or in closed places, to stay informed and follow any advice provided by own healthcare providers. This may require further changes in the planning of healthcare activities, both by using different prioritization criteria for outpatient visits, diagnostic tests and surgical interventions and by continuing to use treatment strategies that have worked well during the pandemic such as telemedicine, psychological support to patients and the educational function of patient associations (Table 1) . cache = ./cache/cord-317151-cxx5pcln.txt txt = ./txt/cord-317151-cxx5pcln.txt === reduce.pl bib === id = cord-307201-keec6fzo author = Barberio, Brigida title = Should IBD Patients Be Tested for Active COVID-19 Prior Starting a Biological Treatment? date = 2020-08-30 pages = extension = .txt mime = text/plain words = 655 sentences = 43 flesch = 44 summary = title: Should IBD Patients Be Tested for Active COVID-19 Prior Starting a Biological Treatment? aimed to provide recommendations regarding the management of patients with inflammatory bowel disease (IBD) in the era of COVID-19 pandemic. The AGA suggests that IBD patients should not stop their current treatments in order to prevent infection or adverse outcome with COVID-19. However, there was no specific international guidance with respect to COVID-19 testing in patients starting immunosuppressive treatment, particularly if they are asymptomatic, and the article by Rubin et al did not cover this topic either. 6 Overall, we believe that screening for active COVID-19 infection should be performed in order to avoid potential complications and to adjust therapy accordingly prior starting biological treatment. Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak Are patients with inflammatory bowel disease at increased risk for COVID-19 infection ? cache = ./cache/cord-307201-keec6fzo.txt txt = ./txt/cord-307201-keec6fzo.txt === reduce.pl bib === id = cord-316354-pix0hmpj author = Kennedy, Nicholas A title = Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic date = 2020-06-15 pages = extension = .txt mime = text/plain words = 5234 sentences = 264 flesch = 49 summary = ► Essential services for inflammatory bowel disease (IBD) patients including outpatient care, advice lines, endoscopy and infusion units may be affected. The number of whole-time equivalent gastroenterologists and IBD nurses providing elective outpatient care decreased significantly between baseline (median 4, IQR 4-7.5 and median 3, IQR 2-4) to the point of survey (median 2, IQR 1-4.8 and median 2, IQR 1-3) in the 6-week period following the onset of the COVID-19 pandemic (p<0.001 for both comparisons). The number of whole-time equivalent gastroenterologists and IBD nurses providing elective outpatient care decreased significantly between baseline (median 4, IQR 4-7.5 and median 3, IQR 2-4) to the point of survey (median 2, IQR 1-4.8 and median 2, IQR 1-3) in the 6-week period following the onset of the COVID-19 pandemic (p<0.001 for both comparisons). cache = ./cache/cord-316354-pix0hmpj.txt txt = ./txt/cord-316354-pix0hmpj.txt === reduce.pl bib === id = cord-322957-clf8f90t author = Crespo, Javier title = Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG date = 2020-04-28 pages = extension = .txt mime = text/plain words = 5297 sentences = 364 flesch = 51 summary = The general objectives of these recommendations include: • To protect our patients against the risks of infection with SARS-CoV-2 and to provide them with high-quality care. These recommendations are based on the sparse, changing evidence available, and will be updated in the future according to daily needs and the availability of expendable materials to suit them; in each department they will be implemented depending upon the cumulative incidence of SARS-CoV-2 infection in each region, and the burden the pandemic has represented for each hospital. These recommendations are based on the sparse, changing evidence available, and will be updated in the future according to daily needs and the availability of expendable materials to suit them; in each department they will be implemented depending upon the cumulative incidence of SARS-CoV-2 infection in each region, and the burden the pandemic has represented for each hospital. cache = ./cache/cord-322957-clf8f90t.txt txt = ./txt/cord-322957-clf8f90t.txt === reduce.pl bib === id = cord-331703-4hwmajt3 author = Occhipinti, Vincenzo title = Impact of COVID-19 outbreak on the management of patients with severe IBD: a domino effect date = 2020-05-12 pages = extension = .txt mime = text/plain words = 772 sentences = 43 flesch = 47 summary = The International Organization for the study of Inflammatory Bowel Diseases (IOIBD) recently published on Gastroenterology a consensus 1 about the management of IBD patients during the coronavirus disease 19 (COVID-19) pandemic, addressing several topics of interest such as the risk of infection in IBD patients, how to manage therapies and how to safely provide continuity of biological therapy. Thus, we decided to transfer the patient to a COVID-free hospital with IBD-specialized gastroenterologists and surgeons (Rho Hospital, in the Northern area of Milan) for further management. This case clearly highlights some unanticipated difficulties in providing adequate care to patients with severe IBD in a high-prevalence area of COVID-19. Management of Patients with Crohn's Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an International Meeting Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a "Red Zone" Area in Northern Italy cache = ./cache/cord-331703-4hwmajt3.txt txt = ./txt/cord-331703-4hwmajt3.txt === reduce.pl bib === id = cord-343832-xg3swuzs author = Pugliese, Daniela title = The management of Inflammatory Bowel Diseases in the era of COVID-19 pandemic: when “non-urgent” does not mean “deferrable” date = 2020-06-18 pages = extension = .txt mime = text/plain words = 1742 sentences = 92 flesch = 43 summary = authors: Pugliese, Daniela; Papi, Claudio; Privitera, Giuseppe; Aratari, Annalisa; Festa, Stefano; Armuzzi, Alessandro Accordingly, Inflammatory Bowel Disease (IBD) Units throughout the country had to re-organize their own agenda, limiting the accesses to 3 categories of outpatients: 1) patients undergoing biological therapies, for whom the risk of disease relapse is considered more worrying than the risk of COVID-19 infection; 2) patients enrolled in clinical trials in order to guarantee the prosecution of therapies and 3) patients complaining of acute symptoms, not manageable with telemedicine. 1-2 Examples of "non deferrable" visits are for patients complaining of moderate-to-severe IBD symptoms, new onset/relapse of extra-intestinal manifestations, active perianal disease or sub-acute obstruction symptoms requiring surgery. 4 Accordingly, highly suspect CD patients should be promptly investigated in order to start early and effective treatment strategies, aimed to impact the long-term clinical course and to reduce the risk of complications. cache = ./cache/cord-343832-xg3swuzs.txt txt = ./txt/cord-343832-xg3swuzs.txt === reduce.pl bib === id = cord-337896-mct29erg author = Kornbluth, Asher title = Management of Inflammatory Bowel Disease and COVID-19 in New York City 2020: The Epicenter of IBD in the First Epicenter of the Global Pandemic date = 2020-09-03 pages = extension = .txt mime = text/plain words = 5111 sentences = 212 flesch = 55 summary = A number of the major GI societies, the Crohn's & Colitis Foundation, 3 British Society of Gastroenterology, 4 European Crohn's and Colitis Organization, 5 The American Gastroenterology Association, 6 and the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) 7 have published guidelines regarding treating the IBD patient with SARS-CoV-2 and COVID-19. 8 The key features are that the patient without proven or suspected SARS-CoV-2 should continue on their current medications with aggressive attempts to reduce steroid usage because this is the only single agent that has been associated with increased poor outcomes with COVID-19, defined in the SECURE registry as a composite score of hospitalization, intubation, or death. 14 We are now participating in the development of a database that will follow patients after clearance of the SARS-CoV-2 virus to determine the courses and outcomes of the IBD and of any sequelae or recurrence of COVID-19 after any drug therapy has been suspended. cache = ./cache/cord-337896-mct29erg.txt txt = ./txt/cord-337896-mct29erg.txt === reduce.pl bib === id = cord-351566-z6onmkrn author = Bezzio, Cristina title = SEVERE IBD FLARES AND COVID-19: EXPAND THE GASTROENTEROLOGY-SURGERY TEAM TO INCLUDE AN INFECTIOUS DISEASE SPECIALIST date = 2020-06-16 pages = extension = .txt mime = text/plain words = 473 sentences = 32 flesch = 50 summary = title: SEVERE IBD FLARES AND COVID-19: EXPAND THE GASTROENTEROLOGY-SURGERY TEAM TO INCLUDE AN INFECTIOUS DISEASE SPECIALIST Perhaps because of the lack of empirical evidence, these guidelines did not specifically address the challenging case of IBD patients hospitalized due to a severe flare of disease with subsequent or concomitant pneumonia due to SARS-CoV-2. Especially in ulcerative colitis, a severe flare of disease is a life-threatening emergency that requires prompt recognition, hospitalization, early initiation of treatment and close monitoring (4). However, in the COVID-19 pandemic, this professional pair may not be enough to effectively manage the infection in an IBD patient with a severe disease flare. Nonetheless, we think that the issues raised by this case are of great interest to physicians managing IBD patients during the COVID-19 pandemic. In particular, we suggest that an infectious disease specialist join the gastroenterologist and surgeon on the team managing IBD patients hospitalized for a severe flare of disease. cache = ./cache/cord-351566-z6onmkrn.txt txt = ./txt/cord-351566-z6onmkrn.txt === reduce.pl bib === id = cord-349500-603v8lfb author = Neurath, Markus F title = Covid-19 and immunomodulation in IBD date = 2020-04-16 pages = extension = .txt mime = text/plain words = 6548 sentences = 386 flesch = 45 summary = Although covid-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. Although covid-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infects ACE2 expressing epithelial cells in the lung and/or the intestine. The covid-19 receptor ACE2 is particularly highly expressed in intestinal epithelial cells from the terminal ileum and to a lesser extent in the colon, where mucosal inflammation in patients with IBD (Crohn's disease (CD); UC) is frequently detected. cache = ./cache/cord-349500-603v8lfb.txt txt = ./txt/cord-349500-603v8lfb.txt === reduce.pl bib === id = cord-303942-77nbi3ws author = Segal, Jonathan P title = Prevention of COVID-19 in patients with IBD date = 2020-05-20 pages = extension = .txt mime = text/plain words = 632 sentences = 39 flesch = 53 summary = We read with interest the Correspondence from Ping An and colleagues 1 describing their efforts to prevent coronavirus disease 2019 in patients with inflammatory bowel disease (IBD) in Wuhan, China. Indeed, the National Health Service, in conjunction with the British Society of Gastroenterology (BSG), relied on individual health-care trusts to highlight patients at high risk with IBD so advice could be delivered by post regarding shielding and stringent physical distancing. BSG guidance suggests that patients should continue on their current medications, including infliximab, as active disease remains the biggest risk to a patient with IBD. As further evidence accumulates, our understanding of COVID-19-related risks in IBD populations globally will improve. Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China BSG COVID-19 Guidance on IBD patient risk groups British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic cache = ./cache/cord-303942-77nbi3ws.txt txt = ./txt/cord-303942-77nbi3ws.txt === reduce.pl bib === id = cord-347607-ydbyonbg author = Spagnuolo, Rocco title = COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey date = 2020-08-13 pages = extension = .txt mime = text/plain words = 3726 sentences = 176 flesch = 46 summary = The aim of this survey is to evaluate knowledge about clinical importance of COVID-19, disease management, prevention measures, and anxiety level during pandemic among patients with IBD. The questionnaire consisted of five sections: (1) anthropometric, demographic and clinical characteristics, (2) knowledge about clinical importance of COVID-19, (3) IBD management, (4) prevention measures, (5) anxiety level during pandemic. Taken together with findings that an active disease status compromises knowledge of IBD management and the high level of anxiety related to increasing age, these data suggest the need of further supporting patient-oriented strategies in IBD during Covid-19 pandemic. The aim of this study is to perform a survey about knowledge about clinical importance of COVID-19, knowledge of disease management, prevention measures, and anxiety level during the pandemic among patients with IBD. The questionnaire was defined and organized into five sections, dealing with: (1) demographic and clinical characteristic, (2) knowledge about clinical importance of COVID-19, (3) knowledge about management of IBD, (4) knowledge of prevention measures, (5) anxiety level during pandemic, respectively. cache = ./cache/cord-347607-ydbyonbg.txt txt = ./txt/cord-347607-ydbyonbg.txt === reduce.pl bib === id = cord-345786-1o9nx7z9 author = Bernstein, Charles N title = Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey date = 2020-08-14 pages = extension = .txt mime = text/plain words = 3737 sentences = 214 flesch = 52 summary = METHODS: Members of the World Gastroenterology Organization (WGO) IBD Task Force contacted colleagues in countries largely beyond North America and Europe, inviting them to review the WGO website for IBD and COVID-19 introduction, with links to guideline documents, and then to respond to 9 ancillary open-ended management questions. [1] [2] [3] The management of IBD may differ by geography with economically more advanced countries having greater access to health care resources such as endoscopy and expensive therapies like biologics. 8 Recommendations include continuing all immunomodulatory medications in patients with IBD, reducing steroid doses as much as possible, limiting elective endoscopies, and encouraging telemedicine in place of in-person clinic visits. Respondents from 8 countries, both low and high resource regions, reported that they routinely tested persons with IBD with new gastrointestinal symptoms. However, even with reports from 1 or 2 clinicians from each country, it allows insight into the uniformity or key differences in the practice of IBD around the world during the COVID-19 pandemic. cache = ./cache/cord-345786-1o9nx7z9.txt txt = ./txt/cord-345786-1o9nx7z9.txt === reduce.pl bib === id = cord-022888-dnsdg04n author = nan title = Poster Sessions date = 2009-08-19 pages = extension = .txt mime = text/plain words = 188640 sentences = 9313 flesch = 45 summary = Methods: Phospho-specific Western blot analyses were performed to verify the functionality of the different IFN-g pathway components, intra-and extracellular flow cytometry experiments were employed to determine the expression of antigen processing components and HLA class I cell surface antigens, quantitative real time-PCR experiments to confirm the absence of JAK2 and presence of pathway relevant molecules as well as, genomic PCR and chromosome typing technique to prove the deletion of JAK2. In order to accomplish these objectives we induced priming or tolerance of ovalbumin (OVA 323-339 peptide)-specific T cells from DO11.10 TCR transgenic mice in vitro or, following adoptive transfer of near physiologically relevant numbers of such cells into recipients, in vivo and correlated functional outcome (via proliferation and cytokine readout assays or antibody production) with E3 ubiquitin-protein ligases expression and the ubiquitination status of the TCR signalling machinery. cache = ./cache/cord-022888-dnsdg04n.txt txt = ./txt/cord-022888-dnsdg04n.txt === reduce.pl bib === id = cord-023095-4dannjjm author = nan title = Research Abstract Program of the 2011 ACVIM Forum Denver, Colorado, June 15–18, 2011 date = 2011-05-03 pages = extension = .txt mime = text/plain words = 134226 sentences = 6834 flesch = 51 summary = The purpose of this study was to determine the short-term effects of ivabradine on heart rate (HR), blood pressure, left ventricular (LV) systolic and diastolic function, left atrial (LA) performance, and clinical tolerance in healthy cats after repeated oral doses. The goal of this study was to investigate the relationship between heart rate and ECG time intervals to body mass in apparently healthy horses and ponies and to calculate normal ranges for different weight groups. This study aimed to investigate the prevalence of hypercoagulability in PLN dogs based on thromboelastography (TEG), and to determine whether hypercoagulability in these patients could be predicted by clinical assessments that identify systemic hypertension (systolic blood pressure 4 160 mmHg), hypoalbuminemia (serum albumin o 2.7 mg/dl), antithrombin activity (o 70%), and degree of proteinuria (urine protein:creatinine ratio [UPC] ! cache = ./cache/cord-023095-4dannjjm.txt txt = ./txt/cord-023095-4dannjjm.txt === reduce.pl bib === id = cord-014527-nvzfpntu author = nan title = Research Communications of the 25th ECVIM‐CA Congress date = 2015-11-09 pages = extension = .txt mime = text/plain words = 89238 sentences = 4996 flesch = 52 summary = A negative outcome was associated with higher fecal S100A12 concentrations in CE dogs, but the response to different forms of treatment and fecal S100A12 has not been reported, and this information will be important to further evaluate the utility of fecal S100A12 as a biomarker for gastrointestinal disease. Statistical analysis was performed using non-parametric 2-or multiple-group comparisons, the likelihood ratio to evaluate the association between groups of dogs and response to treatment, and a receiver operating characteristic curve to calculate sensitivity and specificity at the optimum cut-off concentration. The objectives of this study were to describe pulmonary transit time and myocardial perfusion normalized to heart rate (nPTT and nMP, respectively), evaluated by means of contrast echocardiography, in dogs with stable stage C ACVIM myxomatous mitral valve disease (MMVD), and to assess short-term effects of pimobendan on these parameters. cache = ./cache/cord-014527-nvzfpntu.txt txt = ./txt/cord-014527-nvzfpntu.txt ===== Reducing email addresses cord-300963-1n1f8mf2 Creating transaction Updating adr table ===== Reducing keywords cord-017342-qsfykh1k cord-013370-gktnz644 cord-256143-9u5a0jqz cord-259585-mjtxiu0t cord-258066-ncuegrq7 cord-026792-jsqa4pmu cord-027386-23exaaik cord-267260-8l831mre cord-253001-xmcwuuk4 cord-026025-xqj877en cord-031937-qhlatg84 cord-014516-r59usk02 cord-276267-77903fld cord-281275-i9920nvm cord-285820-g8b7u3yf cord-266392-bayabroa cord-287885-1jwwmoys cord-261029-befymalm cord-283279-1qcdnd1y cord-263419-qeo6qn0d cord-022555-a7ie82fs cord-275447-nx45kwn6 cord-300963-1n1f8mf2 cord-288014-rrr4x755 cord-284234-9cd2v6bt cord-275199-y7b12vml cord-288439-srzysoqy cord-290750-85731og8 cord-295066-76se8mxq cord-302717-hn3airxq cord-032753-icteg34y cord-306760-05my504t cord-255930-2bobmkvu cord-285238-bpk3xl8x cord-280023-r3qgdgeu cord-285426-iyl12ber cord-269390-4yn8c34i cord-306325-9alfvda1 cord-266648-962r0vm8 cord-258930-60yn4hg7 cord-307769-rjseio5s cord-023134-y665agnh cord-286912-cww4ha3j cord-310042-9z8rkzq8 cord-311162-kbqh7beq cord-269835-mz7i66qp cord-021852-o0k2r0yo cord-311804-39mu0tdr cord-312663-hhd5f823 cord-312374-gu9tq48n cord-317151-cxx5pcln cord-337204-14gxpeaf cord-316354-pix0hmpj cord-297768-tjqpiyp1 cord-306859-aqfgl9cm cord-323553-bukm9m9q cord-307201-keec6fzo cord-331703-4hwmajt3 cord-343832-xg3swuzs cord-322957-clf8f90t cord-337896-mct29erg cord-349500-603v8lfb cord-351566-z6onmkrn cord-303942-77nbi3ws cord-347607-ydbyonbg cord-345786-1o9nx7z9 cord-022888-dnsdg04n cord-014527-nvzfpntu cord-023095-4dannjjm Creating transaction Updating wrd table ===== Reducing urls cord-267260-8l831mre cord-031937-qhlatg84 cord-022555-a7ie82fs cord-032753-icteg34y cord-255930-2bobmkvu cord-306760-05my504t cord-280023-r3qgdgeu cord-317151-cxx5pcln cord-306859-aqfgl9cm cord-349500-603v8lfb cord-022888-dnsdg04n Creating transaction Updating url table ===== Reducing named entities cord-013370-gktnz644 cord-256143-9u5a0jqz cord-259585-mjtxiu0t cord-026792-jsqa4pmu cord-258066-ncuegrq7 cord-017342-qsfykh1k cord-267260-8l831mre cord-253001-xmcwuuk4 cord-027386-23exaaik cord-031937-qhlatg84 cord-276267-77903fld cord-281275-i9920nvm cord-285820-g8b7u3yf cord-266392-bayabroa cord-287885-1jwwmoys cord-263419-qeo6qn0d cord-283279-1qcdnd1y cord-275447-nx45kwn6 cord-026025-xqj877en cord-288014-rrr4x755 cord-290750-85731og8 cord-300963-1n1f8mf2 cord-284234-9cd2v6bt cord-288439-srzysoqy cord-014516-r59usk02 cord-275199-y7b12vml cord-302717-hn3airxq cord-295066-76se8mxq cord-032753-icteg34y cord-022555-a7ie82fs cord-255930-2bobmkvu cord-306760-05my504t cord-269390-4yn8c34i cord-285426-iyl12ber cord-285238-bpk3xl8x cord-266648-962r0vm8 cord-280023-r3qgdgeu cord-258930-60yn4hg7 cord-310042-9z8rkzq8 cord-311162-kbqh7beq cord-307769-rjseio5s cord-286912-cww4ha3j cord-312374-gu9tq48n cord-269835-mz7i66qp cord-312663-hhd5f823 cord-311804-39mu0tdr cord-297768-tjqpiyp1 cord-021852-o0k2r0yo cord-306859-aqfgl9cm cord-337204-14gxpeaf cord-023134-y665agnh cord-261029-befymalm cord-317151-cxx5pcln cord-323553-bukm9m9q cord-307201-keec6fzo cord-316354-pix0hmpj cord-322957-clf8f90t cord-331703-4hwmajt3 cord-343832-xg3swuzs cord-337896-mct29erg cord-306325-9alfvda1 cord-351566-z6onmkrn cord-303942-77nbi3ws cord-349500-603v8lfb cord-347607-ydbyonbg cord-345786-1o9nx7z9 cord-014527-nvzfpntu cord-023095-4dannjjm cord-022888-dnsdg04n Creating transaction Updating ent table ===== Reducing parts of speech cord-013370-gktnz644 cord-256143-9u5a0jqz cord-258066-ncuegrq7 cord-259585-mjtxiu0t cord-026792-jsqa4pmu cord-267260-8l831mre cord-253001-xmcwuuk4 cord-281275-i9920nvm cord-027386-23exaaik cord-287885-1jwwmoys cord-266392-bayabroa cord-017342-qsfykh1k cord-285820-g8b7u3yf cord-263419-qeo6qn0d cord-276267-77903fld cord-283279-1qcdnd1y cord-261029-befymalm cord-288014-rrr4x755 cord-275447-nx45kwn6 cord-290750-85731og8 cord-284234-9cd2v6bt cord-295066-76se8mxq cord-285426-iyl12ber cord-300963-1n1f8mf2 cord-275199-y7b12vml cord-269390-4yn8c34i cord-306760-05my504t cord-288439-srzysoqy cord-032753-icteg34y cord-302717-hn3airxq cord-285238-bpk3xl8x cord-258930-60yn4hg7 cord-266648-962r0vm8 cord-280023-r3qgdgeu cord-306325-9alfvda1 cord-310042-9z8rkzq8 cord-311162-kbqh7beq cord-311804-39mu0tdr cord-031937-qhlatg84 cord-255930-2bobmkvu cord-286912-cww4ha3j cord-307769-rjseio5s cord-021852-o0k2r0yo cord-312663-hhd5f823 cord-297768-tjqpiyp1 cord-312374-gu9tq48n cord-337204-14gxpeaf cord-306859-aqfgl9cm cord-269835-mz7i66qp cord-307201-keec6fzo cord-331703-4hwmajt3 cord-351566-z6onmkrn cord-323553-bukm9m9q cord-343832-xg3swuzs cord-303942-77nbi3ws cord-317151-cxx5pcln cord-322957-clf8f90t cord-316354-pix0hmpj cord-337896-mct29erg cord-345786-1o9nx7z9 cord-347607-ydbyonbg cord-349500-603v8lfb cord-026025-xqj877en cord-023134-y665agnh cord-014516-r59usk02 cord-022555-a7ie82fs cord-014527-nvzfpntu cord-023095-4dannjjm cord-022888-dnsdg04n Creating transaction Updating pos table Building ./etc/reader.txt cord-023095-4dannjjm cord-014527-nvzfpntu cord-022888-dnsdg04n cord-255930-2bobmkvu cord-026025-xqj877en cord-022555-a7ie82fs number of items: 69 sum of words: 805,178 average size in words: 11,669 average readability score: 47 nouns: dogs; patients; cells; disease; cats; study; cell; treatment; expression; infection; results; cases; blood; group; response; serum; analysis; data; time; bowel; samples; risk; protein; diagnosis; mice; therapy; levels; role; studies; colitis; age; concentrations; activity; years; days; signs; groups; diseases; cat; gene; control; activation; use; test; inflammation; presence; effects; effect; function; responses verbs: use; associated; increased; including; shows; compared; reporting; induced; find; suggested; performing; follow; evaluate; determine; based; identifying; treated; occurring; considered; assess; observing; affected; present; reduce; required; describe; expressed; measure; causing; demonstrated; obtained; develop; results; providing; investigate; involving; indicate; detected; see; remain; decreased; receiving; leading; infect; confirm; test; known; activated; analyzed; relates adjectives: clinical; inflammatory; specific; significant; high; immune; human; different; healthy; normal; non; higher; severe; anti; positive; canine; intestinal; chronic; small; gastrointestinal; important; present; common; low; feline; acute; lower; viral; median; first; many; primary; available; respiratory; negative; several; possible; large; fecal; similar; potential; covid-19; bacterial; active; new; cardiac; diagnostic; novel; mean; total adverbs: also; significantly; however; well; respectively; therefore; often; previously; usually; even; commonly; furthermore; recently; highly; currently; clinically; moreover; still; especially; particularly; prior; less; frequently; approximately; statistically; alone; typically; interestingly; finally; mainly; together; additionally; now; least; directly; rapidly; potentially; relatively; specifically; daily; naturally; far; rather; almost; yet; later; already; strongly; generally; newly pronouns: we; it; their; our; its; they; i; them; us; one; his; itself; he; you; themselves; yϕ; she; your; her; ourselves; mg; my; interleukin-15; igmcic; himself; euthanasia; esat-6; e2f2-/-mice; crx-527; Ò; yourself; turns; trl2x4; thbs1; srd)dogs; s; rab3b; pi3kg; pep005; muty; mtecs; l).the; il-1β; il)-2r; igg1; ifnl4; idc; hrgal3; high‐dose; h.&e. proper nouns: IBD; T; COVID-19; SARS; mg; CoV-2; AE; Crohn; CD4; TNF; IFN; CD8; PCR; L; C; GI; ELISA; University; HLA; kg; UC; ACE2; CD; C.; MHC; E.; B; China; TCR; II; Disease; A; DC; RNA; M.; •; IL-10; Group; S.; gd; Fig; CI; CHF; CKD; NKT; TG; Health; CRP; IL-6; LA keywords: ibd; covid-19; sars; patient; cat; study; pcr; disease; university; group; dog; crohn; dna; ckd; chf; veterinary; treatment; tnf; rna; protein; infection; hla; fip; elisa; concentration; cell; ace2; western; vegf; tsg-6; tmprss2; tlr5; tlr4; tlr; time; th2; th1; tgf; test; tcr; staphylococcus; ssh; small; sle; sign; sbp; sample; sam; risk; result one topic; one dimension: dogs file(s): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577405/ titles(s): Providing Guidance During a Global Viral Pandemic for the Care of Patients With Inflammatory Bowel Disease three topics; one dimension: dogs; cells; cats file(s): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913621/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163517/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158306/ titles(s): Research Communications of the 25th ECVIM‐CA Congress | Poster Sessions | Digestive System, Liver, and Abdominal Cavity five topics; three dimensions: dogs cats study; cells cell il; patients ibd covid; cats may disease; ahsg fmt il file(s): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913621/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163517/, https://www.ncbi.nlm.nih.gov/pubmed/32874484/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158306/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520878/ titles(s): Research Communications of the 25th ECVIM‐CA Congress | Poster Sessions | Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic | Digestive System, Liver, and Abdominal Cavity | Microbial therapeutics for acute colitis based on genetically modified Lactococcus lactis hypersecreting IL-1Ra in mice Type: cord title: keyword-ibd-cord date: 2021-05-25 time: 00:27 username: emorgan patron: Eric Morgan email: emorgan@nd.edu input: keywords:ibd ==== make-pages.sh htm files ==== make-pages.sh complex files ==== make-pages.sh named enities ==== making bibliographics id: cord-013370-gktnz644 author: Abreu, Maria T title: Providing Guidance During a Global Viral Pandemic for the Care of Patients With Inflammatory Bowel Disease date: 2020-10-21 words: 1840 sentences: 83 pages: flesch: 56 cache: ./cache/cord-013370-gktnz644.txt txt: ./txt/cord-013370-gktnz644.txt summary: We have partnered closely with the European Crohn''s and Colitis Organisation because of our shared desire to provide the best guidance to patients with inflammatory bowel disease at a global level, as well as to the physicians that are caring for these patients. The process is called a RAND panel wherein the members of IOIBD, as well as other very knowledgeable practitioners of IBD, voted on a series of statements largely having to do with the risk of infection with the SARS-CoV-2 virus and the development of COVID-19 in patients who have IBD. We urge you to continue to check the IOIBD or the ECCO websites for the most up-to-date information, and we hope to keep updating the guidance in all of the various dimensions of IBD care. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577405/ doi: 10.1093/ecco-jcc/jjaa116 id: cord-276267-77903fld author: Al‐Ani, Aysha H. title: Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient date: 2020-05-26 words: 5481 sentences: 355 pages: flesch: 42 cache: ./cache/cord-276267-77903fld.txt txt: ./txt/cord-276267-77903fld.txt summary: 6 Consequently, there is a concern that IBD patients are at greater risk of developing COVID-19 and at increased risk of progressing to a more severe clinical course or even death compared to the general population. 18 Furthermore, there is a recent case report of a possible SARS-CoV-2 gastrointestinal infection causing acute haemorrhagic colitis and signalling COVID-19 disease. Clinical assessment of risk factors for infection in inflammatory bowel disease patients Protection of 318 inflammatory bowel disease patients from the outbreak and rapid spread of COVID-19 infection in Wuhan Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials abstract: BACKGROUND: The current COVID‐19 pandemic, caused by SARS‐CoV‐2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary management of IBD involves treating uncontrolled inflammation with most patients requiring immune‐based therapies. However, these therapies may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complications including those from COVID‐19. AIM: To summarise the scale of the COVID‐19 pandemic, review unique concerns regarding IBD management and infection risk during the pandemic and assess COVID‐19 management options and drug interactions in the IBD population. METHODS: A literature review on IBD, SARS‐CoV‐2 and COVID‐19 was undertaken and relevant literature was summarised and critically examined. RESULTS: IBD patients do not appear to be more susceptible to SARS‐CoV‐2 infection and there is no evidence of an association between IBD therapies and increased risk of COVID‐19. IBD medication adherence should be encouraged to prevent disease flare but where possible high‐dose systemic corticosteroids should be avoided. Patients should exercise social distancing, optimise co‐morbidities and be up to date with influenza and pneumococcal vaccines. If a patient develops COVID‐19, immune suppressing medications should be withheld until infection resolution and if trial medications for COVID‐19 are being considered, potential drug interactions should be checked. CONCLUSION: IBD patient management presents a challenge in the current COVID‐19 pandemic. The primary focus should remain on keeping bowel inflammation controlled and encouraging medication adherence. url: https://www.ncbi.nlm.nih.gov/pubmed/32348598/ doi: 10.1111/apt.15779 id: cord-310042-9z8rkzq8 author: Aysha, Al‐Ani title: Practical management of inflammatory bowel disease patients during the COVID‐19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty date: 2020-07-12 words: 3471 sentences: 214 pages: flesch: 43 cache: ./cache/cord-310042-9z8rkzq8.txt txt: ./txt/cord-310042-9z8rkzq8.txt summary: This review aims to summarise the current literature and provide guidance on the management of inflammatory bowel disease (IBD) patients in the context of the COVID‐19 pandemic in the Australasian setting. A significant proportion of IBD patients are treated with long-term immunomodulator/immunosuppressive therapy which potentially places them at increased risk of infections and associated complications. Practitioners and patients alike are therefore concerned about the risk and implications of COVID-19 infection in the IBD patient, despite a paucity of evidence supporting an altered predisposition to disease or more severe disease course. Despite concerns regarding immunosuppression and consequent predisposition to infection, there is no evidence to suggest increased infection rates of COVID-19 in IBD patients to date. 8, 9 Hence, expert consensus currently is that patients with IBD do not appear to be at increased risk of SARS-CoV-2 infection compared with the general population. 2 • Reducing disease activitythere is evidence that moderate to severe disease activity increases the risk of infection in IBD patients. abstract: The COVID‐19 pandemic, caused by the novel coronavirus SARS‐CoV‐2, has emerged as a public health emergency and challenged healthcare systems globally. In a minority of patients, SARS‐CoV‐2 manifests with a severe acute respiratory illness and currently there are insufficient data regarding the virulence of COVID‐19 in inflammatory bowel disease patients taking immunosuppressive therapy. This review aims to summarise the current literature and provide guidance on the management of inflammatory bowel disease (IBD) patients in the context of the COVID‐19 pandemic in the Australasian setting. url: https://doi.org/10.1111/imj.14889 doi: 10.1111/imj.14889 id: cord-283279-1qcdnd1y author: Barberio, Brigida title: The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients During COVID-19 Pandemic: Is It Really a Problem? date: 2020-07-17 words: 662 sentences: 42 pages: flesch: 51 cache: ./cache/cord-283279-1qcdnd1y.txt txt: ./txt/cord-283279-1qcdnd1y.txt summary: title: The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients During COVID-19 Pandemic: Is It Really a Problem? 1 a evaluating the adherence to infusible biologic therapies, defined as receiving an infusion within ten weeks of the prior infusion, in patients with Inflammatory Bowel Disease (IBD) during the current Coronavirus disease 2019 (COVID-19) pandemic. 4, 5 For instance, at our Center, one week before the infusion, patients were contacted by email to reassure about the lack of risk in moving to the Hospital and the benefit of continuing medical therapy. We should explain to our patients with chronic diseases why it is important that they adhere to therapies which are relative safe and manageable despite the COVID-19 pandemic. Adherence of infusible biologics during the time of COVID-19 among patients with Inflammatory Bowel Disease: A nationwide VA cohort study abstract: nan url: https://api.elsevier.com/content/article/pii/S001650852034943X doi: 10.1053/j.gastro.2020.07.017 id: cord-307201-keec6fzo author: Barberio, Brigida title: Should IBD Patients Be Tested for Active COVID-19 Prior Starting a Biological Treatment? date: 2020-08-30 words: 655 sentences: 43 pages: flesch: 44 cache: ./cache/cord-307201-keec6fzo.txt txt: ./txt/cord-307201-keec6fzo.txt summary: title: Should IBD Patients Be Tested for Active COVID-19 Prior Starting a Biological Treatment? aimed to provide recommendations regarding the management of patients with inflammatory bowel disease (IBD) in the era of COVID-19 pandemic. The AGA suggests that IBD patients should not stop their current treatments in order to prevent infection or adverse outcome with COVID-19. However, there was no specific international guidance with respect to COVID-19 testing in patients starting immunosuppressive treatment, particularly if they are asymptomatic, and the article by Rubin et al did not cover this topic either. 6 Overall, we believe that screening for active COVID-19 infection should be performed in order to avoid potential complications and to adjust therapy accordingly prior starting biological treatment. Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak Are patients with inflammatory bowel disease at increased risk for COVID-19 infection ? abstract: nan url: https://doi.org/10.1053/j.gastro.2020.08.049 doi: 10.1053/j.gastro.2020.08.049 id: cord-302717-hn3airxq author: Bayoumy, Ahmed B. title: Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom date: 2020-09-11 words: 6481 sentences: 347 pages: flesch: 54 cache: ./cache/cord-302717-hn3airxq.txt txt: ./txt/cord-302717-hn3airxq.txt summary: title: Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom BACKGROUND: Thioguanine (TG) is a thiopurine which has been used for patients with inflammatory bowel disease (IBD), who have failed azathioprine (AZA) or mercaptopurine (MP) due to adverse events or suboptimal response. The aim of this study was to investigate the long-term efficacy and safety of low-dose TG therapy in IBD patients failing AZA and MP. METHODS: A retrospective multicentre study was performed in IBD patients who failed prior treatment with conventional thiopurines with or without following immunomodulation (thiopurine-allopurinol, biologicals, methotrexate, tacrolimus) and were subsequently treated with TG as rescue monotherapy between 2003 and 2019 at three hospitals in the United Kingdom. They reported results of 11 studies, comprising of 353 patients who were treated with a median TG starting dose of 20 mg/day after failing prior conventional thiopurine therapy. abstract: BACKGROUND: Thioguanine (TG) is a thiopurine which has been used for patients with inflammatory bowel disease (IBD), who have failed azathioprine (AZA) or mercaptopurine (MP) due to adverse events or suboptimal response. Its widespread use has been hampered due to concerns about nodular regenerative hyperplasia (NRH) of the liver. The aim of this study was to investigate the long-term efficacy and safety of low-dose TG therapy in IBD patients failing AZA and MP. METHODS: A retrospective multicentre study was performed in IBD patients who failed prior treatment with conventional thiopurines with or without following immunomodulation (thiopurine-allopurinol, biologicals, methotrexate, tacrolimus) and were subsequently treated with TG as rescue monotherapy between 2003 and 2019 at three hospitals in the United Kingdom. Clinical response, adverse events, laboratory results, imaging and liver biopsies were retrospectively collected. RESULTS: A total of 193 patients (57% female and 64% Crohn’s disease) were included, with a median daily TG dose of 20 mg (range: 20–40 mg), a median treatment duration of 23 months (IQR 10–47) and a median follow-up of 36 months (IQR 22–53). The clinical response rate at 12 months was 65 and 54% remained on TG until the end of follow-up. Adverse events consisted primarily of elevated liver tests (6%), myelotoxicity (7%) and rash (5%). NRH was histologically diagnosed in two patients and two other patients (1%) developed non-cirrhotic portal hypertension. The median 6-TGN and TPMT levels were 953 pmol/8 × 10(5) RBC (IQR 145–1761) and 47 mu/L (IQR 34.5–96). CONCLUSIONS: Long-term follow-up suggests that TG can be an effective and well-tolerated therapy in more than half of difficult-to-treat and multi-therapy failing IBD patients. Findings of this study indicate that TG can be used safely and the occurrence of hepatotoxicity was low. The incidence rate of NRH was within the background incidence. url: https://doi.org/10.1186/s12876-020-01441-6 doi: 10.1186/s12876-020-01441-6 id: cord-311162-kbqh7beq author: Behzad, Catherine title: Establishing Safe Out-of-Hospital Infusion Centers May Improve the Quality of Care in Patients With IBD During the COVID-19 Pandemic date: 2020-09-09 words: 491 sentences: 33 pages: flesch: 55 cache: ./cache/cord-311162-kbqh7beq.txt txt: ./txt/cord-311162-kbqh7beq.txt summary: title: Establishing Safe Out-of-Hospital Infusion Centers May Improve the Quality of Care in Patients With IBD During the COVID-19 Pandemic We read with great interest the article by Occhipinti and Pastorelli 1 about the challenges in the care of patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic. However, 2 medical wards were maintained COVID-19-free to provide care for patients with urgent situations and essential services. In addition, we gave special consideration to patients with IBD who were on immunosuppressive therapy and decided to continue biologic infusions in the hospital''s COVID-19-free wards. In our experience, 92% of the patients whose scheduled biologic infusion dates were during the peak of the outbreak in early February through March refused to come to the hospital to receive their infusions. Challenges in the care of IBD patients during the CoViD-19 pandemic: report from a "Red Zone" area in Northern Italy abstract: nan url: https://doi.org/10.1093/ibd/izaa246 doi: 10.1093/ibd/izaa246 id: cord-345786-1o9nx7z9 author: Bernstein, Charles N title: Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey date: 2020-08-14 words: 3737 sentences: 214 pages: flesch: 52 cache: ./cache/cord-345786-1o9nx7z9.txt txt: ./txt/cord-345786-1o9nx7z9.txt summary: METHODS: Members of the World Gastroenterology Organization (WGO) IBD Task Force contacted colleagues in countries largely beyond North America and Europe, inviting them to review the WGO website for IBD and COVID-19 introduction, with links to guideline documents, and then to respond to 9 ancillary open-ended management questions. [1] [2] [3] The management of IBD may differ by geography with economically more advanced countries having greater access to health care resources such as endoscopy and expensive therapies like biologics. 8 Recommendations include continuing all immunomodulatory medications in patients with IBD, reducing steroid doses as much as possible, limiting elective endoscopies, and encouraging telemedicine in place of in-person clinic visits. Respondents from 8 countries, both low and high resource regions, reported that they routinely tested persons with IBD with new gastrointestinal symptoms. However, even with reports from 1 or 2 clinicians from each country, it allows insight into the uniformity or key differences in the practice of IBD around the world during the COVID-19 pandemic. abstract: BACKGROUND AND AIMS: Persons with inflammatory bowel disease (IBD) may be particularly vulnerable to COVID-19 either because of their underlying disease or its management. Guidance has been presented on the management of persons with IBD in the time of this pandemic by different groups. We aimed to determine how gastroenterologists around the world were approaching the management of IBD. METHODS: Members of the World Gastroenterology Organization (WGO) IBD Task Force contacted colleagues in countries largely beyond North America and Europe, inviting them to review the WGO website for IBD and COVID-19 introduction, with links to guideline documents, and then to respond to 9 ancillary open-ended management questions. RESULTS: Fifty-two gastroenterologists from 33 countries across 6 continents completed the survey (April 14 to May 16, 2020). They were all adhering for the most part to published guidelines on IBD management in the COVID-19 era. Some differences and reductions in services related to access, and some related to approach within their communities in terms of limiting virus spread. In particular, most gastroenterologists reduced in-person clinics (43 of 52), limited steroid use (47 of 51), limited elective endoscopy (45 of 52), and limited elective surgeries (48 of 51). If a patient was diagnosed with COVID-19, immunomodulatory therapy was mostly held. CONCLUSIONS: In most countries, the COVID-19 pandemic significantly altered the approach to persons with IBD. The few exceptions were mostly based on low burden of COVID-19 in individual communities. Regardless of resources or health care systems, gastroenterologists around the world took a similar approach to the management of IBD. url: https://doi.org/10.1093/ibd/izaa202 doi: 10.1093/ibd/izaa202 id: cord-351566-z6onmkrn author: Bezzio, Cristina title: SEVERE IBD FLARES AND COVID-19: EXPAND THE GASTROENTEROLOGY-SURGERY TEAM TO INCLUDE AN INFECTIOUS DISEASE SPECIALIST date: 2020-06-16 words: 473 sentences: 32 pages: flesch: 50 cache: ./cache/cord-351566-z6onmkrn.txt txt: ./txt/cord-351566-z6onmkrn.txt summary: title: SEVERE IBD FLARES AND COVID-19: EXPAND THE GASTROENTEROLOGY-SURGERY TEAM TO INCLUDE AN INFECTIOUS DISEASE SPECIALIST Perhaps because of the lack of empirical evidence, these guidelines did not specifically address the challenging case of IBD patients hospitalized due to a severe flare of disease with subsequent or concomitant pneumonia due to SARS-CoV-2. Especially in ulcerative colitis, a severe flare of disease is a life-threatening emergency that requires prompt recognition, hospitalization, early initiation of treatment and close monitoring (4). However, in the COVID-19 pandemic, this professional pair may not be enough to effectively manage the infection in an IBD patient with a severe disease flare. Nonetheless, we think that the issues raised by this case are of great interest to physicians managing IBD patients during the COVID-19 pandemic. In particular, we suggest that an infectious disease specialist join the gastroenterologist and surgeon on the team managing IBD patients hospitalized for a severe flare of disease. abstract: nan url: https://www.ncbi.nlm.nih.gov/pubmed/32553764/ doi: 10.1053/j.gastro.2020.05.082 id: cord-295066-76se8mxq author: Botti, Fiorenzo title: URGENT SURGERY FOR INFLAMMATORY BOWEL DISEASES DURING THE COVID-19 OUTBREAK IN A HIGH INCIDENCE AREA - EXPERIENCE FROM A HIGH-VOLUME CENTRE date: 2020-08-31 words: 1720 sentences: 80 pages: flesch: 47 cache: ./cache/cord-295066-76se8mxq.txt txt: ./txt/cord-295066-76se8mxq.txt summary: [4] As a tertiary referral centre for the surgical management of IBD patients, it was important to clearly define which complicated IBD cases were to be operated, by taking into account several variables including disease severity and quality of life, presence of comorbidities, feasibility of an alternative procedure. According to the British Society of Gastroenterology (BSG) guidelines on the IBD management during the COVID-19 pandemic, [5] routine elective operations should be deferred, while emergency procedures (e.g. colectomy in acute severe ulcerative colitis [UC] or intestinal resection in septic complications of penetrating Crohn''s disease [CD]) should continue. Complex surgical IBD cases should also be deferred when possible and its timing must be regularly reviewed at multidisciplinary meetings, trying to optimize medical treatment (e.g. using partial or exclusive enteral nutrition regimens or draining abscesses in combination with antibiotic therapy) and to avoid surgery or change the timing from emergency to urgent or semi-urgent. abstract: nan url: https://doi.org/10.1016/j.dld.2020.08.039 doi: 10.1016/j.dld.2020.08.039 id: cord-266392-bayabroa author: Brenner, Erica J. title: BENIGN EVOLUTION OF SARS-CoV2 INFECTIONS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM TWO INTERNATIONAL DATABASES date: 2020-10-12 words: 1244 sentences: 82 pages: flesch: 46 cache: ./cache/cord-266392-bayabroa.txt txt: ./txt/cord-266392-bayabroa.txt summary: 2 Since highest ACE2 expression is in the terminal ileum and colon, further upregulated during inflammation, and many COVID-19 patients experience gastrointestinal symptoms, longitudinal data are necessary determine whether inflammatory bowel diseases (IBD) patients are at risk for severe or complicated COVID-19. A recent analysis in IBD patients from the SECURE-IBD registry revealed older age, steroid medication and comorbidities as risk factors for severe evolution, while the same study showed that the 29 IBD patients less 20 years had only mild disease courses. Factors associated with hospitalization included comorbid conditions other than IBD (50% hospitalized vs 12% not; p value <0.01), moderate/severe IBD disease activity (64% vs 15%; p value <0.01 overall), gastrointestinal symptoms (71% vs 19%, p value <0.01), sulfasalazine/mesalamine use (57% vs 21%; p value 0.01), and steroid use (29% vs 8%, p value 0.03). The six-year-old colitis patient requiring ICU care in this series is in line with the recent reports of multi-systemic inflammatory (Kawasaki-like) syndrome temporarily related to SARS-CoV-2 infection in children. abstract: nan url: https://www.ncbi.nlm.nih.gov/pubmed/33059040/ doi: 10.1016/j.cgh.2020.10.010 id: cord-267260-8l831mre author: Brenner, Erica J. title: Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry date: 2020-05-18 words: 3136 sentences: 170 pages: flesch: 43 cache: ./cache/cord-267260-8l831mre.txt txt: ./txt/cord-267260-8l831mre.txt summary: Risk factors for severe COVID-19 among IBD patients included increasing age (adjusted odds ratio [aOR] 1.04, 95% CI 1.01-1.02), ≥2 comorbidities (aOR 2.9, 95% CI 1.1-7.8), systemic corticosteroids (aOR 6.9, 95% CI 2.3-20.5), and sulfasalazine or 5-aminosalicylate use (aOR 3.1, 95% CI 1.3-7.7). To understand the impact of IBD on case fatality, we computed expected and observed deaths and age-standardized mortality ratios (SMR) utilizing published agestratified COVID-19 case fatality rates from China and Italy 2, 23 and publically available data from the U.S. 24, 25 Multivariable logistic regression estimated the independent effects of age, sex, disease (CD vs UC/IBD-U), disease activity, smoking, BMI ≥30, and number of comorbidities (0, 1, ≥2) on the primary outcome of severe COVID-19, defined as a composite of ICU admission, ventilator use, and/or death, consistent with existing COVID-19 literature. In our exploratory analyses, we found that TNF antagonist combination therapy, compared to monotherapy, was positively associated with the outcome of hospitalization or death (aOR 5.0, 95% CI 2.0-12.3), after adjusting for clinical and demographic variables and use of systemic corticosteroids and 5-ASA/sulfasalazine. abstract: Background and Aims The impact of Coronavirus disease 2019 (COVID-19) on patients with inflammatory bowel disease (IBD) is unknown. We sought to characterize the clinical course of COVID-19 among IBD patients and evaluate the association between demographics, clinical characteristics, and immunosuppressant treatments on COVID-19 outcomes. Methods Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is a large, international registry created to monitor outcomes of IBD patients with confirmed COVID-19. We calculated age-standardized mortality ratios (SMRs) and utilized multivariable logistic regression to identify factors associated with severe COVID-19, defined as intensive care unit admission, ventilator use, and/or death. Results 525 cases from 33 countries were reported (Median age 43 years, 53% men). Thirty-seven patients (7%) had severe COVID-19, 161 (31%) were hospitalized, and 16 patients died (3% case fatality rate). SMRs for IBD patients were 1.8 (95% confidence interval [CI] 0.9-2.6), 1.5 (95% CI 0.7-2.2), and 1.7 (95% CI 0.9-2.5) relative to data from China, Italy, and the US, respectively. Risk factors for severe COVID-19 among IBD patients included increasing age (adjusted odds ratio [aOR] 1.04, 95% CI 1.01-1.02), ≥2 comorbidities (aOR 2.9, 95% CI 1.1-7.8), systemic corticosteroids (aOR 6.9, 95% CI 2.3-20.5), and sulfasalazine or 5-aminosalicylate use (aOR 3.1, 95% CI 1.3-7.7). TNF antagonist treatment was not associated with severe COVID-19 (aOR 0.9, 95% CI 0.4-2.2). Conclusions Increasing age, comorbidities, and corticosteroids are associated with severe COVID-19 among IBD patients, although a causal relationship cannot be definitively established. Notably, TNF antagonists do not appear to be associated with severe COVID-19. url: https://doi.org/10.1053/j.gastro.2020.05.032 doi: 10.1053/j.gastro.2020.05.032 id: cord-306859-aqfgl9cm author: Clough, Jennie N title: Managing an IBD Infusion Unit During the COVID-19 Pandemic: Service Modifications and the Patient Perspective date: 2020-06-27 words: 518 sentences: 36 pages: flesch: 58 cache: ./cache/cord-306859-aqfgl9cm.txt txt: ./txt/cord-306859-aqfgl9cm.txt summary: title: Managing an IBD Infusion Unit During the COVID-19 Pandemic: Service Modifications and the Patient Perspective The COVID-19 pandemic has posed significant challenges to the provision of inflammatory bowel disease (IBD) unit infusion services in terms of the redeployment of specialist staff and reduced capacity because of social distancing. Given the recommendation for patients to remain on their usual biologic medication wherever possible, 1 we modified our service to ensure that our patients were adequately protected on the unit and surveyed attenders regarding their views and concerns. Patients were telephoned 24 hours before their infusion to screen for COVID-19 symptoms and were advised to attend the unit unaccompanied. In addition, 25.2% of patients felt "very" or "somewhat uncomfortable" at the prospect of attending hospital for their usual infusion, but 80.2% felt on attending that the measures taken to reduce the risk of contact with COVID-19 were "completely adequate." abstract: nan url: https://www.ncbi.nlm.nih.gov/pubmed/32592475/ doi: 10.1093/ibd/izaa171 id: cord-322957-clf8f90t author: Crespo, Javier title: Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG date: 2020-04-28 words: 5297 sentences: 364 pages: flesch: 51 cache: ./cache/cord-322957-clf8f90t.txt txt: ./txt/cord-322957-clf8f90t.txt summary: The general objectives of these recommendations include: • To protect our patients against the risks of infection with SARS-CoV-2 and to provide them with high-quality care. These recommendations are based on the sparse, changing evidence available, and will be updated in the future according to daily needs and the availability of expendable materials to suit them; in each department they will be implemented depending upon the cumulative incidence of SARS-CoV-2 infection in each region, and the burden the pandemic has represented for each hospital. These recommendations are based on the sparse, changing evidence available, and will be updated in the future according to daily needs and the availability of expendable materials to suit them; in each department they will be implemented depending upon the cumulative incidence of SARS-CoV-2 infection in each region, and the burden the pandemic has represented for each hospital. abstract: Abstract The set of measures proposed by SEPD, AEEH, GETECCU and AEG are aimed to help departments in their resumption of usual activity. We have prepared a number of practical recommendations regarding patient management and the stepwise resumption of healthcare activity. These recommendations are based on the sparse, changing evidence available, and will be updated in the future according to daily needs and the availability of expendable materials to suit them; in each department they will be implemented depending upon the cumulative incidence of SARS-CoV-2 infection in each region, and the burden the pandemic has represented for each hospital. The general objectives of these recommendations include: • To protect our patients against the risks of infection with SARS-CoV-2 and to provide them with high-quality care. • To protect all healthcare professionals against the risks of infection with SARS-CoV-2. • To resume normal functioning of our departments in a setting of ongoing risk for infection with SARS-CoV-2. url: https://api.elsevier.com/content/article/pii/S2444382420300717 doi: 10.1016/j.gastre.2020.04.001 id: cord-287885-1jwwmoys author: D''Amico, Ferdinando title: Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey date: 2020-05-13 words: 599 sentences: 38 pages: flesch: 49 cache: ./cache/cord-287885-1jwwmoys.txt txt: ./txt/cord-287885-1jwwmoys.txt summary: title: Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey Therefore, we did an anonymous web survey with the support of the European Federation of Crohn''s and Ulcerative Colitis Associations (EFCCA) between March 30 and April 16, 2020, to investigate the concerns, fears, and behaviours of patients with IBD during the early phase of the COVID-19 pandemic. The European Crohn''s and Colitis Organisation, the British Society of Gastroenterology, and the International Organization for the Study of Inflammatory Bowel Diseases have responded to this request, providing practical guidelines for the management of patients with IBD during the pandemic, focusing not only on drug treatment but also on advice for daily life (eg, social distancing, use of masks, and travel avoidance). Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic abstract: nan url: https://www.sciencedirect.com/science/article/pii/S2468125320301515 doi: 10.1016/s2468-1253(20)30151-5 id: cord-290750-85731og8 author: Danese, Silvio title: Management of IBD during the COVID-19 outbreak: resetting clinical priorities date: 2020-03-25 words: 1798 sentences: 86 pages: flesch: 49 cache: ./cache/cord-290750-85731og8.txt txt: ./txt/cord-290750-85731og8.txt summary: Because of the very high transmission capacity, the WHO declared the outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 infection a public health emergency of international concern. Additional recommendations for patients with IBD from the IOIBD: • Medicines such as mesalamine are safe • If possible, withdraw from steroid use • Biologic agents used to treat IBD (e.g. anti-TNF agents, ustekinumab and vedolizumab) are generally safe; there are no recommendations to stop taking these medications and the effects of these drugs are present for many months • Thiopurines and tofacitinib tend to inhibit the immune response to viral infections, but stopping these agents in the short-term will not help • Get the influenza vaccination • Stay at home and minimize social contact c | Strategies to enable maintenance of our biologic agent clinic during the COVID-19 outbreak in Italy include checkpoints at hospital entrances for symptom screening and use of surgical masks for clinical staff and patients. abstract: The coronavirus disease (COVID-19) worldwide outbreak has led to a dramatic challenge for all healthcare systems, including inflammatory bowel disease (IBD) centres. Here, we describe the fast changes and clinical issues that IBD specialists could face during this SARS-CoV-2 infection pandemic, highlighting the potential rearrangements of care and resetting of clinical priorities. url: https://doi.org/10.1038/s41575-020-0294-8 doi: 10.1038/s41575-020-0294-8 id: cord-297768-tjqpiyp1 author: Day, Alice S. title: Practical guidance for dietary management of patients with inflammatory bowel disease during the SARS-CoV2 pandemic date: 2020-07-20 words: 1180 sentences: 56 pages: flesch: 44 cache: ./cache/cord-297768-tjqpiyp1.txt txt: ./txt/cord-297768-tjqpiyp1.txt summary: Coronavirus disease (COVID-19) has resulted in considerable morbidity and mortality along with major disruption to global financial markets and social function with mandated social isolation precautions in many countries. 6, 7 It must 55 be acknowledged that it is unlikely any high quality evidence will allow timely production of 56 guidelines specific for IBD patients during the COVID-19 pandemic, so observational data 57 and anecdotal lessons learned from the first countries affected by the novel coronavirus are 58 providing direction for the rest of the world. 2 59 60 Despite reassuring registry data and published guidelines, many patients with IBD and their 61 treating clinicians alike may be reticent to persist with immunosuppressive therapy in the 62 setting of the COVID-19 pandemic. 8 Moreover, EEN has been shown to delay or avoid IBD surgery, 70 which is critical at a time when hospitalization increases risk of COVID-19 exposure as well 71 as in the setting of stretched health care resources. abstract: Abstract The recent outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) pandemic has affected almost every nation worldwide. Coronavirus disease (COVID-19) has resulted in considerable morbidity and mortality along with major disruption to global financial markets and social function with mandated social isolation precautions in many countries. Severe COVID-19 have been reported in older people and those with medical comorbidities, raising concern for those with pre-existing gastrointestinal illness. url: https://api.elsevier.com/content/article/pii/S2212267220309667 doi: 10.1016/j.jand.2020.07.019 id: cord-280023-r3qgdgeu author: Dipasquale, Valeria title: Challenges in paediatric inflammatory bowel diseases in the COVID-19 time date: 2020-04-08 words: 1064 sentences: 56 pages: flesch: 42 cache: ./cache/cord-280023-r3qgdgeu.txt txt: ./txt/cord-280023-r3qgdgeu.txt summary: The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in China in December 2019, now involves the whole world [1 , 2] . Currently no cases of IBD patients infected by SARS-CoV-2 have been reported. As the risk of infections is generally higher in case of combination therapy (biologics plus immunomodulators) in adult and paediatric patients with IBD [6 , 7] , caution should be used with this therapeutic strategy during the COVID-19 epidemic. In conclusion, while waiting for more specific data concerning the risk of COVID-19 in children with IBD and, more generally, in paediatric patients on immunosuppressive therapy, it seems reasonable to carefully weigh the risks/benefits ratio of treatment with immunomodulators and biologics, especially in areas of high infection rate or outbreaks. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China abstract: nan url: https://doi.org/10.1016/j.dld.2020.03.015 doi: 10.1016/j.dld.2020.03.015 id: cord-285238-bpk3xl8x author: Dong, Xiuli title: Intestinal and Peripheral Fibrinogen-Like Protein 2 Expression in Inflammatory Bowel Disease date: 2013-11-28 words: 3457 sentences: 196 pages: flesch: 47 cache: ./cache/cord-285238-bpk3xl8x.txt txt: ./txt/cord-285238-bpk3xl8x.txt summary: AIM: The purpose of this work was to investigate intestinal and peripheral expression of FGL2 in patients with inflammatory bowel disease (IBD), mainly ulcerative colitis (UC) and Crohn''s disease (CD). Correlations of FGL2 expression with disease type, activity, and location, and with measured laboratory data, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), were examined. However, our study demonstrated that intestinal and peripheral expression of FGL2 was significantly higher in UC and CD patients with active disease, and decreased in inactive disease. Reduced FGL2 expression in patients with inactive disease may be because successful treatment, including immune modifiers, anti-TNF-a therapy, and other anti-inflammatory treatment, made up for the deficiency of Treg cells, or reversed the deficiency to exert sufficient suppression against other subsets of T lymphocytes through multiple other suppression molecules. abstract: BACKGROUND: Fibrinogen-like protein 2 (FGL2), a new member of the fibrinogen-like family, has recently been identified as a novel immunosuppressive molecule. AIM: The purpose of this work was to investigate intestinal and peripheral expression of FGL2 in patients with inflammatory bowel disease (IBD), mainly ulcerative colitis (UC) and Crohn’s disease (CD). METHODS: FGL2 expression in mucosal biopsies from three groups (UC group (n = 61), CD group (n = 54), and controls group (n = 35)) was detected by immunohistochemistry. Concentrations of FGL2 in plasma from 50 UC patients, 45 CD patients, and 30 controls were analyzed by enzyme-linked immunosorbent assay. Western blot of FGL2 protein and real-time fluorescent quantitative PCR of FGL2 mRNA expression by peripheral mononuclear cells was performed. Correlations of FGL2 expression with disease type, activity, and location, and with measured laboratory data, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), were examined. RESULTS: Intestinal and peripheral FGL2 protein data showed that FGL2 expression was significantly up-regulated in both UC and CD patients compared with controls (P < 0.001). Expression of FGL2 was higher in UC and CD patients with active disease than in those with inactive disease (P < 0.001). Moreover, FGL2 mRNA expression was significantly higher in patients with active disease than in those with inactive disease (P < 0.050). Expression of FGL2 protein was correlated with disease activity indices, CRP levels, and ESR levels. CONCLUSION: Expression of FGL2 was up-regulated in IBD patients with active disease. Measurement of FGL2 may be used as a helpful biomarker for understanding immunopathogenesis and for assessment of IBD. url: https://doi.org/10.1007/s10620-013-2962-9 doi: 10.1007/s10620-013-2962-9 id: cord-258930-60yn4hg7 author: D’Amico, Ferdinando title: Inflammatory bowel diseases and COVID-19: the invisible enemy date: 2020-04-16 words: 1027 sentences: 65 pages: flesch: 47 cache: ./cache/cord-258930-60yn4hg7.txt txt: ./txt/cord-258930-60yn4hg7.txt summary: All biological and immunosuppressive treatments were discontinued, visits in person were replaced by online consultations, and 318 patients were daily recommended to wash their hands frequently, to reduce the time spent outside the home and to use masks outside the home 7 . It is important to underline that a relevant percentage of evaluated patients had risk factors of infection: chronic diseases (15.4%), immunosuppressive agent therapy (11.0%), elderly (10.4%), high-risk professional categories (7.5%), and biological therapy (6.3%) 7 . Telemedicine has also been associated with a reduction in gastroenterological consultations and hospitalizations and could be a valid alternative to improve the quality of IBD patient care during the COVID-19 outbreak 23 . Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis Protection of 318 inflammatory bowel disease patients from the outbreak and rapid spread of COVID-19 infection in Wuhan abstract: nan url: https://doi.org/10.1053/j.gastro.2020.04.032 doi: 10.1053/j.gastro.2020.04.032 id: cord-275447-nx45kwn6 author: Ehrenpreis, Eli D. title: Rapid Review: Nonsteroidal Anti-inflammatory Agents and Aminosalicylates in COVID-19 Infections date: 2020-06-10 words: 2326 sentences: 130 pages: flesch: 45 cache: ./cache/cord-275447-nx45kwn6.txt txt: ./txt/cord-275447-nx45kwn6.txt summary: Since 5-ASAs are a mainstay treatment for inflammatory bowel disease, the authors review the pharmacology of both classes of drugs and discuss the potential relevance of 5-ASAs in the ongoing discussion of medication use in patients infected with COVID-19. T here has been recent controversy regarding the risk that ibuprofen (and possibly other nonsteroidal antiinflammatory drugs, NSAIDs) may worsen the clinical course of patients that are infected with COVID-19. It is therefore the purpose of this brief review to inform practitioners treating patients with 5-ASAs about the potential relationships between 5-ASAs and NSAIDs. At the time of this writing, both the World Health Organization (WHO) and the Food and Drug Administration (FDA) have not recommended the avoidance of ibuprofen in patients with known or suspected COVID-19 infections. abstract: In the current COVID-19 pandemic, there has been concern regarding the use of ibuprofen and other nonsteroidal anti-inflammatory agents by COVID-19 infected patients. Aminosalicylates (5-ASAs) are structurally similar and have anti-inflammatory functions that resemble those of nonsteroidal anti-inflammatory agents. Since 5-ASAs are a mainstay treatment for inflammatory bowel disease, the authors review the pharmacology of both classes of drugs and discuss the potential relevance of 5-ASAs in the ongoing discussion of medication use in patients infected with COVID-19. url: https://www.ncbi.nlm.nih.gov/pubmed/32530870/ doi: 10.1097/mcg.0000000000001371 id: cord-263419-qeo6qn0d author: Fiorino, Gionata title: Protecting patients with IBD during the COVID-19 pandemic date: 2020-05-20 words: 417 sentences: 31 pages: flesch: 44 cache: ./cache/cord-263419-qeo6qn0d.txt txt: ./txt/cord-263419-qeo6qn0d.txt summary: An and colleagues stopped biologics (infliximab infusions) and immunosuppressive treatments for all patients with IBD. Indeed, a systematic review 4 showed that the risk of hospital admission (odds ratio 0·48, 95% CI 0·29-0·80) and surgery (0·67, 0·46-0·97) is significantly reduced by use of biologics for patients with IBD. The probability of relapse after stopping effective immunomodulators or biological therapy is about 50% and is associated with an increased need for steroids, and risk of hospital admission and surgery. Thus, the risk and benefits of continuing or stopping biologics should be carefully balanced and should not be assumed to be a general rule for all patients with IBD, especially given the length of time the pandemic is likely to last. Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease abstract: nan url: https://www.sciencedirect.com/science/article/pii/S2468125320301527 doi: 10.1016/s2468-1253(20)30152-7 id: cord-312663-hhd5f823 author: Fiorino, Gionata title: Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience date: 2020-03-24 words: 2199 sentences: 109 pages: flesch: 52 cache: ./cache/cord-312663-hhd5f823.txt txt: ./txt/cord-312663-hhd5f823.txt summary: The outbreak of the COVID-19 caused by coronavirus SARS-CoV2, is rapidly spreading worldwide. IBD patients are severely worried about the impact of their disease and medications on the risk and the prognosis of COVID-19, and many of them are forced to come to hospital because of active disease, complications and drug administration. Patients scheduled for a follow-up visit are required to stay at home and to complete a questionnaire about IBD symptoms and quality of life, together with their routine laboratory tests, to the nurse and the dedicated doctor, who give recommendations and information about therapy and follow-up procedures. Based on the assumption that the risk of coronavirus infection is not different between the general population and IBD patients, but that IBD flares are difficult to manage in this situation, we advise all patients to continue their therapies, especially if in remission. abstract: The outbreak of the COVID-19 caused by coronavirus SARS-CoV2, is rapidly spreading worldwide. This is the first pandemic caused by a coronavirus in history. More than 150 000 confirmed cases worldwide are reported involving the SARS-CoV2, with more than 5000 COVID-19-related deaths on March 14, 2020. Fever, chills, cough, shortness of breath, generalised myalgia, malaise, drowsiness, diarrhoea, confusion, dyspnoea, and bilateral interstitial pneumonia are the common symptoms. No therapies are available, and the only way to contain the virus spread is to regularly and thoroughly clean one’s hands with an alcohol-based hand rub or wash them with soap and water, to maintain at least 1 m [3 feet] distance from anyone who is coughing or sneezing, to avoid touching eyes, nose, and mouth, and to stay home if one feels unwell. No data are available on the risk of COVID-19 and outcomes in inflammatory bowel disease [IBD] patients. Outbreak restrictions can impact on the IBD care. We aim to give a viewpoint on how operationally to manage IBD patients and ensure quality of care in the current pandemic era. url: https://www.ncbi.nlm.nih.gov/pubmed/32211765/ doi: 10.1093/ecco-jcc/jjaa058 id: cord-269835-mz7i66qp author: Furfaro, Federica title: SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience date: 2020-06-11 words: 7275 sentences: 295 pages: flesch: 38 cache: ./cache/cord-269835-mz7i66qp.txt txt: ./txt/cord-269835-mz7i66qp.txt summary: The current coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has required a complete change in the management of patients with inflammatory bowel disease (IBD) who need to undergo endoscopic procedures. In particular, recommendations regarding the use of personal protective equipment to prevent COVID-19 transmission, both for patients and health-care professionals, are proposed and different scenarios in endoscopic IBD management are evaluated to suggest when endoscopy could be rescheduled and replaced by alternative biomarkers. The panel of experts con sidered possible aerosolization during colonoscopy, in particular during the insertion and removal of instruments through the biopsy channel and the presence of the virus in the stool and advised on the use of N95 masks for lower gastrointestinal procedures as a precautionary measure to protect the endoscopist from the risk of possible COVID-19 transmission from the patient if infected by SARS-CoV-2 (ref. abstract: The current coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has required a complete change in the management of patients with inflammatory bowel disease (IBD) who need to undergo endoscopic procedures. Several preventive measures must be taken to avoid the spread of infection among health-care professionals and patients with IBD, including the use of personal protective equipment, greater attention to endoscopic room hygiene and rescheduling of non-urgent procedures. This Perspective aims to provide a guide based on the Italian and French experience to better face the difficulties encountered by endoscopists during this global health emergency. In particular, recommendations regarding the use of personal protective equipment to prevent COVID-19 transmission, both for patients and health-care professionals, are proposed and different scenarios in endoscopic IBD management are evaluated to suggest when endoscopy could be rescheduled and replaced by alternative biomarkers. url: https://www.ncbi.nlm.nih.gov/pubmed/32528139/ doi: 10.1038/s41575-020-0319-3 id: cord-300963-1n1f8mf2 author: Gajendran, Mahesh title: Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned date: 2020-10-12 words: 6681 sentences: 350 pages: flesch: 46 cache: ./cache/cord-300963-1n1f8mf2.txt txt: ./txt/cord-300963-1n1f8mf2.txt summary: Previous studies based on SARS-CoV-1 showed that the "cytokine storm" was strongly associated with viral sepsis, inflammation-induced lung injury, and acute respiratory distress syndrome (ARDS) [32, 34] . With regard to IBD-specific risk factors, it is speculated that patients on immunosuppressive agents, those with active IBD symptoms, malnutrition, and frequent visits to clinics or hospitals are at greater risk of acquiring SARS-CoV-2 infection [50] . The International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) maintains a registry for reporting COVID-19 in IBD patients called SECURE-IBD registry. Hence, all the societies have recommended that patients continue their IBD medications to sustain remission, because the risk of disease flare-up outweighs the chance of contracting SARS-CoV-2 infection. The management strategy will depend on multiple factors, such as the patient''s age, the severity of the COVID-19 infection, the clinical status of the IBD, and the presence of other comorbid conditions. abstract: The current outbreak of COVID-19 pandemic caused by SARS-CoV-2 has affected nearly 188 countries. Patients with severe COVID-19 are more commonly elderly and suffer from comorbidities such as hypertension, diabetes mellitus, coronary artery disease, chronic pulmonary disease, obesity, and cancer. Inflammatory bowel disease (IBD) affects as many as 6.8 million people globally, and a significant proportion of them are treated with immunosuppressants. Hence, there is an ongoing concern over the impact of COVID-19 on IBD patients and their susceptibility to it. So far, there are about 1439 IBD patients in the Surveillance Epidemiology of Coronavirus under Research Exclusion (SECURE-IBD) registry reported to be infected with SARS-CoV-2. There are many unique challenges and dilemmas that need to be taken into account when managing an IBD patient with COVID-19. The management of each patient should be individualized. The IBD societies and experts have strongly recommended that patients should not discontinue their IBD medications. If the patients have symptoms of COVID-19 or IBD flare-up, they are recommended to call their IBD physician first to discuss their medication. In addition, IBD patients are urged to practice social distancing strictly to minimize the chances of infection. As COVID-19 is rapidly evolving, our experience and understanding of its impact on the IBD population may potentially change in the near future. url: https://doi.org/10.20524/aog.2020.0547 doi: 10.20524/aog.2020.0547 id: cord-306325-9alfvda1 author: Galmozzi, E. title: Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks? date: 2014-02-04 words: 1009 sentences: 59 pages: flesch: 47 cache: ./cache/cord-306325-9alfvda1.txt txt: ./txt/cord-306325-9alfvda1.txt summary: 1 The authors have evaluated and discussed current evidence regarding the roles of vitamin D deficiency in the pathogenesis and progression of inflammatory bowel disease (IBD). [4] [5] [6] It is therefore interesting that vitamin D deficiency has been shown to play a role in both psychological 7 and sleep disorders 8 in non-IBD populations, although the underlying mechanisms are still unknown. There is no study till now evaluating the effects of vitamin D deficiency on psychological health or sleep quality in IBD patients. Although several factors can affect psycho-logical health and sleep quality in IBD patients including demographic-and disease-related factors, 2, 4 a role for vitamin D deficiency is also plausible. 1, 2 We agree that our study does not provide insights on the causal relationship between IFNL4 and treatment response in patients with chronic hepatitis C virus (HCV) infection. abstract: nan url: https://www.ncbi.nlm.nih.gov/pubmed/24494849/ doi: 10.1111/apt.12615 id: cord-285426-iyl12ber author: Ghavami, Shaghayegh Baradaran title: IBD Patients Could Be Silent Carriers for Novel Coronavirus and Less Prone to its Severe Adverse Events: True or False? date: 2020-09-08 words: 1967 sentences: 111 pages: flesch: 47 cache: ./cache/cord-285426-iyl12ber.txt txt: ./txt/cord-285426-iyl12ber.txt summary: Interestingly, in the recent pandemic of coronavirus disease (COVID19) , and the SARS-CoV epidemic in 2003, while the fecal samples of these patients were positive for the virus, they did not present any severe respiratory distress syndrome (4). Remarkably, the angiotensin-converting enzyme-2 (ACE2) is the receptor for SARS-CoV-2 and it is expressed in different organs including the lungs, testis and ileum. showed that when rheumatoid arthritis patients were treated with anti-TNF-α biologicals (infliximab, adalimumab, and certolizumab pegol), the expression of IFN-α-regulated genes was increased in the peripheral blood mononuclear cell (PBMC) compared to the control group. Besides, in IBD patients, particularly those who are under anti-TNF-α treatment, the host innate immune system interferes more efficiently with viral replication cycle and the clinical presentations are more moderate (9, 12) . Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? abstract: Inflammatory bowel diseases (IBDs) are chronic disorders of the gastrointestinal tract. The goal of IBD treatment is to reduce the inflammation period and induce long-term remission. Use of anti-inflammatory drugs including corticosteroids, immunosuppressants and biologicals, is often the first step in the treatment of IBD. Therefore, IBD patients in pandemic of infectious diseases are considered a high-risk group. The public believes that IBD patients are at a higher risk in the current coronavirus 2 pandemic. Nevertheless, these patients may experience mild or moderate complications compared to healthy people. This might be because of particular anti-TNF-α treatment or any immunosuppressant that IBD patients receive. Moreover, these patients might be silent carrier for the virus. url: https://www.ncbi.nlm.nih.gov/pubmed/32779446/ doi: 10.22074/cellj.2020.7603 id: cord-256143-9u5a0jqz author: Grassia, Roberto title: Inflammatory Bowel Diseases and Biological Treatment in SARS-CoV-2 Era. Why Not? date: 2020-05-09 words: 535 sentences: 45 pages: flesch: 56 cache: ./cache/cord-256143-9u5a0jqz.txt txt: ./txt/cord-256143-9u5a0jqz.txt summary: title: Inflammatory Bowel Diseases and Biological Treatment in SARS-CoV-2 Era. Why Not? 1 In this setting, the initial indication from the inflammatory bowel disease (IBD) center in Wuhan was to discontinue all biological and immunosuppressive treatments. 3 In an Italian observational study, among 522 IBD patients (89% adults), 16% under biological therapy, none was hospitalized for COVID-19. Further studies are needed to investigate if IBD patients under biological treatment could be protected against the COVID-19 pneumonia, whereas those under immunosuppressive therapy (ie, thiopurines) could remain at higher risk of developing the disease due to the different mechanism of action. Protection of 318 Inflammatory Bowel Disease Patients from the Outbreak and Rapid Spread of COVID-19 Infection in Wuhan Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? abstract: nan url: https://www.ncbi.nlm.nih.gov/pubmed/32386056/ doi: 10.1093/ibd/izaa110 id: cord-266648-962r0vm8 author: Grossberg, Laurie B title: Review of Societal Recommendations Regarding Management of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic date: 2020-07-03 words: 3613 sentences: 234 pages: flesch: 50 cache: ./cache/cord-266648-962r0vm8.txt txt: ./txt/cord-266648-962r0vm8.txt summary: title: Review of Societal Recommendations Regarding Management of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic Although data in patients with IBD contracting COVID-19 are still limited, both providers and patients have particular concerns regarding the risk of infection with SARS-CoV-2 and how to manage their medications during the COVID-19 pandemic. Information regarding risk factors, prevention, routine care (including office visits, testing, endoscopy, and surgery), and medication management of patients with IBD in the setting of COVID-19 was collected from each reference and is summarized in the Results. 10, 11 Other organizations, including the American Gastroenterological Association doi: 10.1093/ibd/izaa174 Published online 3 July 2020 (AGA), the Gastroenterological Society of Australia, and the European Crohn''s and Colitis Organisation (ECCO), agree that there are no data to support an increased risk of infection among patients with IBD. abstract: nan url: https://doi.org/10.1093/ibd/izaa174 doi: 10.1093/ibd/izaa174 id: cord-255930-2bobmkvu author: Kaplan, Gilaad G. title: The four epidemiological stages in the global evolution of inflammatory bowel disease date: 2020-10-08 words: 9023 sentences: 417 pages: flesch: 44 cache: ./cache/cord-255930-2bobmkvu.txt txt: ./txt/cord-255930-2bobmkvu.txt summary: Inflammatory bowel disease (IBD) is a global disease; its evolution can be stratified into four epidemiological stages: Emergence, Acceleration in Incidence, Compounding Prevalence and Prevalence Equilibrium. Western regions will eventually transition to the Prevalence Equilibrium stage, in which the accelerating prevalence levels off as the IBD population ages and possibly as a result of an unexpected rise in mortality during the COVID-19 pandemic. The evolution of IBD occurs within Omran''s Degenerative and Human-Influenced Diseases age and has occurred across three distinct epidemiological stages ( Fig. 1) : Emergence, Acceleration in Incidence and Compounding Prevalence. In the meantime, developing, newly industrialized regions and countries of the Western world all need to innovate their current health-care delivery to address the evolving demographics of their IBD populations as they transition across epidemiological stages. abstract: Inflammatory bowel disease (IBD) is a global disease; its evolution can be stratified into four epidemiological stages: Emergence, Acceleration in Incidence, Compounding Prevalence and Prevalence Equilibrium. In 2020, developing countries are in the Emergence stage, newly industrialized countries are in the Acceleration in Incidence stage, and Western regions are in the Compounding Prevalence stage. Western regions will eventually transition to the Prevalence Equilibrium stage, in which the accelerating prevalence levels off as the IBD population ages and possibly as a result of an unexpected rise in mortality during the COVID-19 pandemic. Mitigating the global burden of IBD will require concerted efforts in disease prevention and health-care delivery innovations that respond to changing demographics of the global IBD population. In this Perspective, we summarize the global epidemiology of IBD and use these data to stratify disease evolution into four epidemiological stages. url: https://doi.org/10.1038/s41575-020-00360-x doi: 10.1038/s41575-020-00360-x id: cord-316354-pix0hmpj author: Kennedy, Nicholas A title: Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic date: 2020-06-15 words: 5234 sentences: 264 pages: flesch: 49 cache: ./cache/cord-316354-pix0hmpj.txt txt: ./txt/cord-316354-pix0hmpj.txt summary: ► Essential services for inflammatory bowel disease (IBD) patients including outpatient care, advice lines, endoscopy and infusion units may be affected. The number of whole-time equivalent gastroenterologists and IBD nurses providing elective outpatient care decreased significantly between baseline (median 4, IQR 4-7.5 and median 3, IQR 2-4) to the point of survey (median 2, IQR 1-4.8 and median 2, IQR 1-3) in the 6-week period following the onset of the COVID-19 pandemic (p<0.001 for both comparisons). The number of whole-time equivalent gastroenterologists and IBD nurses providing elective outpatient care decreased significantly between baseline (median 4, IQR 4-7.5 and median 3, IQR 2-4) to the point of survey (median 2, IQR 1-4.8 and median 2, IQR 1-3) in the 6-week period following the onset of the COVID-19 pandemic (p<0.001 for both comparisons). abstract: OBJECTIVE: To determine the challenges in diagnosis, monitoring, support provision in the management of inflammatory bowel disease (IBD) patients and explore the adaptations of IBD services. METHODS: Internet-based survey by invitation of IBD services across the UK from 8 to 14 April 2020. RESULTS: Respondents from 125 IBD services completed the survey. The number of whole-time equivalent gastroenterologists and IBD nurses providing elective outpatient care decreased significantly between baseline (median 4, IQR 4–7.5 and median 3, IQR 2–4) to the point of survey (median 2, IQR 1–4.8 and median 2, IQR 1–3) in the 6-week period following the onset of the COVID-19 pandemic (p<0.001 for both comparisons). Almost all (94%; 112/119) services reported an increase in IBD helpline activity. Face-to-face clinics were substituted for telephone consultation by 86% and video consultation by 11% of services. A variation in the provision of laboratory faecal calprotectin testing was noted with 27% of services reporting no access to faecal calprotectin, and a further 32% reduced access. There was also significant curtailment of IBD-specific endoscopy and elective surgery. CONCLUSIONS: IBD services in the UK have implemented several adaptive strategies in order to continue to provide safe and high-quality care for patients. National Health Service organisations will need to consider the impact of these changes in current service delivery models and staffing levels when planning exit strategies for post-pandemic IBD care. Careful planning to manage the increased workload and to maintain IBD services is essential to ensure patient safety. url: https://www.ncbi.nlm.nih.gov/pubmed/32874484/ doi: 10.1136/flgastro-2020-101520 id: cord-337896-mct29erg author: Kornbluth, Asher title: Management of Inflammatory Bowel Disease and COVID-19 in New York City 2020: The Epicenter of IBD in the First Epicenter of the Global Pandemic date: 2020-09-03 words: 5111 sentences: 212 pages: flesch: 55 cache: ./cache/cord-337896-mct29erg.txt txt: ./txt/cord-337896-mct29erg.txt summary: A number of the major GI societies, the Crohn''s & Colitis Foundation, 3 British Society of Gastroenterology, 4 European Crohn''s and Colitis Organization, 5 The American Gastroenterology Association, 6 and the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) 7 have published guidelines regarding treating the IBD patient with SARS-CoV-2 and COVID-19. 8 The key features are that the patient without proven or suspected SARS-CoV-2 should continue on their current medications with aggressive attempts to reduce steroid usage because this is the only single agent that has been associated with increased poor outcomes with COVID-19, defined in the SECURE registry as a composite score of hospitalization, intubation, or death. 14 We are now participating in the development of a database that will follow patients after clearance of the SARS-CoV-2 virus to determine the courses and outcomes of the IBD and of any sequelae or recurrence of COVID-19 after any drug therapy has been suspended. abstract: nan url: https://doi.org/10.1093/ibd/izaa212 doi: 10.1093/ibd/izaa212 id: cord-286912-cww4ha3j author: Manolakis, Anastassios C title: α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease date: 2017-01-21 words: 5348 sentences: 272 pages: flesch: 48 cache: ./cache/cord-286912-cww4ha3j.txt txt: ./txt/cord-286912-cww4ha3j.txt summary: METHODS: AHSG serum levels were determined in treatment-naïve newly-diagnosed patients, 96 with ulcerative colitis (UC), 84 with Crohn''s disease (CD), 62 with diarrhea-predominant or mixed irritable bowel syndrome (IBS, Dand Mtypes) and 180 healthy controls (HC), by an enzyme linked immunosorbent assay (ELISA). Low levels of AHSG have been recorded in patients on hemodialysis, those with cirrhosis, hepatoma or rheumatoid arthritis (RA), an entity sharing common inflammatory pathways with IBD, and have been linked to vascular -excessive valvular and coronary artery calcification, ischemic events-and skeletal disorders -osteopenia [14, 17, 18] . In order to perform additional testing of the link between lower AHSG levels and complicated disease behavior, logistic regression was applied, while considering penetrating or stricturing CD, as dependent, and AHSG concentrations, in quartiles -lowest, low, high, highest -as independent variables. After multivariate analysis -also considering age, sex, activity, duration, smoking status-the inverse association between AHSG and need for anti-TNFα therapy or surgery remained statistically significant (partial correlation coefficients: -0.33 and -0.41, respectively -P < 0.05, in both cases). abstract: AIM: To investigate the impact of inflammatory bowel disease (IBD) on α2-Heremans-Schmid Glycoprotein (AHSG/fetuin A) and potential associations with disease and patient characteristics. METHODS: AHSG serum levels were determined in treatment-naïve newly-diagnosed patients, 96 with ulcerative colitis (UC), 84 with Crohn's disease (CD), 62 with diarrhea-predominant or mixed irritable bowel syndrome (IBS, D- and M- types) and 180 healthy controls (HC), by an enzyme linked immunosorbent assay (ELISA). All patients were followed for a minimum period of 3 years at the Gastroenterology Department of the University Hospital of Larissa, Greece. C-reactive protein (CRP), anti-glycan antibodies, anti-Saccharomyces cerevisiae mannan antibodies IgG, anti-mannobioside carbohydrate antibodies IgG, anti-laminariobioside carbohydrate antibodies IgG and anti-chitobioside carbohydrate antibodies IgA were also determined via immunonephelometry and ELISA, respectively. RESULTS: The mean ± SE of serum AHSG, following adjustment for confounders, was 0.32 ± 0.02 g/L in IBD, 0.32 ± 0.03 g/L in CD and 0.34 ± 0.03 g/L in UC patients, significantly lower than in IBS patients (0.7 ± 0.018 g/L) and HC (0.71 ± 0.02 g/L) (P < 0.0001, in all cases). AHSG levels were comparable between the CD and UC groups. Based on AHSG levels IBD patients could be distinguished from HC with about 90% sensitivity and specificity. Further adjusted analysis verified the inverse association between AHSG and penetrating, as well as stricturing CD (partial correlation coefficient: -0.45 and -0.33, respectively) (P < 0.05). After adjusting for confounding factors, inverse correlations between AHSG and CRP and the need for anti-TNFα therapy or surgery, were found (partial correlation coefficients: -0.31, -0.33, -0.41, respectively, P < 0.05, in all cases). Finally, IBD individuals who were seropositive, for at least one marker, had AHSG levels falling within the two lower quartiles (OR = 2.86, 95%CI: 1.5-5.44, P < 0.001) while those with at least two serological markers positive exhibited AHSG concentrations within the lowest quartile (OR = 5.03, 95%CI: 2.07-12.21, P < 0.001), after adjusting for age, sex and smoking. CONCLUSION: AHSG can be used to distinguish between IBD and IBS patients or HC while at the same time "predicting" complicated disease behavior, need for therapy escalation and surgery. Moreover, AHSG may offer new insights into the pathogenesis of IBD, since it is involved in key processes. url: https://doi.org/10.3748/wjg.v23.i3.437 doi: 10.3748/wjg.v23.i3.437 id: cord-312374-gu9tq48n author: Martin Arranz, Eduardo title: Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey date: 2020-06-04 words: 2486 sentences: 131 pages: flesch: 48 cache: ./cache/cord-312374-gu9tq48n.txt txt: ./txt/cord-312374-gu9tq48n.txt summary: The survey included items in 5 sections asking about the structure of IBD units, structural changes adopted because of the current pandemic, recommendations regarding immunosuppressive and biologic treatments during the SARS-CoV-2 pandemic, adopted measures regarding suspected COVID-19 in patients with IBD, and management of patients with IBD with confirmed COVID-19. During the COVID-19 crisis, 100% of hospitals surveyed have cancelled elective onsite consultation and changed to phone assistance, 40% have also attended patients via e-mail, and 13% have used social media to inform patients about the latest updates regarding IBD and SARS-CoV-2. The COVID-19 pandemic has severely affected Spain, with 205,905 cases confirmed by polymerase chain reaction and 22,902 deaths registered up to April 24, 2020, and has forced all hospitals to change their clinical practice, suspending all ambulatory procedures to minimize the risk of infection and relocating doctors and nurses to attend COVID-19 patients. abstract: BACKGROUND: The outbreak of COVID-19 has rapidly evolved into a pandemic that has represented a challenge to health systems worldwide. Inflammatory bowel disease (IBD) units have been forced to change their practices to address the disease and to ensure the quality of care. METHODS: We conducted a national survey among IBD gastroenterologist members of the Spanish Working Group on Crohn’s Disease and Colitis regarding changes of practice, IBD treatments, and diagnosis and treatment of COVID-19. RESULTS: We received 54 answers from Spanish hospitals. One hundred percent of the IBD units rescheduled onsite visits to telematic consultation, and elective endoscopic and surgical procedures were delayed. Protective measures were also taken in the infusion units (100% of health centers) and hospital pharmacies, with 40.7% sending subcutaneous medications to patients. No switching between intravenous and subcutaneous anti-tumor necrosis factor drugs were made. We also found that 96.1% of IBD units advised their patients to maintain treatment if they were asymptomatic for COVID-19. For patients with COVID-19 symptoms, 92.6% of IBD units referred them to primary care or the emergency department. In addition, 7.5% of IBD units made a COVID-19 diagnosis through polymerase chain reaction and/or chest x-ray. Modifications in IBD treatment and treatment recommended for COVID-19 are also discussed. CONCLUSIONS: We report a representative national survey of changes made in the structure, diagnosis of COVID-19, and modifications in IBD treatments within IBD units. url: https://doi.org/10.1093/ibd/izaa142 doi: 10.1093/ibd/izaa142 id: cord-032753-icteg34y author: Namai, Fu title: Microbial therapeutics for acute colitis based on genetically modified Lactococcus lactis hypersecreting IL-1Ra in mice date: 2020-09-28 words: 5311 sentences: 313 pages: flesch: 51 cache: ./cache/cord-032753-icteg34y.txt txt: ./txt/cord-032753-icteg34y.txt summary: Oral administration of these gmLAB suppressed body weight reduction and exacerbation of the disease activity index score in mice with acute colitis and decreased the number of CD4(+) IL-17A(+) cells in the mesenteric lymph nodes. HE staining of colon sections removed on the last day revealed a decrease in immune cell infiltration in the NZ-IL1Ra administration group and a significant decrease in the total mucosal tissue area (Fig. 5e-g) . Production of IL-2 by EL4.NOB-1 cells stimulated with IL-1β was suppressed by increasing the concentration of rmIL-1Ra purified from NZ-IL1Ra supernatant, commercially available mIL-1Ra, or hIL-1Ra. These results indicate that rmIL-1Ra produced by gmLAB can play an effective role as an endogenous antagonist of IL-1. In conclusion, we successfully constructed gmLAB that hypersecrete bioactive mIL-1Ra. Oral administration of NZ-IL1Ra to acute colitis mice alleviated colitis symptoms and suppressed excessive immune reactions in the intestinal tract and MLNs. These results suggest that rmIL-1Ra reaches the colon via NZ-IL1Ra and inhibits IL-1 signaling. abstract: The increased incidence of inflammatory bowel disease (IBD) in Western and rapidly Westernizing developing countries poses a global pandemic threat. The development of affordable drugs for treating IBD worldwide is thus a priority. Genetically modified lactic acid bacteria (gmLAB) as microbial therapeutics are inexpensive protein producers suitable for use as carriers of protein to the intestinal mucosa. Here, we successfully constructed gmLAB hypersecreting interleukin 1 receptor antagonist (IL-1Ra). Oral administration of these gmLAB suppressed body weight reduction and exacerbation of the disease activity index score in mice with acute colitis and decreased the number of CD4(+) IL-17A(+) cells in the mesenteric lymph nodes. These data suggest that the gmLAB deliver IL-1Ra to the colon, where it inhibits IL-1 signaling. We thus developed a novel IBD therapeutic that blocks IL-1 signaling using a gmLAB protein delivery system. This system could be an inexpensive oral microbial therapeutic. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520878/ doi: 10.1038/s12276-020-00507-5 id: cord-017342-qsfykh1k author: Nedelsky, Natalia B. title: Inflammatory Bowel Disease at the Intersection of Autophagy and Immunity: Insights from Human Genetics date: 2013-06-21 words: 8796 sentences: 424 pages: flesch: 36 cache: ./cache/cord-017342-qsfykh1k.txt txt: ./txt/cord-017342-qsfykh1k.txt summary: Although historically considered to be a relatively nonselective process of degradation of cytosolic contents, autophagy has recently been revealed to have several selective and immune-specific functions that are relevant to the maintenance of intestinal homeostasis, including xenophagy, mitophagy, antigen presentation, secretion, and inflammasome regulation. We summarize the basic molecular events underlying general and selective autophagy and present evidence suggesting possible pathogenic mechanisms revealed by studies of IBD-associated risk alleles of ATG16L1 and IRGM. As mentioned above, autophagy has been implicated in several immune-related processes that infl uence IBD pathogenesis, including xenophagy, mitophagy, antigen presentation, secretion and vesicular traffi cking, and cytokine-based regulation of infl ammasome activity. In epithelial cells, bacteria become ubiquitinated and targeted for autophagic degradation in a process that requires the CD-associated genes ATG16L1 and IRGM appears to have different effects on these functions depending on the cell type examined [ 42 , 67 ] . abstract: Studies using human genetics have identified more than 160 loci that affect the risk of developing inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). Several of these genes have been found to play key roles in the process of autophagy, a lysosome-based degradation pathway. Although historically considered to be a relatively nonselective process of degradation of cytosolic contents, autophagy has recently been revealed to have several selective and immune-specific functions that are relevant to the maintenance of intestinal homeostasis, including xenophagy, mitophagy, antigen presentation, secretion, and inflammasome regulation. In this chapter, we review the evidence that links autophagy-related genes, their immune-specific functions, and possible mechanisms of IBD pathogenesis. We summarize the basic molecular events underlying general and selective autophagy and present evidence suggesting possible pathogenic mechanisms revealed by studies of IBD-associated risk alleles of ATG16L1 and IRGM. Finally, we review chemical biology-based experimental approaches for identifying autophagy regulatory pathways that may have implications for the development of therapeutics. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121872/ doi: 10.1007/978-1-4614-8256-7_12 id: cord-349500-603v8lfb author: Neurath, Markus F title: Covid-19 and immunomodulation in IBD date: 2020-04-16 words: 6548 sentences: 386 pages: flesch: 45 cache: ./cache/cord-349500-603v8lfb.txt txt: ./txt/cord-349500-603v8lfb.txt summary: Although covid-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. Although covid-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infects ACE2 expressing epithelial cells in the lung and/or the intestine. The covid-19 receptor ACE2 is particularly highly expressed in intestinal epithelial cells from the terminal ileum and to a lesser extent in the colon, where mucosal inflammation in patients with IBD (Crohn''s disease (CD); UC) is frequently detected. abstract: The current coronavirus pandemic is an ongoing global health crisis due to covid-19, caused by severe acute respiratory syndrome coronavirus 2. Although covid-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. This situation causes various major challenges for gastroenterology. In the context of IBD, several key questions arise. For instance, it is an important question to understand whether patients with IBD (eg, due to intestinal ACE2 expression) might be particularly susceptible to covid-19 and the cytokine release syndrome associated with lung injury and fatal outcomes. Another highly relevant question is how to deal with immunosuppression and immunomodulation during the current pandemic in patients with IBD and whether immunosuppression affects the progress of covid-19. Here, the current understanding of the pathophysiology of covid-19 is reviewed with special reference to immune cell activation. Moreover, the potential implications of these new insights for immunomodulation and biological therapy in IBD are discussed. url: https://doi.org/10.1136/gutjnl-2020-321269 doi: 10.1136/gutjnl-2020-321269 id: cord-259585-mjtxiu0t author: Occhipinti, Vincenzo title: Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a “Red Zone” Area in Northern Italy date: 2020-04-21 words: 2803 sentences: 122 pages: flesch: 46 cache: ./cache/cord-259585-mjtxiu0t.txt txt: ./txt/cord-259585-mjtxiu0t.txt summary: Every possible effort was made to quickly increase the capacity of intensive care units (ICUs) to accommodate the alarming numbers of very sick CoViD-19 patients, including constructing new units in unused areas of the hospital or converting surgical rooms into ICUs. These drastic measures were implemented in a very short period of time, and although necessary to counteract the devastation brought about by the outbreak, they also posed tremendous challenges to the care of patients with GI conditions, including those with inflammatory bowel diseases (IBD). However, for patients on biologic therapies, we have implemented a mandatory phone call-in the day before any planned hospital visit to screen for possible CoViD-19 symptoms or contact with infected individuals and to reassure patients that all possible precautions are being taken by the IBD center to reduce the risk of infection. abstract: nan url: https://doi.org/10.1093/ibd/izaa084 doi: 10.1093/ibd/izaa084 id: cord-331703-4hwmajt3 author: Occhipinti, Vincenzo title: Impact of COVID-19 outbreak on the management of patients with severe IBD: a domino effect date: 2020-05-12 words: 772 sentences: 43 pages: flesch: 47 cache: ./cache/cord-331703-4hwmajt3.txt txt: ./txt/cord-331703-4hwmajt3.txt summary: The International Organization for the study of Inflammatory Bowel Diseases (IOIBD) recently published on Gastroenterology a consensus 1 about the management of IBD patients during the coronavirus disease 19 (COVID-19) pandemic, addressing several topics of interest such as the risk of infection in IBD patients, how to manage therapies and how to safely provide continuity of biological therapy. Thus, we decided to transfer the patient to a COVID-free hospital with IBD-specialized gastroenterologists and surgeons (Rho Hospital, in the Northern area of Milan) for further management. This case clearly highlights some unanticipated difficulties in providing adequate care to patients with severe IBD in a high-prevalence area of COVID-19. Management of Patients with Crohn''s Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an International Meeting Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a "Red Zone" Area in Northern Italy abstract: nan url: https://www.sciencedirect.com/science/article/pii/S001650852030620X?v=s5 doi: 10.1053/j.gastro.2020.05.027 id: cord-026025-xqj877en author: PETRAS, ROBERT E. title: Large Intestine (Colon) date: 2009-10-30 words: 48309 sentences: 3034 pages: flesch: 42 cache: ./cache/cord-026025-xqj877en.txt txt: ./txt/cord-026025-xqj877en.txt summary: 27, 28 These guidelines consider colonoscopic polypectomy definitive treatment for a patient with a malignant polyp if the following criteria are fulfilled: (1) the polyp is considered completely excised at endoscopy, (2) the specimen is properly processed by the pathology laboratory, (3) the cancer is not poorly differentiated, (4) no histologic evidence of vascular or lymphatic involvement exists, and (5) the resection margin is not involved by carcinoma. Pathologic features of colorectal cancer that suggest MSI/Lynch''s syndrome include right-sided location, synchronous or metachronous large bowel cancers, large and bulky polypoid tumors with circumscribed pushing margins, tumors showing prominent lymphoid infiltrate, and cancers of poor differentiation (medullary or undifferentiated carcinoma) or mucinous and signet ring cell histologic pattern (Figs. [352] [353] [354] [355] The trauma-type histologic features can be seen in the solitary rectal ulcer syndrome, localized colitis cystica profunda, inflammatory cloacogenic polyp, the mucosa adjacent to orifices of colonic diverticula, 356 and inflammatory cap polyposis 357 and are frequent findings adjacent to neoplasia and in the vicinity of the ileocecal valve. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271214/ doi: 10.1016/b978-1-4160-3966-2.00023-0 id: cord-253001-xmcwuuk4 author: Papa, Alfredo title: Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease date: 2020-08-19 words: 1451 sentences: 79 pages: flesch: 49 cache: ./cache/cord-253001-xmcwuuk4.txt txt: ./txt/cord-253001-xmcwuuk4.txt summary: A retrospective study from the United States including a large cohort of patients with IBD reported that the use of antitumor necrosis factor (TNF)-a agents or thiopurines was not associated with an increased risk of developing COVID-19 (9) . In the Surveillance Epidemiology of Coronavirus Under Research Exclusion-IBD database, we found evidence of greater prevalence of milder COVID-19 cases in patients treated with anti-TNF-a than that in patients undergoing steroid treatments (3) . Further support to this theory comes from the results of the Italian Group for the Study of Inflammatory Bowel Disease study, which reported a 60% reduction in mortality among patients receiving anti-TNF-a antibodies (although not statistically significant); however, corticosteroid use was associated, with a trend toward statistical significance, with COVID-19-related pneumonia (P 5 0.05) and death (P 5 0.064) (4). Furthermore, anti-TNF-a agents could achieve effective control of inflammatory mediators, which makeup the "cytokine storm" that occurs in severe COVID-19-related pneumonia, thereby mitigating the course of the disease. abstract: INTRODUCTION: It has been hypothesized that people suffering from inflammatory bowel disease (IBD) have an increased risk of coronavirus disease (COVID-19). However, it is not known whether immunosuppressive therapies exacerbate the COVID-19 outcome. METHODS: We reviewed data on the prevalence and clinical outcomes of COVID-19 in patients with IBD. RESULTS: COVID-19 prevalence in patients with IBD was comparable with that in the general population. Therapies using antitumor necrosis factor-α agents have been associated with better clinical outcomes. DISCUSSION: Management and treatments provided by gastroenterologists were effective in reducing COVID-19 risk. Antitumor necrosis factor-α agents seem to mitigate the course of COVID-19. url: https://www.ncbi.nlm.nih.gov/pubmed/32826572/ doi: 10.14309/ajg.0000000000000830 id: cord-317151-cxx5pcln author: Papa, Alfredo title: Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase date: 2020-10-24 words: 5030 sentences: 254 pages: flesch: 44 cache: ./cache/cord-317151-cxx5pcln.txt txt: ./txt/cord-317151-cxx5pcln.txt summary: 14 Since the beginning of the pandemic, the World Health Organization has provided general recommendations for the prevention of They include: to wash hands frequently and properly with soap or alcohol-based sanitizer, to maintain social distancing (at least 1 m of distance), to avoid touching eyes, nose and mouth, to cover mouth and nose when coughing or sneezing, to seek medical care early when fever, cough or difficulty in breathing are recorded, to wear personal protective equipment (PPE), in particular the facial mask when social distancing is not possible to maintain or in closed places, to stay informed and follow any advice provided by own healthcare providers. This may require further changes in the planning of healthcare activities, both by using different prioritization criteria for outpatient visits, diagnostic tests and surgical interventions and by continuing to use treatment strategies that have worked well during the pandemic such as telemedicine, psychological support to patients and the educational function of patient associations (Table 1) . abstract: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised several concerns for patients with chronic immune-mediated diseases, including inflammatory bowel disease (IBD). As the outbreak appears to be in the descending phase, at least in some part of the world, as in most European countries, guidance is urgently needed to provide optimal care for our IBD patients in order to gradually and safely reduce the gap in care that has been accumulated in the months of lockdown and to face all the backlogs. Therefore, we have provided a decalogue of practical recommendations for gastroenterologists to manage patients with IBD in the post-peak phase of the COVID-19 pandemic. They include all the aspects of IBD care, not only pharmacological ones but also endoscopy, surgery, psychological treatment, telemedicine, diagnostics and educational tasks provided by doctors and patient associations. url: https://doi.org/10.1177/1756284820968747 doi: 10.1177/1756284820968747 id: cord-337204-14gxpeaf author: Piciucchi, Matteo title: Preliminary considerations regarding the risk of COVID-19 and disease severity in chronic gastrointestinal conditions date: 2020-05-25 words: 1637 sentences: 90 pages: flesch: 43 cache: ./cache/cord-337204-14gxpeaf.txt txt: ./txt/cord-337204-14gxpeaf.txt summary: Since the discovery of SARS-CoV-2 at the end of 2019, several studies of the epidemiology, risk factors, clinical findings, therapy and virological features of this infection have become available and are totally free to clinicians via a PubMed search [1, 2] . In particular, several risk factors that are involved in acquiring the infection and that affect the clinical course and severity of COVID-19related diseases have been identified (Figure 1 ), but conclusive data are still lacking [2, 4] . As far as inflammatory bowel disease (IBD) is concerned, there are no data to suggest a higher risk of SARS-CoV-2 infection or a higher severity of related diseases in these patients, compared to the general population. More specifically, prospective studies to analyze the risk of the infection and its possible course in patients with IBD, pancreatitis and liver diseases are needed in order to improve care for these patients. abstract: The novel RNA betacoronavirus SARS-CoV-2 is driving great efforts in clinical and basic research and several studies of the epidemiology, risk factors, clinical and virological features of this infection are already available. However COVID-19 is a totally new pathological entity, and many gray areas regarding associated diseases still need to be elucidated, especially in the group of patients who suffer from preexistent gastrointestinal disease. The aim of this review is to summarize the published data on the correlation between chronic gastrointestinal disorders and COVID-19. url: https://doi.org/10.20524/aog.2020.0498 doi: 10.20524/aog.2020.0498 id: cord-343832-xg3swuzs author: Pugliese, Daniela title: The management of Inflammatory Bowel Diseases in the era of COVID-19 pandemic: when “non-urgent” does not mean “deferrable” date: 2020-06-18 words: 1742 sentences: 92 pages: flesch: 43 cache: ./cache/cord-343832-xg3swuzs.txt txt: ./txt/cord-343832-xg3swuzs.txt summary: authors: Pugliese, Daniela; Papi, Claudio; Privitera, Giuseppe; Aratari, Annalisa; Festa, Stefano; Armuzzi, Alessandro Accordingly, Inflammatory Bowel Disease (IBD) Units throughout the country had to re-organize their own agenda, limiting the accesses to 3 categories of outpatients: 1) patients undergoing biological therapies, for whom the risk of disease relapse is considered more worrying than the risk of COVID-19 infection; 2) patients enrolled in clinical trials in order to guarantee the prosecution of therapies and 3) patients complaining of acute symptoms, not manageable with telemedicine. 1-2 Examples of "non deferrable" visits are for patients complaining of moderate-to-severe IBD symptoms, new onset/relapse of extra-intestinal manifestations, active perianal disease or sub-acute obstruction symptoms requiring surgery. 4 Accordingly, highly suspect CD patients should be promptly investigated in order to start early and effective treatment strategies, aimed to impact the long-term clinical course and to reduce the risk of complications. abstract: nan url: https://doi.org/10.1016/j.dld.2020.05.053 doi: 10.1016/j.dld.2020.05.053 id: cord-027386-23exaaik author: Rao, Vishwas title: A Machine-Learning-Based Importance Sampling Method to Compute Rare Event Probabilities date: 2020-05-25 words: 4292 sentences: 303 pages: flesch: 57 cache: ./cache/cord-027386-23exaaik.txt txt: ./txt/cord-027386-23exaaik.txt summary: title: A Machine-Learning-Based Importance Sampling Method to Compute Rare Event Probabilities We develop a novel computational method for evaluating the extreme excursion probabilities arising from random initialization of nonlinear dynamical systems. The method uses excursion probability theory to formulate a sequence of Bayesian inverse problems that, when solved, yields the biasing distribution. To alleviate the computational cost, we build machine-learning-based surrogates to solve the Bayesian inverse problems that give rise to the biasing distribution. The most commonly used method to determine the probability of rare and extreme events is Monte Carlo simulation (MCS). In this paper, we build on our recent algorithm [25] , which we used to construct an importance biasing distribution (IBD) to accelerate the computation of extreme event probabilities. IS, instead, uses problem-specific information to construct an IBD; computing the rare event probability using the IBD requires fewer samples. abstract: We develop a novel computational method for evaluating the extreme excursion probabilities arising from random initialization of nonlinear dynamical systems. The method uses excursion probability theory to formulate a sequence of Bayesian inverse problems that, when solved, yields the biasing distribution. Solving multiple Bayesian inverse problems can be expensive; more so in higher dimensions. To alleviate the computational cost, we build machine-learning-based surrogates to solve the Bayesian inverse problems that give rise to the biasing distribution. This biasing distribution can then be used in an importance sampling procedure to estimate the extreme excursion probabilities. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304705/ doi: 10.1007/978-3-030-50433-5_14 id: cord-269390-4yn8c34i author: Rimondi, Alessandro title: Fogging IBD Management: An Unusual Case of IBD Flare-up During the COVID-19 Outbreak date: 2020-07-28 words: 605 sentences: 44 pages: flesch: 51 cache: ./cache/cord-269390-4yn8c34i.txt txt: ./txt/cord-269390-4yn8c34i.txt summary: We have read with interest the article by Occhipinti and Pastorelli, with particular reference to the management of inflammatory bowel diseases (IBD) relapse during the COVID-19 outbreak. 1 Diagnostic challenges may arise in the presence of symptoms that overlap between active IBD and COVID-19, and concerns about the use of immunosuppressive drugs, mainly corticosteroids, which potentially lead to an increased risk for infections. We hereby report on a representative case of how COVID-19 has redefined priorities and changed our clinical approach to active IBD patients. 3 Therefore, the differential diagnosis between IBD relapse and SARS-CoV-2 infection has possibly proved challenging at the peak of the COVID-19 outbreak. Ageusia, as reported by our patient, contributed to increase the suspicion of SARS-CoV-2 infection and made the differential diagnosis trickier. Challenges in the care of IBD patients during the CoViD-19 pandemic: report from a "Red Zone" area in Northern Italy abstract: nan url: https://doi.org/10.1093/ibd/izaa184 doi: 10.1093/ibd/izaa184 id: cord-026792-jsqa4pmu author: Samanta, Jayanta title: 2019 Novel Coronavirus Infection: Gastrointestinal Manifestations date: 2020-05-16 words: 3792 sentences: 218 pages: flesch: 51 cache: ./cache/cord-026792-jsqa4pmu.txt txt: ./txt/cord-026792-jsqa4pmu.txt summary: The modern world is facing a major public health crisis due to novel corona virus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) which has caused a pandemic involving at least 210 countries. The extrapulmonary effects and modes of transmission gained attention when the first confirmed case of SARS-CoV-2 reported from the United States had gastrointestinal (GI) complaints of nausea and vomiting followed later by diarrhea and patient''s fecal specimen tested positive on day 7 of illness. This review aims to comprehensively outline the GI manifestations of this virus, its potential to spread via the feco-oral route and its implications and an overview of management strategies for other GI diseases, such as inflammatory bowel disease (IBD) coexisting with coronavirus-19 disease (COVID-19) infection. abstract: The world is witnessing a major public health crisis in the wake of the third coronavirus strain pandemic, a novel coronavirus (severe acute respiratory syndrome coronavirus 2). Although initially thought to be a pure respiratory pathogen, recent reports have highlighted not only the extrapulmonary effects of the virus but also, importantly, the gastrointestinal tract (GIT) effects. Various studies have looked into the effects of this novel coronavirus infection (coronavirus-19 disease [COVID-19]) on GIT involvement with reports of more frequent involvement than previously expected. With feco-oral transmission, debate being conclusively proven with fecal samples testing positive for COVID-19 and longer shedding time, it only underlines the importance of GIT involvement. Moreover, the presence of other GI diseases, such as inflammatory bowel disease, with COVID-19 infection might wreak havoc leading to poor patient outcomes. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295271/ doi: 10.1055/s-0040-1712077 id: cord-281275-i9920nvm author: Schlabitz, Franziska title: Inflammatory Bowel Disease and COVID-19—“Preventive” Sick Certificates as a Frequent Coping Strategy in the Face of the Pandemic date: 2020-06-12 words: 629 sentences: 40 pages: flesch: 52 cache: ./cache/cord-281275-i9920nvm.txt txt: ./txt/cord-281275-i9920nvm.txt summary: title: Inflammatory Bowel Disease and COVID-19—"Preventive" Sick Certificates as a Frequent Coping Strategy in the Face of the Pandemic 1 The authors report their experiences and challenges in managing patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic. We complement this important information by presenting a survey conducted among German patients with IBD regarding their personal evaluation of their work-related risk of contracting SARS-CoV-2. However, during the COVID-19 pandemic, the survey participants have used this coping strategy frequently. Clearly, the ability to work is very important to most patients with IBD. Therefore, straightforward recommendations stating clearly who is at risk and who should avoid which type of work are very important for managing the daily life of our patients. Niels Teich: acquisition of data, analysis, critical revision of the manuscript for important intellectual content. Challenges in the care of IBD patients during the CoViD-19 pandemic: report from a "Red Zone" area in Northern Italy abstract: nan url: https://doi.org/10.1093/ibd/izaa155 doi: 10.1093/ibd/izaa155 id: cord-284234-9cd2v6bt author: Sebastian, S title: Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD date: 2020-06-10 words: 4483 sentences: 256 pages: flesch: 44 cache: ./cache/cord-284234-9cd2v6bt.txt txt: ./txt/cord-284234-9cd2v6bt.txt summary: Understandable concerns have been raised on the safety of steroids, immunosuppressive drugs, and biologics used in patients for a variety of indications including immune mediated inflammatory disease such as inflammatory bowel diseases (IBD), which do increase the risk of opportunistic bacterial, viral and fungal infections (5) . Therefore, continuing concerns remain both from IBD patients and the A c c e p t e d M a n u s c r i p t clinicians managing them, regarding the potential of IBD related drugs causing more frequent infections by SARS-CoV2, and increased risk of severe complications from COVID-19 (13) . Corticosteroids are thought to have a divergent effect on viral infections including SARS COV viruses; on one hand they inhibit host immune response acting on migration and chemokines production leading to impaired viral clearance and the resultant prolonged Moreover, a prospective, randomized double-blinded, placebo-controlled trial compared early hydrocortisone treatment (before day seven of the illness) with a placebo and found that early hydrocortisone therapy was associated with a higher subsequent plasma viral load (61) . abstract: The Coronavirus 2019 (COVID-19) pandemic has posed challenges in the routine care of patients with inflammatory bowel disease. One of the key challenges needing addressing is the quantification of the risks of immunosuppressive and biologic therapies in IBD patients during the pandemic. The similarities and differences between the previous coronavirus outbreaks and the pathobiology of the infections can give useful information in understanding the risks, and perhaps potential beneficial aspects of drugs used in IBD. Although clinical, immunological and pharmacological data from the experience with the previous coronavirus outbreaks cannot be automatically translated to predict the safety of IBD therapies during COVID-19 pandemic, the signals so far from these outbreaks on IBD patients who are on immunomodulators and biologics are reassuring to patients and clinicians alike. url: https://doi.org/10.1093/ecco-jcc/jjaa120 doi: 10.1093/ecco-jcc/jjaa120 id: cord-303942-77nbi3ws author: Segal, Jonathan P title: Prevention of COVID-19 in patients with IBD date: 2020-05-20 words: 632 sentences: 39 pages: flesch: 53 cache: ./cache/cord-303942-77nbi3ws.txt txt: ./txt/cord-303942-77nbi3ws.txt summary: We read with interest the Correspondence from Ping An and colleagues 1 describing their efforts to prevent coronavirus disease 2019 in patients with inflammatory bowel disease (IBD) in Wuhan, China. Indeed, the National Health Service, in conjunction with the British Society of Gastroenterology (BSG), relied on individual health-care trusts to highlight patients at high risk with IBD so advice could be delivered by post regarding shielding and stringent physical distancing. BSG guidance suggests that patients should continue on their current medications, including infliximab, as active disease remains the biggest risk to a patient with IBD. As further evidence accumulates, our understanding of COVID-19-related risks in IBD populations globally will improve. Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China BSG COVID-19 Guidance on IBD patient risk groups British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic abstract: nan url: https://api.elsevier.com/content/article/pii/S2468125320301539 doi: 10.1016/s2468-1253(20)30153-9 id: cord-288439-srzysoqy author: Segal, Jonathan P. title: Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease date: 2020-09-03 words: 6842 sentences: 359 pages: flesch: 38 cache: ./cache/cord-288439-srzysoqy.txt txt: ./txt/cord-288439-srzysoqy.txt summary: Faecal microbiota transplantation (FMT) is currently a recommended therapy for recurrent/ refractory Clostridioides difficile infection (CDI). Faecal microbiota transplantation (FMT) is currently a recommended therapy for recurrent/ refractory Clostridioides difficile infection (CDI). Rodent studies supported the concept that restoration of bacterial bile-metabolising capacity to the gut microbiota was protective against CDI, 39 prompting interest into whether this could also be a mechanism of efficacy of FMT. difficile; administration of an FXR agonist in a mouse model of colitis resulted in significantly reduced colonic inflammation and a more intact intestinal barrier, 44 while microbially mediated production of particular secondary bile acids exhibit anti-inflammatory effects on intestinal epithelial cells 45 and have been recently recognised as promoting generation of peripheral regulatory T cells. Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection abstract: Faecal microbiota transplantation (FMT) is currently a recommended therapy for recurrent/refractory Clostridioides difficile infection (CDI). The success of FMT for CDI has led to interest in its therapeutic potential in many other disorders. The mechanisms that underpin the efficacy of FMT are not fully understood. Importantly, FMT remains a crucial treatment in managing CDI and understanding the mechanisms that underpin its success will be critical to improve its clinical efficacy, safety and usability. Furthermore, a deeper understanding of this may allow us to expose FMT’s full potential as a therapeutic tool for other disease states. This review will explore the current understanding of the mechanisms underlying the efficacy of FMT across a variety of diseases. url: https://www.ncbi.nlm.nih.gov/pubmed/32952613/ doi: 10.1177/1756284820946904 id: cord-307769-rjseio5s author: Sim, Winnie H title: Expression profile of genes involved in pathogenesis of pediatric Crohn''s disease date: 2012-05-24 words: 4673 sentences: 270 pages: flesch: 41 cache: ./cache/cord-307769-rjseio5s.txt txt: ./txt/cord-307769-rjseio5s.txt summary: Methods: We used suppressive subtractive hybridization (SSH) and differential screening analysis to profile the mRNA expression patterns of children with CD and age‐ and sex‐matched controls without inflammatory bowel disease (IBD). The real-time RT-PCR results validated that genes represented by > 10 clones enriched by subtractive hybridization were expressed in higher abundance in CD as compared with non-IBD ileal biopsies. To contextualize our SSH findings, we compared our results with the data tables from seven microarray studies published previously, that had reported differential expression of genes between inflamed biopsies of CD and non-inflamed biopsies of non-IBD controls. The antigen presentation, inflammatory response and cancer gene network (Network 1) comprise one-third Figure 1 The relative expression levels of REG1A, MMP2 and ANPEP in ileal biopsies from 13 Crohn''s disease (CD) and nine non-inflammatory bowel disease (IBD) patients. Primers used for real-time reverse transcription polymerase chain reaction quantification of ANPEP, REG1A, MMP2 and RPL32 Table S2 Differentially expressed genes specific to Crohn''s Disease (CD) ileum. abstract: Background and Aim: Expression profiling of genes specific to pediatric Crohn's Disease (CD) patients was performed to elucidate the molecular mechanisms underlying disease cause and pathogenesis at disease onset. Methods: We used suppressive subtractive hybridization (SSH) and differential screening analysis to profile the mRNA expression patterns of children with CD and age‐ and sex‐matched controls without inflammatory bowel disease (IBD). Results: Sequence analysis of 1000 clones enriched by SSH identified 75 functionally annotated human genes, represented by 430 clones. The 75 genes have potential involvement in gene networks, such as antigen presentation, inflammation, infection mechanism, connective tissue development, cell cycle and cancer. Twenty‐eight genes were previously described in association with CD, while 47 were new genes not previously reported in the context of IBD. Additionally, 29 of the 75 genes have been previously implicated in bacterial and viral infections. Quantitative real‐time reverse transcription polymerase chain reaction performed on ileal‐derived RNA from 13 CD and nine non‐IBD patients confirmed the upregulation of extracellular matrix gene MMP2 (P = 0.001), and cell proliferation gene REG1A (P = 0.063) in our pediatric CD cohort. Conclusion: The retrieval of 28 genes previously reported in association with adult CD emphasizes the importance of these genes in the pediatric setting. The observed upregulation of REG1A and MMP2, and their known impact on cell proliferation and extracellular matrix remodeling, agrees with the clinical behavior of the disease. Moreover, the expressions of bacterial‐ and virus‐related genes in our CD‐patient tissues support the concept that microbial agents are important in the etiopathogenesis of CD. url: https://www.ncbi.nlm.nih.gov/pubmed/22098497/ doi: 10.1111/j.1440-1746.2011.06973.x id: cord-021852-o0k2r0yo author: Simpson, Kenneth W. title: The Role of the Microbiota in Feline Inflammatory Bowel Disease date: 2015-12-04 words: 3665 sentences: 189 pages: flesch: 33 cache: ./cache/cord-021852-o0k2r0yo.txt txt: ./txt/cord-021852-o0k2r0yo.txt summary: The only culture-independent study of the duodenal mucosal bacteria in cats to date employed FISH analysis to evaluate the numbers and types of bacteria associated with the duodenal mucosa and their relationship to clinical signs, histopathology, and mucosal cytokines. This study shows that changes in the number and type of mucosa-associated bacteria are related to the presence and severity of IBD in cats and raises the possibility that abnormal mucosal flora are involved in the etiopathogenesis of feline IBD. 13 For example, FISH analysis enabled the identification of invasive spiral bacteria in the ileum, colon, and regional lymph nodes of a cat with pyogranulomatous ileocolitis associated with recurrent episodes of fever and leukocytosis whose inflammatory process was considered sterile on the basis of histopathology (see Figure 10 -4C). abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152113/ doi: 10.1016/b978-0-323-22652-3.00010-4 id: cord-323553-bukm9m9q author: Song, Woo-Jin title: Canine adipose tissue-derived mesenchymal stem cells pre-treated with TNF-alpha enhance immunomodulatory effects in inflammatory bowel disease in mice date: 2019-08-31 words: 4238 sentences: 256 pages: flesch: 52 cache: ./cache/cord-323553-bukm9m9q.txt txt: ./txt/cord-323553-bukm9m9q.txt summary: title: Canine adipose tissue-derived mesenchymal stem cells pre-treated with TNF-alpha enhance immunomodulatory effects in inflammatory bowel disease in mice Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF-α)-induced gene/protein 6 (TSG-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for IBD treatment in veterinary medicine. (C) Canine adipose tissue-derived mesenchymal stem cells (cAT-MSCs) stimulated with TNF-α released higher concentrations of immunomodulatory factors such as TSG-6 and PGE2 compared to levels released by naive cAT-MSCs. Results are shown as the mean ± standard deviation of three independent experiments. Canine adipose tissue-derived mesenchymal stem cells (cAT-MSCs) stimulated with TNF-α showed enhanced therapeutic effects on mice with dextran sodium sulfate (DSS)-induced colitis. Canine adipose tissue-derived mesenchymal stem cells (cAT-MSCs) stimulated with TNF-α showed enhanced therapeutic effects on mice with dinitrobenzene sulfonic acid (DNBS)-induced colitis. abstract: Abstract Canine inflammatory bowel disease (IBD) is an intractable autoimmune disorder that results in various gastrointestinal and systemic symptoms. Mesenchymal stem cells (MSCs), which release immunomodulatory factors such as tumor necrosis factor-α (TNF-α)-induced gene/protein 6 (TSG-6) and prostaglandin E2 (PGE2), have been suggested as an alternative therapeutic option for IBD treatment in veterinary medicine. Furthermore, although it is known that MSCs pre-treated with pro-inflammatory cytokines show enhanced anti-inflammatory properties via the secretion of soluble factors, the underlying mechanisms of IBD remain unclear. The aim of this study was to demonstrate the therapeutic effects and corresponding mechanisms of canine adipose tissue-derived (cAT)-MSCs stimulated with TNF-α in mouse models of IBD. Mice with dextran sulfate sodium (DSS)- or dinitrobenzene sulfonic acid (DNBS)-induced colitis were injected intraperitoneally with cAT-MSCs pre-treated with TNF-α. Colitis severity was assessed and colon tissues were collected for histopathological, enzyme-linked immunosorbent assay, and flow cytometry analysis. cAT-MSCs stimulated with TNF-α secreted higher concentrations of immunomodulatory factors such as TSG-6 and PGE2, which play a key role in inducing phenotypic alterations in macrophages. Consequently, TNF-α-pre-treated cAT-MSCs further regulated colonic inflammatory cytokines such as interleukin (IL)-1β, IL-6, and IL-10, and ameliorated DSS- or DNBS-induced colitis in mice. Additionally, we demonstrated that M1 macrophages (F4/80+/iNOS+ cells) were decreased in colon tissues from mice treated with TNF-α-pre-treated cAT-MSCs, whereas M2 macrophages (F4/80+/CD206+ cells) were increased. These results may suggest a new cell-based therapeutic option for treating IBD. url: https://doi.org/10.1016/j.rvsc.2019.06.012 doi: 10.1016/j.rvsc.2019.06.012 id: cord-347607-ydbyonbg author: Spagnuolo, Rocco title: COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey date: 2020-08-13 words: 3726 sentences: 176 pages: flesch: 46 cache: ./cache/cord-347607-ydbyonbg.txt txt: ./txt/cord-347607-ydbyonbg.txt summary: The aim of this survey is to evaluate knowledge about clinical importance of COVID-19, disease management, prevention measures, and anxiety level during pandemic among patients with IBD. The questionnaire consisted of five sections: (1) anthropometric, demographic and clinical characteristics, (2) knowledge about clinical importance of COVID-19, (3) IBD management, (4) prevention measures, (5) anxiety level during pandemic. Taken together with findings that an active disease status compromises knowledge of IBD management and the high level of anxiety related to increasing age, these data suggest the need of further supporting patient-oriented strategies in IBD during Covid-19 pandemic. The aim of this study is to perform a survey about knowledge about clinical importance of COVID-19, knowledge of disease management, prevention measures, and anxiety level during the pandemic among patients with IBD. The questionnaire was defined and organized into five sections, dealing with: (1) demographic and clinical characteristic, (2) knowledge about clinical importance of COVID-19, (3) knowledge about management of IBD, (4) knowledge of prevention measures, (5) anxiety level during pandemic, respectively. abstract: Background and objectives: Spreading of SARS-CoV-2 infection from China to countries with a higher prevalence of inflammatory bowel disease (IBD) has generated concern among gastroenterologists and patients. The aim of this survey is to evaluate knowledge about clinical importance of COVID-19, disease management, prevention measures, and anxiety level during pandemic among patients with IBD. Material and methods: From 15th March to 15th April 2020, a questionnaire survey was administered to 200 patients with IBD by email or phone application. The questionnaire consisted of five sections: (1) anthropometric, demographic and clinical characteristics, (2) knowledge about clinical importance of COVID-19, (3) IBD management, (4) prevention measures, (5) anxiety level during pandemic. Results: One hundred forty two questionnaires were completed. Ninety-seven patients (68.3%) were males with a mean age of 46 years (SD 13; range 17–76). Fifty-four individuals (38%) were affected by Crohn disease and 88 (62%) by Ulcerative Colitis. Most patients reported high knowledge about clinical importance of COVID-19 (80%), IBD management (72%), and prevention measures (97%). Sixty-two percent of them showed moderate-high level of anxiety. High education level was independently associated with high knowledge about clinical importance of COVID-19 (odds ratio [OR] 5, 95% confidence interval [CI] 1.49–16.6, p = 0.009) and older age (OR 1, 95%, CI 1.01–1.1, p = 0.01), while the receipt of e-format educational material with low knowledge about clinical importance of COVID-19 (OR 3, 95%, CI 1.08–9.3, p = 0.03). Displaying an active disease appeared to be independently associated with low knowledge of IBD management (OR 5.8, 95% CI 1.4–22.8, p = 0.01) and no variables other than an older age was independently associated with higher level of anxiety (OR 1.04, 95% CI 1.009–1.09, p = 0.01). Conclusions: High educational level and aging promote knowledge about clinical importance of COVID-19, while e-format educational material does not. Taken together with findings that an active disease status compromises knowledge of IBD management and the high level of anxiety related to increasing age, these data suggest the need of further supporting patient-oriented strategies in IBD during Covid-19 pandemic. url: https://doi.org/10.3390/medicina56080407 doi: 10.3390/medicina56080407 id: cord-261029-befymalm author: Sultan, Keith title: Review of inflammatory bowel disease and COVID-19 date: 2020-10-07 words: 3257 sentences: 153 pages: flesch: 48 cache: ./cache/cord-261029-befymalm.txt txt: ./txt/cord-261029-befymalm.txt summary: Early reports of the virus, now known as severe acute respiratory syndrome coronavirus 2, and its clinical disease coronavirus disease 2019 (COVID-19), has shown higher rates of morbidity and mortality in the elderly and those with pre-existing medical conditions. The authors also reported that there had been no cases of IBD/SARS-CoV-2 infected patients in the three largest tertiary IBD centers in Wuhan (Tongji Hospital, Union Hospital, and Zhongnan Hospital) at the time their manuscript was prepared, March 8, 2020. Rodriguez-Lago et al [29] reported on 40 cases of IBD (21 hospitalized) with confirmed positive tests for SARS-CoV-2 from 5 sites in the Basque Country (Spain), median age 59 years, 60% male, 32% Crohn''s disease (CD), with 28% on immune therapy, 18% biologic, and 10% systemic corticosteroids. To date, the largest national case reporting has come from a combined 24 IBD referral centers in Italy, affiliated with the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) [32] . abstract: The first cases of a novel corona virus infection were reported in Wuhan China in December of 2019, followed by the declaration of an international pandemic by the World Health Organization in March 2020. Early reports of the virus, now known as severe acute respiratory syndrome coronavirus 2, and its clinical disease coronavirus disease 2019 (COVID-19), has shown higher rates of morbidity and mortality in the elderly and those with pre-existing medical conditions. Of particular concern is the safety of those with compromised immune systems. Inflammatory Bowel disease (IBD) is itself caused by a disordered immune response, with the most effective medical therapies being immune suppressing or modifying. As such, the risk of COVID-19, virus related outcomes, and appropriate management of IBD patients during the global pandemic is of immediate concern to gastroenterologists worldwide. There has been a rapid accumulation of clinical data and expert opinion on the topic. This review will highlight the latest source information on clinical observation/outcomes of the IBD population and provide a concise summary of the most up to date perspectives on IBD management in the age of COVID-19. url: https://www.ncbi.nlm.nih.gov/pubmed/33088153/ doi: 10.3748/wjg.v26.i37.5534 id: cord-275199-y7b12vml author: Suárez-Fariñas, Mayte title: Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease date: 2020-09-25 words: 5683 sentences: 331 pages: flesch: 47 cache: ./cache/cord-275199-y7b12vml.txt txt: ./txt/cord-275199-y7b12vml.txt summary: The RISK cohort 18 : ACE2 and TMPRSS2 in treatment-free pediatric CD (<17 years of age) patients was studied using RNA-seq expression profiles from GSE57945, which includes ileal biopsies from endoscopically defined inflamed samples (n=160), non-inflamed (n=53) and non-IBD controls (n=42). Genes differentially expressed in blood 22 , lung NHBE/A549 23 or human small intestinal organoids 24 (hSIO) following SARS-CoV-2 infection; IBD inflammation; or response to medications were separately projected onto various BGRNs allowing for 1 or 2 nearest neighbors depending on the signature sizes. The expression of ACE2 and TMPRSS2 was similar when comparing active smokers to non-smokers, either between healthy controls or IBD patients (data not shown) and no significant interactions with inflammation status, region or other covariates were found. We observed that genes: up-regulated with inflammation, or positively associated with macroscopic or microscopic measures of disease, or associated with the risk of IBD, were significantly enriched with genes up-regulated by SARS-CoV2 infection of lung epithelial cells ( Figure S10e ). abstract: Background and Aims The presence of gastrointestinal symptoms and high levels of viral RNA in the stool suggest active Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) replication within enterocytes. Methods Here, in multiple, large cohorts of patients with inflammatory bowel disease (IBD), we have studied the intersections between Coronavirus Disease 2019 (COVID-19), intestinal inflammation and IBD treatment. Results A striking expression of ACE2 on the small bowel enterocyte brush border supports intestinal infectivity by SARS-CoV-2. Commonly used IBD medications, both biologic and non-biologic, do not significantly impact ACE2 and TMPRSS2 receptor expression in the uninflamed intestines. Additionally, we have defined molecular responses to COVID-19 infection that are also enriched in IBD, pointing to shared molecular networks between COVID-19 and IBD. Conclusions These data generate a novel appreciation of the confluence of COVID-19- and IBD-associated inflammation and provide mechanistic insights supporting further investigation of specific IBD drugs in the treatment of COVID-19. url: https://www.sciencedirect.com/science/article/pii/S0016508520352100?v=s5 doi: 10.1053/j.gastro.2020.09.029 id: cord-285820-g8b7u3yf author: Taxonera, Carlos title: Innovation in IBD Care During the COVID-19 Pandemic: Results of a Cross-Sectional Survey on Patient-Reported Experience Measures date: 2020-08-19 words: 2788 sentences: 143 pages: flesch: 45 cache: ./cache/cord-285820-g8b7u3yf.txt txt: ./txt/cord-285820-g8b7u3yf.txt summary: We evaluated the feasibility of a strategy based on the conversion of face-to-face visits to telephone consultations to manage IBD outpatients during the COVID-19 pandemic. 8, 9 The aim of this study was to assess the feasibility of a strategy based on the conversion of face-to-face visits to remote telephone consultations to improve care of patients with IBD during the COVID-19 pandemic, and to evaluate satisfaction of patients with telephone consultations. 10 Here, we report the outcomes and patient perception of a strategy based on the conversion of face-to-face visits to remote telephone consultations to improve care of outpatients with IBD during the COVID-19 pandemic. Results of a global telemedicine survey among gastroenterologists by the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) demonstrated the shift from face-to face clinics to remote telemedicine during COVID-19, with telephone consultations increasing the most, currently accounting for over half of all IBD visits. abstract: BACKGROUND: The coronavirus 2019 (COVID-19) pandemic is a clinical situation that could be used as prototype for implementation of new systems of care. METHODS: This was a single-center, cross-sectional study. We evaluated the feasibility of a strategy based on the conversion of face-to-face visits to telephone consultations to manage IBD outpatients during the COVID-19 pandemic. A 4-item telephone survey (3 closed questions and a 100-point numeric description scale) was conducted to evaluate satisfaction of patients with telephone consultations. RESULTS: Between March 11 and April 8, 2020, 98% of the 216 scheduled face-to-face visits could be converted to telephone consultations, and we resolved an additional 162 urgent consultations by telephone. The rate of IBD-related hospitalization and visits to the emergency department decreased by 50% and 58%, respectively, compared with rates in the same period the previous year. The 4-item survey was conducted in 171 outpatients. In closed questions, patients reported a very high degree of satisfaction with telephone consultations, with no differences between scheduled (n = 123) and urgent consultations (n = 48; P = NS). The overall satisfaction rating with the telephone consultation evaluated with the numerical description scale was 94% and 93% for scheduled and urgent consultations, respectively (P < 0.82). Less than 20% of patients would have preferred a face-to-face visit to the telephone consultation at the time. CONCLUSIONS: A strategy based on the conversion of face-to-face visits to telephone consultations was able to guarantee a minimum standard quality of care during the COVID-19 pandemic. Patients reported a very high degree of satisfaction with telephone consultations. url: https://doi.org/10.1093/ibd/izaa223 doi: 10.1093/ibd/izaa223 id: cord-306760-05my504t author: Turner, Dan title: Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition date: 2020-03-31 words: 3832 sentences: 209 pages: flesch: 46 cache: ./cache/cord-306760-05my504t.txt txt: ./txt/cord-306760-05my504t.txt summary: METHODS: An electronic reporting system of children with IBD infected with SARS-CoV-2 has been circulated among 102 PIBD centres affiliated with the Porto and Interest-group of ESPGHAN. Standard IBD treatments including biologics should continue at present through the pandemic, especially in children who generally have more severe IBD course on one hand, and milder SARS-CoV-2 infection on the other. In light of the hyperinflammatory immune response seen in patients with COVID-19 it is highly relevant that blockade of IL-6R with tocilizumab resulted in clinical improvement associated with normalisation of fever, lymphocyte counts, and CRP in a retrospective group of 21 adults with severe SARS-CoV-2 infection (20) . Therefore, uninfected children should generally continue their medical treatment, including immunomodulators and biologic therapies, as the risk of a disease flare outweighs any estimated risk of SARS-CoV2 infection. abstract: INTRODUCTION: With the current coronavirus disease 2019 (COVID-19) pandemic, concerns have been raised about the risk to children with inflammatory bowel diseases (IBD). We aimed to collate global experience and provide provisional guidance for managing paediatric IBD (PIBD) in the era of COVID-19. METHODS: An electronic reporting system of children with IBD infected with SARS-CoV-2 has been circulated among 102 PIBD centres affiliated with the Porto and Interest-group of ESPGHAN. A survey has been completed by major PIBD centres in China and South-Korea to explore management during the pandemic. A third survey collected current practice of PIBD treatment. Finally, guidance points for practice have been formulated and voted upon by 37 PIBD authors and Porto group members. RESULTS: Eight PIBD children had COVID-19 globally, all with mild infection without needing hospitalization despite treatment with immunomodulators and/or biologics. No cases have been reported in China and South Korea but biologic treatment has been delayed in 79 children, of whom 17 (22%) had exacerbation of their IBD. Among the Porto group members, face-to-face appointments were often replaced by remote consultations but almost all did not change current IBD treatment. Ten guidance points for clinicians caring for PIBD patients in epidemic areas have been endorsed with consensus rate of 92% to 100%. CONCLUSIONS: Preliminary data for PIBD patients during COVID-19 outbreak are reassuring. Standard IBD treatments including biologics should continue at present through the pandemic, especially in children who generally have more severe IBD course on one hand, and milder SARS-CoV-2 infection on the other. SUPPLEMENTAL DIGITAL CONTENT: An infographic accompanying this article can be found at. url: https://doi.org/10.1097/mpg.0000000000002729 doi: 10.1097/mpg.0000000000002729 id: cord-031937-qhlatg84 author: Verma, Anukriti title: Elucidating potential molecular signatures through host-microbe interactions for reactive arthritis and inflammatory bowel disease using combinatorial approach date: 2020-09-15 words: 6760 sentences: 326 pages: flesch: 31 cache: ./cache/cord-031937-qhlatg84.txt txt: ./txt/cord-031937-qhlatg84.txt summary: In-silico analysis involving text mining, metabolic network reconstruction, simulation, filtering, host-microbe interaction, docking and molecular mimicry studies results in robust drug target/s and biomarker/s for co-evolved IBD and ReA. The contributions of the microorganisms in the co-evolved IBD and ReA as part of the disease network was created through the interactive maps of the essential host interaction proteins (verified using literature survey) and the information processed through gene expression data analysis 64 . The pathways of the above host interacting proteins were found out using KEGG database that provides ontologies for proteins related to biological processes 67 www.nature.com/scientificreports/ Subsequently, the role of drugs or inhibitors used to suppress the effect of IBD and ReA such as indomethacin, prednisone, ciprofloxacin, sulfasalazine, azathioprine, methotrexate and hydroxychloroquine was scored in the disease network through their docking studies against the potential targets (both host as well microbial targets) as per published methodologies 68, 69 . abstract: Reactive Arthritis (ReA), a rare seronegative inflammatory arthritis, lacks exquisite classification under rheumatic autoimmunity. ReA is solely established using differential clinical diagnosis of the patient cohorts, where pathogenic triggers linked to enteric and urogenital microorganisms e.g. Salmonella, Shigella, Yersinia, Campylobacter, Chlamydia have been reported. Inflammatory Bowel Disease (IBD), an idiopathic enteric disorder co-evolved and attuned to present gut microbiome dysbiosis, can be correlated to the genesis of enteropathic arthropathies like ReA. Gut microbes symbolically modulate immune system homeostasis and are elementary for varied disease patterns in autoimmune disorders. The gut-microbiota axis structured on the core host-microbe interactions execute an imperative role in discerning the etiopathogenesis of ReA and IBD. This study predicts the molecular signatures for ReA with co-evolved IBD through the enveloped host-microbe interactions and microbe-microbe ‘interspecies communication’, using synonymous gene expression data for selective microbes. We have utilized a combinatorial approach that have concomitant in-silico work-pipeline and experimental validation to corroborate the findings. In-silico analysis involving text mining, metabolic network reconstruction, simulation, filtering, host-microbe interaction, docking and molecular mimicry studies results in robust drug target/s and biomarker/s for co-evolved IBD and ReA. Cross validation of the target/s or biomarker/s was done by targeted gene expression analysis following a non-probabilistic convenience sampling. Studies were performed to substantiate the host-microbe disease network consisting of protein-marker-symptom/disease-pathway-drug associations resulting in possible identification of vital drug targets, biomarkers, pathways and inhibitors for IBD and ReA. Our study identified Na((+))/H((+)) anti-porter (NHAA) and Kynureninase (KYNU) to be robust early and essential host-microbe interacting targets for IBD co-evolved ReA. Other vital host-microbe interacting genes, proteins, pathways and drugs include Adenosine Deaminase (ADA), Superoxide Dismutase 2 (SOD2), Catalase (CAT), Angiotensin I Converting Enzyme (ACE), carbon metabolism (folate biosynthesis) and methotrexate. These can serve as potential prognostic/theranostic biomarkers and signatures that can be extrapolated to stratify ReA and related autoimmunity patient cohorts for further pilot studies. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492238/ doi: 10.1038/s41598-020-71674-8 id: cord-288014-rrr4x755 author: Wang, Hong-Gang title: Excessive anxiety in IBD patients is unnecessary for COVID-19 date: 2020-05-12 words: 648 sentences: 47 pages: flesch: 62 cache: ./cache/cord-288014-rrr4x755.txt txt: ./txt/cord-288014-rrr4x755.txt summary: To the editor, Currently, 2019 novel coronavirus (SARS-CoV-2) infection disease (COVID-19) broke out in Wuhan, China and spread worldwide [1, 2] . Inflammatory bowel disease (IBD) is a chronic non-specific intestinal disease, including ulcerative colitis (UC) and Crohn''s disease (CD), and many of these patients have anxiety [3] . Analysis of the transcriptome data of these samples, we found that the expression of ACE2 in the terminal ileum was significantly higher than that in the rectal colon, with a fold change of 9.8 times (P < 0.001). The expression of ACE2 in the UC rectum was not significantly higher than that in non-IBD. In the terminal ileum of CD, ACE2 expression was also not higher than that of non-IBD. These results indicate that the expression of ACE2 does not show a significant difference between IBD and non-IBD patients. Compared with non-IBD, there was no significant difference in TMPRSS2 expression in the rectum and terminal ileum of patients with IBD. abstract: nan url: https://doi.org/10.1016/j.clinre.2020.03.001 doi: 10.1016/j.clinre.2020.03.001 id: cord-311804-39mu0tdr author: Zingone, Fabiana title: Screening for Active COVID-19 Infection and Immunization Status Prior to Biologic Therapy in IBD Patients at the Time of the Pandemic Outbreak date: 2020-04-10 words: 866 sentences: 60 pages: flesch: 39 cache: ./cache/cord-311804-39mu0tdr.txt txt: ./txt/cord-311804-39mu0tdr.txt summary: title: Screening for Active COVID-19 Infection and Immunization Status Prior to Biologic Therapy in IBD Patients at the Time of the Pandemic Outbreak When clinical conditions and the disease activity do not allow a treatment delay, before starting a biological therapy, screening of IBD patients for COVID-19 active infection by RT-PCR should be advisable, even in absence of clinical suspicion. When clinical conditions and the disease activity do not allow a treatment delay, before starting a biological therapy, screening of IBD patients for COVID-19 active infection by RT-PCR should be advisable, even in absence of clinical suspicion. Accumulating evidence shows that patients with COVID-19 infection may also experience gastrointestinal symptoms, including diarrhea, nausea, vomiting and abdominal discomfort prior to the common respiratory symptoms Current recommendation suggests postponing the start of treatment with immunosuppressive drugs and biologics, whenever possible, based on an individual risk assessment during the COVID19 pandemic (5-7). abstract: Coronavirus disease 2019 has been recently classified as pandemic infection by the World Health Organization. Patients with inflammatory bowel disease (IBD) are invited to follow the national recommendations as any other person. It is unclear whether a more aggressive clinical course might develop in asymptomatic COVID-19 infected subjects during biological therapy and current evidence does not support treatment suspension. However, during pandemic, the start of treatment with immunosuppressive drugs and biologics should be postponed whenever possible and based on an individual risk assessment. When clinical conditions and the disease activity do not allow a treatment delay, before starting a biological therapy, screening of IBD patients for COVID-19 active infection by RT-PCR should be advisable, even in absence of clinical suspicion. Serum antibody testing, when available, could provide evidence of infection as well as identify patients already immune to the disease. url: https://www.sciencedirect.com/science/article/pii/S1590865820301389?v=s5 doi: 10.1016/j.dld.2020.04.004 id: cord-014516-r59usk02 author: nan title: Research Communications of the 24th ECVIM‐CA Congress date: 2015-01-10 words: 55041 sentences: 2919 pages: flesch: 51 cache: ./cache/cord-014516-r59usk02.txt txt: ./txt/cord-014516-r59usk02.txt summary: Serum prolactin concentration measured in 22/23 dogs at time zero, 6 weeks and 6 months was 3.35 ng/ml (range, 1.4-6.36), 3.57 ng/ml (range, 1.87-7.39) and 3.92 ng/ml (range, 2.01-12.92) and did not differ significantly in either time period when compared with time zero (P = 0.99 and P = 0.52).Altogether, results of this study failed to demonstrate a significant role of thyroid supplementation on the majority of evaluated behavioural symptoms as well as neurohormonal status of hypothyroid dogs during 6 months of therapy. The aims of the present study were (1) to describe a clinical series of recent autochtonous cases and (2) to retrospectively assess Angiostrongylus vasorum qPCR in bronchoalveolar lavage fluid (BALF) samples, collected over the last 7 years from a larger series of dogs, healthy or with other respiratory conditions, in order to investigate the past prevalence of the disease in Belgium. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858066/ doi: 10.1111/jvim.12491 id: cord-014527-nvzfpntu author: nan title: Research Communications of the 25th ECVIM‐CA Congress date: 2015-11-09 words: 89238 sentences: 4996 pages: flesch: 52 cache: ./cache/cord-014527-nvzfpntu.txt txt: ./txt/cord-014527-nvzfpntu.txt summary: A negative outcome was associated with higher fecal S100A12 concentrations in CE dogs, but the response to different forms of treatment and fecal S100A12 has not been reported, and this information will be important to further evaluate the utility of fecal S100A12 as a biomarker for gastrointestinal disease. Statistical analysis was performed using non-parametric 2-or multiple-group comparisons, the likelihood ratio to evaluate the association between groups of dogs and response to treatment, and a receiver operating characteristic curve to calculate sensitivity and specificity at the optimum cut-off concentration. The objectives of this study were to describe pulmonary transit time and myocardial perfusion normalized to heart rate (nPTT and nMP, respectively), evaluated by means of contrast echocardiography, in dogs with stable stage C ACVIM myxomatous mitral valve disease (MMVD), and to assess short-term effects of pimobendan on these parameters. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913621/ doi: 10.1111/jvim.13647 id: cord-022555-a7ie82fs author: nan title: Digestive System, Liver, and Abdominal Cavity date: 2011-12-05 words: 66452 sentences: 3846 pages: flesch: 48 cache: ./cache/cord-022555-a7ie82fs.txt txt: ./txt/cord-022555-a7ie82fs.txt summary: One study found that, of cats investigated for gastrointestinal disease, 9 of 33 cats (27%) had no pathology recognized proximal to the jejunum (i.e., the effective length of diagnostic endoscopes would have precluded diagnosis), and other organs were affected in 9 of 10 cats with inflammatory bowel diseases and 7 of 8 cats with intestinal small cell lymphoma. 60, 64 Quantification of serum cobalamin levels is recommended in cats with clinical signs of small bowel diarrhea, ones suspected to have an infiltrative disease of the small intestine (inflammatory bowel disease or gastrointestinal lymphoma), or ones with pancreatic dysfunction. Survey radiographs may be normal in cats with esophagitis and strictures, but are useful to rule out other causes for the clinical signs, such as a foreign body, or to detect related problems, such as aspiration pneumonia. 8, 29 Other non-neoplastic causes reported for gastric or gastroduodenal ulceration in cats include parasites (e.g., Ollulanus tricuspis, Toxocara cati, Aonchotheca putorii, Gnathostoma spp.), bacterial infections, toxins, inflammatory bowel disease, and foreign bodies. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158306/ doi: 10.1016/b978-1-4377-0660-4.00023-5 id: cord-022888-dnsdg04n author: nan title: Poster Sessions date: 2009-08-19 words: 188640 sentences: 9313 pages: flesch: 45 cache: ./cache/cord-022888-dnsdg04n.txt txt: ./txt/cord-022888-dnsdg04n.txt summary: Methods: Phospho-specific Western blot analyses were performed to verify the functionality of the different IFN-g pathway components, intra-and extracellular flow cytometry experiments were employed to determine the expression of antigen processing components and HLA class I cell surface antigens, quantitative real time-PCR experiments to confirm the absence of JAK2 and presence of pathway relevant molecules as well as, genomic PCR and chromosome typing technique to prove the deletion of JAK2. In order to accomplish these objectives we induced priming or tolerance of ovalbumin (OVA 323-339 peptide)-specific T cells from DO11.10 TCR transgenic mice in vitro or, following adoptive transfer of near physiologically relevant numbers of such cells into recipients, in vivo and correlated functional outcome (via proliferation and cytokine readout assays or antibody production) with E3 ubiquitin-protein ligases expression and the ubiquitination status of the TCR signalling machinery. abstract: No Abtract url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163517/ doi: 10.1002/eji.200990224 id: cord-023095-4dannjjm author: nan title: Research Abstract Program of the 2011 ACVIM Forum Denver, Colorado, June 15–18, 2011 date: 2011-05-03 words: 134226 sentences: 6834 pages: flesch: 51 cache: ./cache/cord-023095-4dannjjm.txt txt: ./txt/cord-023095-4dannjjm.txt summary: The purpose of this study was to determine the short-term effects of ivabradine on heart rate (HR), blood pressure, left ventricular (LV) systolic and diastolic function, left atrial (LA) performance, and clinical tolerance in healthy cats after repeated oral doses. The goal of this study was to investigate the relationship between heart rate and ECG time intervals to body mass in apparently healthy horses and ponies and to calculate normal ranges for different weight groups. This study aimed to investigate the prevalence of hypercoagulability in PLN dogs based on thromboelastography (TEG), and to determine whether hypercoagulability in these patients could be predicted by clinical assessments that identify systemic hypertension (systolic blood pressure 4 160 mmHg), hypoalbuminemia (serum albumin o 2.7 mg/dl), antithrombin activity (o 70%), and degree of proteinuria (urine protein:creatinine ratio [UPC] ! abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166756/ doi: 10.1111/j.1939-1676.2011.0726.x id: cord-023134-y665agnh author: nan title: Oral Research Communications of the 22(nd) ECVIM‐CA Congress date: 2012-11-20 words: 29595 sentences: 1548 pages: flesch: 50 cache: ./cache/cord-023134-y665agnh.txt txt: ./txt/cord-023134-y665agnh.txt summary: Doppler echocardiographic indices of diastolic function of the right ventricle are good prognostic markers during left ventricular (LV) failure secondary to ischemic and dilated cardiomyopathy.The aims of the present study were: to assess LV and RV diastolic function by conventional Doppler and pulsed-wave tissue Doppler imaging (PW-TDI) in dogs with mitral valve disease (MVD), with or without pulmonary hypertension (PH); to test if echocardiographic parameters of LV and RV diastolic dysfunction correlate to the Doppler-estimated pulmonary artery systolic pressure (PASP).114 dogs were prospectively evaluated, including 86 dogs with MVD. The aims of the present study were to assess whether diabetic cats have pathological evidence of islet inflammation or pancreatitis and to define islet lesions in comparison to a well-matched control population.Formalin-fixed, paraffin-embedded pancreatic samples were collected from post-mortem examination performed on diabetic and control cats died due to any disease at the Clinic for Small Animal Internal Medicine, University of Zurich (Switzerland) between 1997 and 2009. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167033/ doi: 10.1111/jvim.12000 id: cord-258066-ncuegrq7 author: nan title: Inflammatory Bowel Disease date: 2013-12-31 words: 621 sentences: 55 pages: flesch: 46 cache: ./cache/cord-258066-ncuegrq7.txt txt: ./txt/cord-258066-ncuegrq7.txt summary: Inflammatory bowel disease (IBD) is a poorly defined and often incorrectly used term in ferrets and other small animals for a systemic inflammatory disease primarily involving the gastrointestinal tract. The umbrella term IBD used in ferrets and other small animals for a variety of gastrointestinal diseases is not the same disease that is seen in humans. • Ferrets are susceptible to several gastrointestinal inflammatory conditions that have erroneously been placed under the umbrella term of IBD. Endoscopic biopsies are often done early, after symptomatic medical therapy (see Acute General Treatment) has failed to control clinical signs. • It is not appropriate for a pathologist to issue a diagnosis of "inflammatory bowel disease." It is more appropriate to list the histologic findings, and to indicate that the changes could be "compatible with" a clinical diagnosis of that syndrome. • Chronic gastrointestinal inflammatory disease in ferrets is not always cured. Treatment of inflammatory bowel disease (IBD) in dogs and cats abstract: nan url: https://api.elsevier.com/content/article/pii/B9781416039693002158 doi: 10.1016/b978-1-4160-3969-3.00215-8 ==== make-pages.sh questions [ERIC WAS HERE] parallel: Warning: Cannot spawn any jobs. Raising ulimit -u or 'nproc' in /etc/security/limits.conf parallel: Warning: or /proc/sys/kernel/pid_max may help. ==== make-pages.sh search /data-disk/reader-compute/reader-cord/bin/make-pages.sh: line 77: /data-disk/reader-compute/reader-cord/tmp/search.htm: No such file or directory Traceback (most recent call last): File "/data-disk/reader-compute/reader-cord/bin/tsv2htm-search.py", line 51, in with open( TEMPLATE, 'r' ) as handle : htm = handle.read() FileNotFoundError: [Errno 2] No such file or directory: '/data-disk/reader-compute/reader-cord/tmp/search.htm' ==== make-pages.sh topic modeling corpus Zipping study carrel